Ticker,Price,Drug,Indication,Stage,Date,Catalyst,Shares_Millions
SNDX,21.86,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD) ,BLA Filing,01/02/2024,"BLA submitteed to the FDA, noted January 2, 2024.",86.0
INCY,65.45,Niktimvo (axatilimab-csfr),Chronic Graft versus host disease (cGvHD) ,BLA Filing,01/02/2024,"BLA submitteed to the FDA, noted January 2, 2024.",195.0
LBPH,25.1,Bexicaserin (LP352) - (DEEp OCEAN),Adolescent and adult patients with developmental and epileptic encephalopathies (DEEs) ,Phase 1/2,01/02/2024,"Phase 1b/2a top-line data reported a median seizure reduction of 53.3% in countable motor seizures compared to 20.8% in the placebo group across the DEE study population, noted January 2, 2024.",39.0
ATAI,1.69,EMP-01,Post-Traumatic Stress Disorder (PTSD) ,Phase 1,01/02/2024,"Phase 1 was well-tolerated, and treatment-related adverse events (AEs) were all expected and generally dose-dependent, noted on January 2, 2024.",214.0
AVXL,6.05,ANAVEX 2-73-RS-003 - (EXCELLENCE),Pediatric Rett Syndrome ,Phase 2/3,01/02/2024,"Phase 2/3 results missed a primary endpoint on the LS Mean difference (SE) points between treated and placebo, noted January 2, 2024.",85.0
ATXI,12,AJ201,Spinal and bulbar muscular atrophy (SBMA) ,Phase 1/2,01/02/2024,"Phase 1b/2 enrollment completed, noted January 2, 2024.",3.0
SPRO,1.52,Tebipenem HBr (SPR994) - (PIVOT-PO),"Complicated urinary tract infection (cUTI), including acute pyelonephritis (AP) ",Phase 3,01/02/2024,"Phase 3 dosing initiated, noted January 2, 2024.",56.0
CTXR,0.81,Mino-Lok,Catheter related blood stream infection (CRBSI) ,Phase 3,01/02/2024,"Phase 3 enrollment was completed, noted January 2, 2024.",17.0
NVS,—,Farabursen (RGLS8429) (MAD),Autosomal Dominant Polycystic Kidney Disease (ADPKD) ,Phase 1b,01/02/2024,"Phase 1b third cohort completed, noted January 2, 2024.",
AGIO,24.02,PYRUKYND (Mitapivat) - (ENERGIZE),Thalassemia ,Phase 3,01/03/2024,"Phase 3 data reported that the trial met its primary endpoint and key secondary endpoints, noted January 3, 2024.",58.0
TEVA,10.95,AVT06 - (EYLEA biosimilar),Eye disorders ,Phase 3,01/03/2024,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.",
ALVO,11.68,AVT06 - (EYLEA biosimilar),Eye disorders ,Phase 3,01/03/2024,"Phase 3 data reported that the trial met its primary endpoint, noted January 3, 2024.",301.0
DYN,14.77,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1) ,Phase 1/2,01/03/2024,"Phase 1/2 MAD data reported a dose-dependent splicing correction and increase in muscle delivery and DMPK knockdown while also showing functional improvement in myotonia, noted January 3, 2024.",142.0
DYN,14.77,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD) ,Phase 1/2,01/03/2024,"Phase 1/2 initial data reported a mean absolute dystrophin level of 0.88% of normal and a 0.28% change from baseline at 6 months, noted January 3, 2024.",142.0
ATHA,3.03,Fosgonimeton (ATH-1017) - (LIFT-AD),Alzheimer’s disease ,Phase 2/3,01/03/2024,"Phase 2/3 trial enrollment completed, noted January 3, 2024.",3.0
APLM,0.96,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ,Phase 3,01/03/2024,"Phase 3 enrollment completed, noted January 3, 2024.",1.0
GLYC,3.03,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ,Phase 3,01/03/2024,"Phase 3 enrollment completed, noted January 3, 2024.",13.0
CMMB,0.53,nebokitug (CM-101) - (SPRING),Primary Sclerosing Cholangitis ,Phase 2,01/03/2024,"Phase 2 early enrollment completed, noted January 3, 2023.",5.0
SLRX,0.64,Seclidemstat,Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) ,Phase 1/2,01/03/2024,"Additional Phase 1/2 data reported that an additional Ewing sarcoma patient treated with seclidemstat, topotecan and cyclophosphamide (TC) has achieved a partial response as demonstrated by at least a",
INTS,7.99,INT230-6,Advanced Soft Tissue Sarcoma ,Phase 3,01/03/2024,"FDA provided ""Study May Proceed"" letter, noted January 3, 2024.",47.0
ENVB,1.32,EB-003 (EVM301 series),Mental health disorders ,Preclinical,01/03/2024,"Preclinical development to commence in early 2024, with IND submission planned in 2024, noted January 3, 2024.",3.0
IFRX,1.83,INF904,Chronic Autoimmune and Inflammatory Diseases ,Phase 1,01/04/2024,Phase 1 MAD results from 24 healthy volunteers showed that study was well tolerated in participants over the entire dose range and resulted in no safety signals of concern. The overall percentage of A,59.0
GLYC,3,GMI-1687,Healthy volunteers ,Phase 1a,01/04/2024,"Phase 1a Initial results demonstrated that subcutaneous dosing achieved target therapeutic plasma concentration and linear pharmacokinetics with rapid renal clearance across all dosing levels, noted",13.0
ADCT,1.88,ADCT-601 (mipasetamab uzoptirine),"Soft tissue sarcomas, pancreatic cancer and AXL-expressing non-small cell lung cancer (NSCLC) ",Phase 1b,01/04/2024,"Preliminary Phase 1 data shows the maximum-tolerated dose has been reached, and the study is currently in dose optimization, noted Janaury 4, 2024.",112.0
ADCT,1.88,ADCT-901,Solid tumors ,Phase 1,01/04/2024,"Program discontinued due to limited signs of efficacy in the dose escalation phase and to reallocate capital to prioritized programs, noted January 4, 2024.",112.0
ALDX,3.34,ADX-629,Sjögren-Larsson Syndrome (SLS) ,Phase 1/2,01/04/2024,Phase 2 biomarker results observed in adult cohort proposed expansion to include pediatric patients expected to be submitted to the FDA in the 1H 2024.,59.0
ALDX,3.34,ADX-246,Systemic Immune-Mediated Diseases and atopic dermatitis ,Phase 1,01/04/2024,"Phase 1 expanded to include patients with atopic dermatitis, noted Janaury 4, 2024.",59.0
KNSA,19.13,Abiprubart (KPL-404),Rheumatoid arthritis ,Phase 2,01/04/2024,"Phase 2 trial met its primary endpoint, noted January 4, 2024.",74.0
RYTM,43.31,Bivamelagon (LB54640),Healthy overweight adults ,Phase 1,01/04/2024,"Phase 1 has shown targeted effect on MC4 receptor without hyperpigmentation, noted January 4, 2024.",66.0
SNGX,0.91,SGX302/hypericin sodium,Psoriasis ,Phase 2a,01/04/2024,"Phase 2a data reported that two patients reached a disease status of ""Almost Clear"" represented by an Investigator Global Assessment (IGA) score of 1, noted January 4, 2024.",4.0
PRTG,1.35,IMM60 - (PORT-2),Refractory NSCLC & Melanoma ,Phase 1,01/04/2024,"Phase 2 paused after a review of Portage's funding requirements, noted January 4, 2024.",2.0
MRK,116.27,IMM60 - (PORT-2),Refractory NSCLC & Melanoma ,Phase 1,01/04/2024,"Phase 2 paused after a review of Portage's funding requirements, noted January 4, 2024.",
IMMP,2.41,Eftilagimod alpha - INSIGHT-004,Solid tumors ,Phase 1,01/04/2024,"Phase 1 dosing initiated, noted January 4, 2024.",145.0
APLT,3.79,AT-001 - (ARISE-HF),Diabetic cardiomyopathy (DbCM) ,Phase 3,01/04/2024,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar",144.0
APLT,3.79,AT-001 - (ARISE-HF),Diabetic cardiomyopathy (DbCM) ,Phase 3,01/04/2024,"Phase 3 topline data demonstrated that while a trend favored active treatment, the difference between active and placebo treated groups (0.30 ml/kg/min) was not statistically significant, noted Januar",144.0
TBPH,10.37,YUPELRI (revefenacin) - (PIFR-2),Chronic obstructive pulmonary disease (COPD) ,Phase 3,01/05/2024,"Phase 4 data reported that the trial did not show a statistically significant difference between YUPELRI and Spiriva HandiHaler on the primary endpoint, noted January 5, 2024.",50.0
CVAC,4.34,CV0601,COVID-19 vaccine ,Phase 2,01/05/2024,"Phase 2 data reported a meaningful immune responses and favorable reactogenicity profiles across all tested doses, including the lowest tested dose, noted January 5, 2024.",224.0
GSK,38.51,XMT-2056,HER2-Expressing Tumors ,Phase 1,01/05/2024,"Phase 1 clinical trial restarting; plan to advance dose escalation in 2024, noted January 5, 2024.",
MRSN,2.27,XMT-2056,HER2-Expressing Tumors ,Phase 1,01/05/2024,"Phase 1 clinical trial restarting; plan to advance dose escalation in 2024, noted January 5, 2024.",4.0
FBIO,2.42,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular Rosacea ,NDA Filing,01/05/2024,"NDA submitted to the FDA, noted January 5, 2024.",29.0
DERM,5.05,"Emrosi (Minocycline Hydrochloride ER Capsules, 40 mg) (DFD-29) - (MVOR-2)",Papulopustular Rosacea ,NDA Filing,01/05/2024,"NDA submitted to the FDA, noted January 5, 2024.",24.0
NOVN,0,ZELSUVMI (berdazimer topical gel),Molluscum Contagiosum ,Approved,01/05/2024,"FDA Approved on January 5, 2023.",28.0
LGND,70.83,ZELSUVMI (berdazimer topical gel),Molluscum Contagiosum ,Approved,01/05/2024,"FDA Approved on January 5, 2023.",19.0
PTHS,—,ZELSUVMI (berdazimer topical gel),Molluscum Contagiosum ,Approved,01/05/2024,"FDA Approved on January 5, 2023.",3.0
VINC,1.36,VIP236,Solid tumors ,Phase 1,01/08/2024,"Phase 1 update observed that 15 patients have been treated, showing a promising safety profile and preliminary evidence of clinical activity with once every 3-week dosing, noted January 8, 2024.",5.0
VINC,1.36,VIP943 (anti-CD123),Hematologic malignancies ,Phase 1,01/08/2024,"Phase 1 enrollment in the second cohort of the VIP943 trial is nearly complete. Preliminary pharmacokinetic results from the first cohort trial showed very little free payload in circulation, consiste",5.0
VINC,1.36,Enitociclib (VIP152) in combination with venetoclax and prednisone - (NIH trial),Peripheral T-cell lymphoma (PTCL) and 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) ,Phase 1,01/08/2024,"Phase 1 preliminary data from investigators from the National Institutes of Health (NIH) reported 2 partial responses (PR) in 3 PTCL patients and 1 PR in DH-DLBCL in ongoing dose-escalation trial, not",5.0
ARGX,413.29,Empasiprubart (ARGX-117) - (ARDA),Multifocal motor neuropathy (MMN) ,Phase 2,01/08/2024,"Phase 2 topline data reported that treatment demonstrated a 91% reduction in the need for IVIg rescue compared to placebo, noted January 8, 2024.",60.0
ABSI,4.18,ABS-101,Inflammatory bowel disease (IBD) ,Preclinical,01/08/2024,"Preclinical data support profile for development of a potential best-in-class drug. IND submission expected in 1Q 2025; Phase 1 trials anticipated to initiate shortly after, noted January 8, 2024.",149.0
VERU,0.56,Enobosarm with semaglutide (Wegovy) - (PLATEAU),Obesity ,IND-Enabling,01/08/2024,"IND submitted to the FDA, noted January 8, 2024.",14.0
BIOR,1.28,BT-600 + NaviCap Platform,Ulcerative Colitis (UC) ,Phase 1,01/08/2024,"Phase 1 dosing initiated, noted January 8, 2024.",4.0
ALT,11.39,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese Volunteers ",Phase 2,01/08/2024,"Phase 2 results presented at NASH-TAG Conference reported that treatment resulted in reductions of up to 76.4% in relative LFC, 15.2 IU/L in serum ALT, and 149.7ms in cT1 at 24 weeks January 6, 2024.",88.0
CLRB,3.2,Iopofosine (CLR 131) - (CLOVER-WaM),Waldenstrom’s macroglobulinemia ,Phase 2b,01/08/2024,"Phase 2b trial met its primary endpoint, noted January 8, 2024.",3.0
ITOS,11.14,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM) ,Phase 1/2,01/08/2024,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",44.0
BMY,51.19,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM) ,Phase 1/2,01/08/2024,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",
GSK,38.94,Belrestotug (EOS-448/GSK4428859A) - (TIG-007) + iberdomide,Relapsed/refractory multiple myeloma (r/r MM) ,Phase 1/2,01/08/2024,"Phase 1/2 was deprioritized after trial assessment, noted January 8, 2024.",
CLNN,0.35,CNM-Au8 - (VISIONARY-MS),Multiple Sclerosis ,Phase 2,01/08/2024,"Phase 2 long term data demonstrated improvement of vision as measured by low contrast visual acuity (LCLA), noted Janaury 8, 2024.",9.0
ABBV,158.39,lutikizumab (ABT-981),Hidradenitis suppurativa (HS) ,Phase 2,01/08/2024,"Phase 2 300 mg weekly or 300 mg dose every other week showed higher response rates in HiSCR 50 at week 16 than those treated with placebo, noted January 8, 2024.",
OKYO,1.89,urcosimod (OK-101),Dry Eye Disease (DED) ,Phase 2,01/08/2024,Phase 2 data presented at the Biotech Showcase showed that dose was statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after d,33.0
NVO,105.64,Icosema - (COMBINE 3),Type 2 diabetes ,Phase 3,01/08/2024,"Phase 3a trial completed, noted January 8, 2024",
MNMD,4.39,MM-120 (LSD),Attention Deficit Hyperactivity Disorder (ADHD) ,Phase 2a,01/08/2024,"Phase 2a trial did not meet its primary endpoint, noted January 8, 2024.",75.0
NRIX,9.96,NX-2127,"B-cell malignancies, chronic lymphocytic leukemia (CLL) ",Phase 1b,01/08/2024,"The company expects to resolve partial hold to enable the introduction of newly manufactured drug product into the ongoing Phase 1 clinical trial., noted January 8, 2024.",76.0
INCY,65.82,INCB123667,"Late-stage cancers, ovarian cancer ",Phase 1,01/08/2024,"Phase 1 early clinical activity was observed with several patients with amplified/overexpression of CCNE1, a cell cycle regulator and potential predictive biomarker, achieving partial response (PR), n",195.0
INCY,65.82,Ruxolitinib Cream (Opzelura),Adults with hidradenitis suppurativa (HS) ,Phase 2,01/08/2024,"Phase 2 primary endpoint was met in its randomized, placebo-controlled study, noted on January 8, 2024.",195.0
NVS,103.22,Scemblix - (ASC4FIRST),1L Chronic myeloid leukemia (CML) ,Phase 3,01/08/2024,"Phase 3 trial met its primary endpoint, noted January 8, 2024.",
CYBN,0.39,CYB004 (IV) and SPL028 (IM),Generalized anxiety disorder (GAD) ,Phase 1,01/08/2024,"Intravenous (IV) CYB004 demonstrated robust and rapid-onset psychedelic effects at lower doses compared to native DMT, suggesting potential as a short-acting, scalable treatment. Intramuscular (IM) do",23.0
FATE,4.12,FT825/ONO-8250,Solid Tumors ,Phase 1,01/08/2024,"Phase 1 trial initiated, noted January 8, 2024.",115.0
BPMC,85.31,BLU-945 with osimertinib - (SYMPHONY),Treatment-resistant EGFR-driven NSCLC ,Phase 1/2,01/08/2024,"Phase 1/2 discontinued investment based on the evolving external landscape, emerging clinical data and partnering considerations, noted January 8, 2024.",64.0
BPMC,85.31,BLU-451 - (CONCERTO),EGFR exon 20 insertion-positive NSCLC ,Phase 1/2,01/08/2024,"Phase 1/2 discontinued investment based on the evolving external landscape, emerging clinical data and partnering considerations, noted January 8, 2024.",64.0
SMMT,2.97,Ivonescimab plus chemotherapy - (AK112-201),Non-small cell lung cancer (NSCLC) ,Phase 2,01/08/2024,"Phase 2 data reported that the 1-year overall survival rate was 85.6%, and the 2-year overall survival rate was 64.8% for patients in Cohort 1 with squamous histology NSCLC, noted January 8, 2024.",744.0
ORIC,8.24,ORIC-944,Metastatic castration resistant prostate cancer (mCRPC) ,Phase 1b,01/08/2024,"Phase 1b data demonstrated potential best-in-class profile, including half-life >10 hours, robust target engagement and well tolerated safety profile, supporting advancement for combination developmen",97.0
BMEA,15.94,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D) ,Phase 2,01/08/2024,"Phase 2 was initiated, noted January 8, 2024.",59.0
NUVB,1.55,NUV-1511,Advanced solid tumors ,IND-Enabling,01/08/2024,"IND cleared by FDA, noted January 8, 2024.",342.0
AFMD,6.61,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancer ",Phase 1/2,01/08/2024,"Phase 1/2a follow-up showed that three of the initially reported responses have now been confirmed (1 CR, 2 PR) and one still awaiting a confirmatory scan, noted January 8, 2024.",15.0
AVIR,3.1,Bemnifosbuvir (AT-527) - (SUNRISE-3),COVID-19 ,Phase 3,01/08/2024,"Phase 3 8-week study showed a 98% SVR4, which exceeds our efficacy criterion of >90% for continuing the study, noted January 8, 2024",79.0
ELTX,5.45,ELI-002 (AMPLIFY-201),Solid Tumors ,Phase 1/2,01/09/2024,"Phase 1/2 data presented in a paper on Nature Medicine showed that ELI-002 administered as a monotherapy induced robust, polyfunctional, and durable KRAS specific CD4+ and CD8+ T cell responses. Tumor",16.0
ALPMY,12.04,Zolbetuximab,HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are CLDN18.2-positive ,CRL,01/09/2024,"CRL issued by the FDA on January 9, 2024.",
VCEL,37.31,NexoBrid (CIDS),Severe burns - pediatric ,BLA Filing,01/09/2024,"sBLA filing review and accepted by the FDA, noted January 9, 2024.",50.0
MDWD,12.49,NexoBrid (CIDS),Severe burns - pediatric ,BLA Filing,01/09/2024,"sBLA filing review and accepted by the FDA, noted January 9, 2024.",11.0
CRBP,7.22,CRB-601,Solid tumors ,IND-Enabling,01/09/2024,"IND cleared by the FDA, noted January 9, 2024",12.0
ALC,76.44,TRYPTYR (acoltremon ophthalmic solution) 0.003%,Dry eye disease (DED) ,Phase 3,01/09/2024,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.",494.0
ALC,76.44,AR-15512 (AVX-012) - (COMET-2),Dry eye disease ,Phase 3,01/09/2024,"Phase 3 pivotal efficacy and safety study met the primary endpoint , noted January 9, 2024.",494.0
MRSN,3.25,Emiltatug Ledadotin (XMT-1660) - (Emi-Le),Metastatic triple-negative breast cancer (TNBC) ,Phase 1,01/10/2024,"Phase 1 data reported that treatment was generally well tolerated, with no Grade 4 or 5 treatment-related adverse events (TRAEs) reported, noted January 10, 2025.",4.0
FDMT,19.14,4D-150 - (SPECTRA),Wet Age-Related Macular Degeneration (wet AMD) ,Phase 2,01/10/2024,"Phase 2 32-week interim data reported that 3E10 vg/eye achieved an 86% reduction in injection burden vs. projected on-label aflibercept 2mg Q8W and dose response with 61% reduction vs. 1E10 vg/eye, wi",46.0
CMND,2.93,CMND-100,Alcohol use disorder (AUD) ,IND-Enabling,01/10/2024,"IND submitted March 16, 2023. Phase 1/2a trial sites selected noted May 22, 2023. Type A meeting completed, noted January 10, 2024.",5.0
ACRS,1.01,ATI-1777-AD-202,Atopic dermatitis ,Phase 2b,01/10/2024,"Phase 2b topline data on ATI-1777 2% QD showed a trend toward significance, ATI-1777 2% BID achieved a statistically significant result in the primary efficacy endpoint at week 4, noted January 10, 2",108.0
VYNE,2.24,Repibresib Gel (VYN201),Vitiligo ,Phase 1b,01/10/2024,"Phase 1b biomarker data reported a median reduction in MMP-9 of 40.8% in lesional skin compared to baseline for subjects in the 2.0% cohort, noted January 10, 2024.",25.0
EYPT,20.23,EYP-1901 - (VERONA),Diabetic macular edema (DME) ,Phase 2,01/10/2024,"Phase 2 dosing initiated, noted January 10, 2024.",68.0
BPTH,11.2,BP1002,Refractory/relapsed lymphoma and chronic lymphocytic leukemia ,Phase 1,01/10/2024,"Phase 1 first cohort completed, noted January 10, 2024.",8.0
SANA,7.18,SC291 - (ARDENT),"Solid tumors, B-cell lymphomas and leukemias ",Phase 1,01/10/2024,Phase 1 early data discussed at the JPMorgan Healthcare Conference showed in a presentation that three patients saw at least a reduction in their disease while two patients had no detectable disease a,237.0
MRK,117.88,KEYTRUDA with external beam radiotherapy (EBRT) plus concurrent chemotherapy - (KEYNOTE-A18),Cervical cancer ,Approved,01/12/2024,"FDA Approved on January 12, 2024.",
ARQT,3.47,"ZORYVE (roflumilast) cream, 0.15%",Atopic dermatitis ,Phase 3,01/15/2024,"Additional Phase 3 data reported that at Week 4, a statistically significant greater percentage of patients achieved a 50% reduction in EASI scores (EASI-50), with 69.2% of patients treated with roflu",119.0
ANIP,55.41,Indomethacin Oral Suspension - (Indocin generic),"Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, acute gouty arthritis, bursitis, and tendinitis ",Approved,01/16/2024,"Approved January 16, 2024.",21.0
CLRB,3.7,CLR 121225 (225Ac-CLR 121225),PLE cancer ,Preclinical,01/16/2024,"Preclinical data reported tumor volume reduction in a dose dependent manner with the highest dose providing near complete eradication of the tumor, noted January 16, 2024.",3.0
ALLK,1.19,Lirentelimab (AK002) - (MAVERICK),Chronic Spontaneous Urticaria ,Phase 2b,01/16/2024,"Phase 2b trial did not meet its primary endpoint, noted January 16, 2024.",90.0
ALLK,1.19,Lirentelimab (AK002) - (ATLAS),Atopic Dermatitis ,Phase 2,01/16/2024,"Phase 2 trial did not meet its primary endpoint, noted January 16, 2024.",90.0
HALO,36.36,HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase),Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) ,Approved,01/16/2024,"Approved January 16, 2024.",116.0
TAK,15.01,HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase),Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) ,Approved,01/16/2024,"Approved January 16, 2024.",
CRSP,63.43,CASGEVY (exagamglogene autotemcel [exa-cel],Beta-thalassemia ,Approved,01/16/2024,"FDA Approved on January 16, 2024.",90.0
VRTX,437.49,CASGEVY (exagamglogene autotemcel [exa-cel],Beta-thalassemia ,Approved,01/16/2024,"FDA Approved on January 16, 2024.",256.0
SRPT,115.39,SRP-9003-301 - (EMERGENE),Limb-girdle muscular dystrophy type 2E (LGMD2E) ,Phase 3,01/16/2024,"Phase 3 screening initiated, noted January 16, 2024.",97.0
BGNE,173.25,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancer ,Phase 2,01/16/2024,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef",106.0
ONC,—,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancer ,Phase 2,01/16/2024,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef",110.0
LPTX,3.47,DKN-01 with bevacizumab - (DeFianCe),Colorectal cancer ,Phase 2,01/16/2024,"Phase 2 part B data due at ASCO GI on January 20, 2024. Phase 2 part A data showed a 30% ORR and 93% DCR across heterogenous second-line CRC patients. Subgroup analysis reveals greatest benefit in lef",41.0
RCUS,16.9,AB680 + Zimberelimab (AB122) - (ARC-8),Pancreatic Cancer ,Phase 1b,01/16/2024,"Phase 1 data showed a median overall survival was 15.7 months for all patients treated with 100 mg quemliclustat-based regimens in the ARC-8 study, which exceeds the historical benchmark data for chem",106.0
ADAG,3.78,muzastotug (ADG126) combined with KEYTRUDA (pembrolizumab) - (ADG126-P001/KEYNOTE-C98),Solid tumors ,Phase 1/2,01/16/2024,"Phase 1/2 data from first tranche of MSS CRC patients treated with ADG126 10 mg/kg every three weeks (Q3W) in dose expansion showed clinical benefit including confirmed responses at higher, more freq",47.0
ACXP,4.52,Ibezapolstat,C. difficile Infection ,Phase 2b,01/17/2024,"Phase 2b data showed that that ibezapolstat outperformed vancomycin, a standard of care to treat patients with CDI, with eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 patients (9",1.0
EVGN,0.79,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma ",Phase 1,01/17/2024,"Phase 1 first patient dosed July 26, 2022. Phase 1 trial enrollment completed, noted January 17, 2024",6.0
BMY,49.4,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma ",Phase 1,01/17/2024,"Phase 1 first patient dosed July 26, 2022. Phase 1 trial enrollment completed, noted January 17, 2024",
KANT,—,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumors ,Phase 1/2,01/17/2024,"Phase 1/2 update reported that KVA12123 was well tolerated with no dose limiting toxicities (DLT) or cytokine related adverse events at any dose level, noted January 17, 2024.",13.0
REGN,929.13,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,01/17/2024,"Phase 2 data reported a 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatme",105.0
MAIA,1.48,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,01/17/2024,"Phase 2 data reported a 100% preliminary disease control rate (DCR) in second-line and 88% in third-line, in highly difficult-to-treat patients who already progressed through previous lines of treatme",32.0
LSTA,2.94,LSTA1,Glioblastoma multiforme (GBM) ,Phase 2a,01/17/2024,"Phase 2a trial initiated, noted January 17, 2024.",8.0
CATX,0.44,212Pb-VMT01,MC1R-positive metastatic melanoma ,Phase 1/2,01/17/2024,"Phase 1/2 second dose escalation cohorts recruitment commenced, noted January 17, 2024.",74.0
CNSP,35.33,Berubicin,Glioblastoma (GBM) (adult) ,Phase 2,01/17/2024,"Enrollment completed, noted January 17, 2024.",
PFE,27.32,CRDF-004,Metastatic colorectal cancer (mCRC) ,Phase 1b,01/17/2024,"Phase 1b findings highlight the safety and promising efficacy of onvansertib in combination with standard-of-care, noted January 17, 2024.",
CRDF,1.47,CRDF-004,Metastatic colorectal cancer (mCRC) ,Phase 1b,01/17/2024,"Phase 1b findings highlight the safety and promising efficacy of onvansertib in combination with standard-of-care, noted January 17, 2024.",66.0
IXHL,4.47,IHL-42X - (RePOSA),Obstructive sleep apnea (OSA) ,Phase 2/3,01/17/2024,"Phase 2/3 IRB approved protocol to asses drug in patients, noted January 17, 2024.",347.0
PBLA,6.65,CPP-1X (eflornithine),Neuroblastoma ,Phase 1,01/18/2024,"Phase 1 data reported that 2 partial responses (PR), 4 minor responses (MR), 10 Stable disease (SD), 7 progressive disease (PD) and 1 unevaluable patient, noted January 18, 2024.",4.0
MTVA,—,DA-1241,Metabolic dysfunction-associated steatohepatitis (MASH) ,Preclinical,01/18/2024,"Pre-clinical results demonstrated that once daily oral administration in rats, of sitagliptin alone (180 mg/kg/day), DA-1241 alone (100 mg/kg/day), or sitagliptin in combination with DA-1241 (up to 18",24.0
CLDX,39.66,Barzolvolimab - (CindU),"Chronic inducible urticaria (CIndU), cold urticaria (ColdU) and symptomatic dermographism (SD), Chronic Spontaneous Urticaria (CSU) ",Phase 2,01/18/2024,"Phase 2 data reported that the trial met primary endpoint with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups, noted January 18",66.0
CHRS,2.4,Casdozokitug (casdozo),Non-small cell lung cancer (NSCLC) ,Phase 2,01/18/2024,"Phase 2 data presented at ASCO GI demonstrated early activity with 38% objective response rate including three complete responses, noted January 18, 2024.",116.0
DCPH,13.89,QINLOCK (ripretinib) - (INTRIGUE),Gastrointestinal Stromal Tumors (GIST) - second-line ,Phase 3,01/18/2024,"Phase 3 long term data median overall survival of 35.5 months versus 31.5 months for sunitinib in the all-Patient intent-to treat-population, noted Janaury 18, 2024.",86.0
ZLAB,23.56,QINLOCK (ripretinib) - (INTRIGUE),Gastrointestinal Stromal Tumors (GIST) - second-line ,Phase 3,01/18/2024,"Phase 3 long term data median overall survival of 35.5 months versus 31.5 months for sunitinib in the all-Patient intent-to treat-population, noted Janaury 18, 2024.",109.0
NVS,104.33,LUTATHERA (lutetium Lu 177) - (NETTER-P),Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ,Phase 3,01/19/2024,Phase 3 data reported that treatment reduced the risk of disease progression or death by 72% as first-line therapy in patients with somatostatin receptor-positive (SSTR+) well-differentiated grade 2/3,
AZN,65.53,IMFINZI (Durvalumab) + TACE - (EMERALD-1),Locoregional Hepatocellular carcinoma (HCC) ,Phase 3,01/19/2024,"Phase 3 data presented at ASCO GI reported that treatment reduced the risk of disease progression or death by 23% compared to TACE alone, noted January 19, 2024.",
TEVA,11.18,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseases ,BsUFA,01/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",
ALVO,14.14,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseases ,BsUFA,01/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",301.0
TEVA,11.18,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. ,BsUFA,01/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",
ALVO,14.14,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. ,BsUFA,01/19/2024,"FDA facility reinspection in Iceland has concluded, the company also received a form 483 with one observation, noted January 19, 2024. Alvotech believes it is in position to receive approval on BsUFA",301.0
RCUS,15.34,AB680 + Zimberelimab (AB122) - (ARC-8),Pancreatic Cancer ,Phase 1b,01/19/2024,"Phase 1b results presented at the ASCO Gastrointestinal Cancers Symposium reported that a 37% reduction in risk of death and a 5.9-month improvement in mOS, noted January 19, 2024.",106.0
BMY,49.53,Opdivo (nivolumab) plus Yervoy - (CheckMate -8HW),Microsatellite Instability–High or Mismatch Repair Deficient Metastatic Colorectal Cancer ,Phase 3,01/20/2024,"Presentation of data reported that it demonstrated significant efficacy benefit compared to chemotherapy as first-line treatment in MSI-H/dMMR mCRC, noted January 20, 2023.",
AZN,66.12,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,01/22/2024,"Phase 1b/2 trial approved by Netherlands, noted June 27, 2023. Phase 1b/2 enrollment commenced January 22, 2024.",
AIM,0.42,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,01/22/2024,"Phase 1b/2 trial approved by Netherlands, noted June 27, 2023. Phase 1b/2 enrollment commenced January 22, 2024.",2.0
CLRB,3.64,Iopofosine (CLR 131) - (CLOVER-WaM),Waldenstrom’s macroglobulinemia ,Phase 2b,01/22/2024,"Phase 2b complete CNS clearance reported in one patient, noted January 22, 2024.",3.0
TVRD,—,KORSUVA (CR845/difelikefalin) oral - (KICK),Stage 3-4 Chronic Kidney Disease-Associated Pruritus ,Phase 3,01/22/2024,"Phase 3 trial was discontinued to focus resources on the notalgia paresthetica (NP) program, noted on January 22, 2024.",9.0
SGMT,18.42,Denifanstat - (FASCINATE-3),Nonalcoholic steatohepatitis (NASH) ,Phase 2b,01/22/2024,"Phase 2b topline data reported NASH resolution without worsening of fibrosis with ≥2-point reduction in NAS (NAFLD Activity Score) in 36% of denifanstat-treated patients vs 13% with placebo (p=0.002),",32.0
AGEN,11.77,Neoadjuvant botensilimab plus balstilimab - (NEST-1),Colorectal cancer ,Phase 2,01/22/2024,"Phase 2 trial data presented at ASCO-GI showed a major tumor regression in 67.5% of patients. The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term d",31.0
IONS,51.01,DAWNZERA (Donidalorsen),Hereditary Angioedema (HAE) ,Phase 3,01/22/2024,"Phase 3 topline data met the primary endpoint with a statistically significant reduction in the rate of HAE attacks in patients treated every 4 weeks or patients treated every 8 weeks, noted January 2",159.0
SEEL,10.24,SLS-002,Acute Suicidal Ideation and Behavior in patients with Major Depressive Disorder (ASIB in MDD) ,Phase 2,01/22/2024,"EoP2 minutes with FDA agreed that the primary endpoint in a Phase 3 trial could be the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 16, rather than",
SPRB,2.44,Tildacerfont - (CAHmelia-204),Congenital Adrenal Hyperplasia (good disease control) ,Phase 2b,01/22/2024,"Phase 2b enrollment completed exceeding target enrollment (100/90), noted January 22, 2024.",
SXTP,0.75,ARAKODA (tafenoquine),Babesiosis ,Phase 2,01/22/2024,"Type C meeting with FDA on January 17, 2024, concluded that the company now plans to conduct a pivotal clinical study in support of a future indication, noted January 22, 2024.",4.0
GILD,77.62,Trodelvy (sacituzumab govitecan-hziy; SG) vs. docetaxel - (EVOKE-01),Non-small cell lung cancer (NSCLC) ,Phase 3,01/22/2024,"Phase 3 trial did not meet its primary endpoint, noted January 22, 2024.",
CRBP,7.3,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinoma ",Phase 1,01/23/2024,"Phase 1 dose escalation data from 2024 ASCO GU reported an anti tumor responses across multiple doses were observed, with the first confirmed stable disease at 0.6mg/kg and the first confirmed partial",12.0
ARTL,1.38,ART26.12,Chemotherapy-Induced Pain ,Preclinical,01/23/2024,"Preclinical data reported that ART26.12 (10 and 25 mg/kg BID for 15 days) with oxaliplatin prevented thermal hyperalgesia, mitigated mechanical allodynia, and attenuated OXA-induced weight loss, noted",1.0
LLY,627.56,AK-OTOF,Hearing loss ,Phase 1/2,01/23/2024,"Phase 1/2 clinical trial showed that hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, noted January 23, 2024.",946.0
VNDA,3.71,VCA-894A,"Charcot-Marie-Tooth disease, axonal, type 2S (CMT2S), caused by cryptic splice site variants within IGHMBP2 ",IND-Enabling,01/23/2024,"Orphan drug designation, noted June 2, 2023. IND clearance by the FDA on January 23, 2024.",59.0
HRTX,2.2,ZYNRELEF (bupivacaine and meloxicam) extended-release,Soft tissue and orthopedic surgical procedures ,Approved,01/23/2024,"FDA Approved on January 23, 2024.",153.0
URGN,15.04,ZUSDURI (VesiGel UGN-102 (mitomycin)) - (ENVISION),Low grade non-muscle invasive bladder cancer (LG-NMIBC) ,NDA Filing,01/24/2024,"NDA was submitted to FDA on January 24, 2024",46.0
ANVS,9.09,Buntanetap,Parkinson's Disease (PD) ,Phase 3,01/24/2024,"Phase 3 data release postponed due to ongoing data cleaning efforts to ensure the accuracy and reliability of the study results, noted January 24, 2024.",19.0
ENSC,1.5,PF614-MPAR-102 - (MPAR),Overdose Protection ,Phase 1,01/25/2024,"Phase 1 data presented at the HEAL Initiative Scientific Meeting reported that the trial successfully met its overdose protection endpoints, noted January 25, 2024.",2.0
PBLA,3.25,SBP-101 in combination with Gemcitabine and Nab-Paclitaxel - (ASPIRE),Pancreatic Ductal Adenocarcinoma (PDA) ,Phase 2/3,01/25/2024,"Phase 2/3 enrollment exceeded 50% moving faster than expected, full enrollment anticipated 1Q 2025, noted January 25, 2024.",4.0
VERA,25.31,Atacicept - (ORIGIN 3),IgA Nephropathy ,Phase 2b,01/25/2024,"Phase 2b OLE data reported a 59% reduction in Gd-IgA1, a reduction in the percentage of participants with hematuria to 41%, and a 47% reduction in UPCR in the PP analysis, noted January 25, 2024.",63.0
CYTK,82.91,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM) ,Phase 2,01/25/2024,"Phase 2 sub-study data reported statistically significant improvements in measures of cardiac structure and function including left ventricular mass index (-11.4 g/m2 ±19.4, p=0.03), maximum left vent",119.0
EXEL,22.09,CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02),Castration-Resistant Prostate Cancer ,Phase 3,01/25/2024,"Phase 3 data presented at ASCO GU showed a reduction of the risk of disease progression or death by 35% in patients. While a trend toward OS improvement was observed, the data were immature and did no",269.0
IPSEY,27.99,CABOMETYX (cabozantinib) and TECENTRIQ (atezolizumab) - (CONTACT-02),Castration-Resistant Prostate Cancer ,Phase 3,01/25/2024,"Phase 3 data presented at ASCO GU showed a reduction of the risk of disease progression or death by 35% in patients. While a trend toward OS improvement was observed, the data were immature and did no",328.0
SRRK,14.91,SRK-439 with apitegromab - (EMBRAZE),Obesity ,Preclinical,01/25/2024,"Preclinical data supports the potential of SRK-439 to preserve lean muscle mass as part of healthy weight loss, noted January 25, 2024.",96.0
PCSA,5.1,NGC-Capecitabine (PCS6422),Gastrointestinal Cancer ,Phase 1b,01/25/2024,"Phase 1b preliminary efficacy data reported that of the 11 cancer patients receiving one of the two highest doses of NGC-Cap, five have completed an efficacy evaluation at this time, and four of these",50.0
EPIX,6.8,EPI-7386 and XTANDI (enzalutamide),Castration-resistant prostate cancer ,Phase 1/2,01/25/2024,"Phase 1/2 data due presented at ASCO GU reported that 88% of patients (14 of 16) achieved PSA50, 81% of patients (13 of 16) achieved PSA90, 69% of patients (11 of 16) achieved PSA90 in less than 90 da",47.0
REGN,948.87,Dupixent (dupilumab),Eosinophilic esophagitis (EoE) in 1-11 year olds ,Approved,01/25/2024,"Approved January 25, 2024.",105.0
SNY,47.88,Dupixent (dupilumab),Eosinophilic esophagitis (EoE) in 1-11 year olds ,Approved,01/25/2024,"Approved January 25, 2024.",
BMY,49.04,BMS-986365 (CC-94676) - (rechARge),Metastatic CRPC ,Phase 1,01/25/2024,"Phase 1 data reported that treatment induces effective and durable suppression of AR signaling, overcomes resistance to existing AR pathway inhibitors (ARPI) therapies and shows promising clinical act",
CRBP,29.49,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinoma ",Phase 1,01/26/2024,"Phase 1 dose escalation data from 2024 ASCO GU reported an ORR of 43% in the mixed tumor population, with no dose discontinuations or reductions in the study to date, noted January 26, 2024.",12.0
MRK,119.33,KEYTRUDA (pembrolizumab) - (AMBASSADOR (A031501) KEYNOTE-123),Localized muscle-invasive urothelial carcinoma (MIUC) ,Phase 3,01/26/2024,"Phase 3 data reported that treatment doubled median DFS as adjuvant therapy versus observation – 29 months versus 14 months, noted January 26, 2024.",
BMY,49.13,Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection,"Solid tumors, Metastatic clear cell renal cell carcinoma (ccRCC) ",Phase 3,01/27/2024,"Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.",
HALO,34.21,Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) Injection,"Solid tumors, Metastatic clear cell renal cell carcinoma (ccRCC) ",Phase 3,01/27/2024,"Phase 3 results presented at ASCO GU reported that with subcutaneous nivolumab demonstrating an ORR of 24.2% vs. 18.2% with IV Opdivo, noted January 27, 2024.",116.0
MRK,119.79,KEYTRUDA (KEYNOTE-564),Renal cell carcinoma (RCC) ,Phase 3,01/29/2024,"Additional Phase 3 data reported that treatment reduced the risk of disease recurrence or death by 32%, noted January 29, 2024.",
NNVC,1.17,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infection ",Phase 1b,01/29/2024,"Phase 1a/1b healthy subjects section of trial completed with no adverse events reported, noted January 29, 2024.",17.0
AZN,66.17,GC012F,Early-line treatment of multiple myeloma (ELMM). ,IND-Enabling,01/29/2024,"IND was cleared by the FDA on January 29, 2024.",
ACXP,3.68,Ibezapolstat,C. difficile Infection ,Phase 2b,01/29/2024,"Phase 2b trial showed that 100% (5 of 5) of ibezapolstat-treated patients who agreed to observation for up to three months following Clinical Cure of CDI experienced no recurrence of infection, noted",1.0
SRPT,120.5,SRP-5051 - (MOMENTUM),Duchenne muscular dystrophy ,Phase 2,01/29/2024,"Phase 2 data at target dose (~30 mg/kg), SRP-5051 dosed monthly resulted in mean dystrophin expression of 5.17% and mean exon skipping of 11.11% at 28 weeks (n=20), noted January 29, 2024.",97.0
PALI,14.4,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,01/29/2024,"Preclinical data demonstrated PALI-2108 to be safe and well tolerated, noted January 29, 2024.",9.0
TAK,14.77,GAMMAGARD LIQUID [Immune Globulin Infusion (Human) 10% solution],Adults with chronic inflammatory demyelinating polyneuropathy (CIDP) ,Approved,01/29/2024,"FDA Approved on January 29, 2024.",
LIXT,2.15,LB-100 with doxorubicin,Ovarian clear cell carcinoma (OCCC) ,Phase 1/2,01/29/2024,"Phase 1b/2 dosing was initiated, noted January 29, 2024.",4.0
IKT,3.21,Risvodetinib - (IkT-148009) - (201 trial),Parkinson’s disease ,Phase 1,01/29/2024,Phase 1 study published at Journal of Parkinson's Disease showed that data demonstrated that Risvodetinib was well tolerated up to 7 days of daily dosing with no serious adverse events in healthy volu,74.0
KRBP,1.77,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,01/29/2024,"Phase 1 efficacy results from first patient reported a stabilization of the disease, indicating a preliminary progression-free survival of one and one-half months, noted January 29, 2024.",1.0
ALVO,15.25,"AVT03-GL-P01 (denosumab) - (PROLIA Biosimilar, Xgeva Biosimilar)",Osteoporosis in postmenopausal women and for bone loss in adult men and women ,Phase 1,01/29/2024,"Pk trial met its primary endpoints, noted January 29, 2024.",301.0
RCUS,15.72,Domvanalimab + zimberelimab vs. zimberelimab vs. chemotherapy - (ARC-10),Non Small Cell Lung Cancer (NSCLC) ,Phase 3,01/30/2024,"Phase 3 trial discontinued January 30, 2024.",106.0
KURA,20.85,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML) ,Phase 1,01/30/2024,"Phase 1 combinations demonstrated encouraging preliminary evidence of clinical activity in patients with refractory/relapsed disease after failure of other agents, including venetoclax, a setting with",86.0
KYKOF,—,Ziftomenib (in combination with SoC cytarabine/daunorubicin (7+3) and venetoclax/azacitidine (ven/aza))- (KOMET-007),Acute myeloid leukemia (AML) ,Phase 1,01/30/2024,"Phase 1 combinations demonstrated encouraging preliminary evidence of clinical activity in patients with refractory/relapsed disease after failure of other agents, including venetoclax, a setting with",540.0
SCYX,1.96,SCY-247,Pulmonary mucormycosis ,Preclinical,01/30/2024,"Preclinical data reported that SCY-247 resulted in 40% and 50% survival at 21 days post infection for the intermediate (32 mg/kg) and high doses (48 mg/kg), respectively, compared to 0% survival in th",41.0
ITRM,1.58,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI) ,Phase 3,01/30/2024,"Phase 3 data met the primary endpoint of non-inferiority to augmentin; and demonstrated statistical superiority, noted January 30, 2024.",44.0
VRTX,446.08,Suzetrigine (VX-548),Acute Pain following bunionectomy or abdominoplasty surgery ,Phase 3,01/30/2024,"Phase 3 trial data reported a statistically significant improvement on the primary endpoint of the time-weighted sum of the pain intensity difference from 0 to 48 hours (SPID48) compared to placebo, n",256.0
NVS,99.74,Sabatolimab (MBG453) - (STIMULUS),Myelodysplastic syndromes (MDS) ,Phase 3,01/31/2024,"Phase 3 trial did not meet its primary endpoint, noted January 31, 2024.",
OTLK,7.72,ONS-5010 / LYTENAVA (bevacizumab-vikg) - (NORSE EIGHT),Wet age-related macular degeneration (wet AMD) ,Phase 3,01/31/2024,"Special Protocol Assessment (SPA) dosing initiated, noted January 31, 2024.",44.0
NVO,113.92,Semaglutide - (STEP HFpEF),"Heart failure with preserved ejection fraction (HFpEF) and obesity, Type 2 diabetes ",Phase 3,01/31/2024,"Phase 3 reported that KCCQ-CSS estimated treatment difference between semaglutide 2.4 mg and placebo of 7.8, noted January 31, 2024.",
RHHBY,32.97,Vabysmo - (BALATON),Macular edema due to branch and central retinal vein occlusion (BRVO and CRVO) ,Phase 3,02/01/2024,"Phase 3 data reported that patients who recieved Vabysmo as a first-line treatment gained 18.1 letters on the eye chart, while people switched from aflibercept to Vabysmo gained 18.8 letters, noted Fe",
EDAP,6.34,Transrectal High-intensity focused ultrasound (TR-HIFU),Rectal Deep Infiltrating Endometriosis ,Phase 3,02/01/2024,"Phase 3 enrolment completed, noted February 1, 2024.",37.0
AZN,64.65,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM) ,Phase 3,02/02/2024,"Additional Phase 3 data reported improved functions and quality of life at 30 months, noted February 2, 2024.",
BBIO,33.91,Attruby (Acoramidis) - (ATTRibute-CM),Amyloid cardiomyopathy (ATTR-CM) ,Phase 3,02/02/2024,"Additional Phase 3 data reported improved functions and quality of life at 30 months, noted February 2, 2024.",191.0
LQDA,13.58,L606 (liposomal treprostinil),Pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) ,Phase 2,02/02/2024,"Open-label trial data presented at the Pulmonary Vascular Research Institute (PVRI) reported that treatment demonstrate sustained plasma levels up to 12 hours, supporting twice daily administration, n",86.0
FDMT,17.49,4D-150 - (PRISM),Wet age-related macular degeneration (AMD) ,Phase 2,02/03/2024,"Phase 2 data reported that the high dose 4D-150 resulted in an 89% reduction in the annualized anti-VEGF injection rate; 84% of patients received 0 or 1 injection, and 63% were injection-free through",46.0
LCTX,0.98,RG6501 - (OpRegen),Geographic atrophy (GA) ,Phase 1/2,02/03/2024,"Additional Phase 1/2a data presented at the Angiogenesis, Exudation, and Degeneration Meeting reported that all patients with extensive delivery to GA showed improvement in outer retinal structure on",228.0
KOD,4.03,KSI-501 (KSI-501ABC) - (DAYBREAK),Retinal diseases w/ inflammatory component ,Phase 1,02/03/2024,"Phase 1 trial initial data presented at the Angiogenesis, Exudation, and Degeneration reported that monthly dosing of KSI-501 was safe and well-tolerated, noted February 3, 2024.",52.0
BRTX,3.45,BRTX-100,Chronic lumbar disc disease ,Phase 2,02/04/2024,"Phase 2 initial data presented at ORS reported that Visual Analog Scale, Oswestry Disability Index, Roland Morris Disability Questionnaire, and Functional Rating Index collected at weeks 26 and 52 pos",7.0
EYPT,27.79,DURAVYU (EYP-1901) - (LUGANO),Wet age-related macular degeneration (AMD) ,Phase 2,02/05/2024,"Phase 2 subgroup analysis reported numerical superiority in change in BCVA along with strong anatomic control compared to the aflibercept control group, noted February 5, 2024.",68.0
KYKOF,15.85,OTL-203 - (HURCULES),Mucopolysaccharidosis type I (MPS-I) ,Phase 3,02/05/2024,"Global Phase 3 registrational trial enrolment initiated across the US and Europe, noted February 5, 2024.",540.0
PLRX,15.8,Bexotegrast (PLN-74809) - (INTEGRIS-PSC),Primary sclerosing cholangitis (PSC) ,Phase 2a,02/05/2024,"Phase 2a data reported that 320 mg group met its primary and secondary endpoints demonstrating that bexotegrast was well tolerated over a 12-week treatment period, noted February 5, 2024.",61.0
RANI,3.69,"RT-111 (RaniPill Containing Ustekinumab Biosimilar, CT-P43)","Plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn's disease, and moderate to severe ulcerative colitis ",Phase 1,02/05/2024,Phase 1 data showed that it well-tolerated and delivered ustekinumab with high bioavailability. Data provided clinical validation of our ability to successfully transform an injectable large molecule,71.0
THAR,6.15,TH104 (AV104),Primary biliary cholangitis (PBC) ,Phase 1,02/05/2024,"Phase 1 dosing of first patient completed, noted February 5, 2024.",4.0
ARCT,35.07,Kostaive (ARCT-154),COVID-19 variant vaccine ,Phase 3,02/05/2024,"Phase 3 results demonstrated continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response, noted February 5, 2024.",27.0
CSLLY,96.43,Kostaive (ARCT-154),COVID-19 variant vaccine ,Phase 3,02/05/2024,"Phase 3 results demonstrated continuous advantage of sa-mRNA over conventional mRNA vaccine in terms of duration of immune response, noted February 5, 2024.",968.0
AIMD,1.08,VELDONA,Mild COVID-19 ,Phase 2,02/05/2024,"Company submitted the clinical hold complete response to the FDA for conducting a Phase 2 trial of its low-dose oral interferon (IFN)-alpha formulation, noted February 5, 2024.",4.0
VRTX,428.89,VX-121/tezacaftor/VX-561 - (SKYLINE-102),Cystic Fibrosis ,Phase 3,02/05/2024,"Phase 3 study met all primary and key secondary endpoints in two randomized controlled trials in people with CF ages 12 years and older, noted February 5, 2024.",256.0
GSK,41.01,Blenrep,Multiple myeloma ,Phase 3,02/06/2024,"Additional Phase 3 data reported a 59% reduction in risk of disease progression or death, noted February 6, 2024.",
SGMO,0.52,Civaparvovec (ST-920) - (STAAR),Fabry disease ,Phase 1/2,02/06/2024,Phase 1/2 clinical data reported a statistically significant improvements in disease severity were reported in the Fabry Outcome Survey adaptation of the Mainz Severity Score Index (FOS-MSSI) age-adju,301.0
LLY,702.66,Tirzepatide - (SYNERGY-NASH),"Nonalcoholic steatohepatitis (NASH), Metabolic dysfunction-associated steatohepatitis (MASH) ",Phase 2,02/06/2024,"Phase 2 trial met its primary endpoint, noted February 6, 2024.",946.0
GANX,4.47,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Preclinical,02/06/2024,"Preclinical data presented at the WORLDSymposium reported that GT-02287 restored motor function in a mouse model, even following a delayed administration of the drug candidate after the initial toxic",35.0
LLY,702.66,VERZENIO (Abemaciclib) - (CYCLONE-2),Prostate Cancer ,Phase 3,02/06/2024,"Phase 3 trial was not successful, noted February 6, 2024.",946.0
ABEO,4.3,UX111 - (ABO-102),Sanfilippo syndrome type A (MPS IIIA) ,Phase 1/2,02/06/2024,"Phase 1/2 presented at the WORLDSymposium demonstrated treatment resulted in rapid and sustained decreased levels of heparan sulfate, noted February 6, 2024.",51.0
RARE,45.89,UX111 - (ABO-102),Sanfilippo syndrome type A (MPS IIIA) ,Phase 1/2,02/06/2024,"Phase 1/2 presented at the WORLDSymposium demonstrated treatment resulted in rapid and sustained decreased levels of heparan sulfate, noted February 6, 2024.",96.0
INKT,0.94,AGENT-797,Acute respiratory distress (ARDS) secondary to COVID-19 ,Phase 1/2,02/06/2024,"Phase 1/2 data showed that agenT-797 holds significant promise in improving patient survival and reducing secondary infections, all while maintaining a favorable safety profile, noted February 6, 2024",4.0
REGN,—,Libtayo (cemiplimab-rwlc),High-risk cutaneous squamous cell carcinoma (CSCC) after surgery ,Phase 3,02/06/2024,"Phase 3 data from ASCO reported a 68% reduction in the risk of disease recurrence or death, noted June 2, 2025.",105.0
HCM,13.7,Fruquintinib and Paclitaxel - (FRUTIGA),Gastric Cancer ,Phase 3,02/07/2024,"Phase 3 data presented at ASCO plenary series noted that the median PFS for patients who received fruquintinib plus paclitaxel was 5.6 months, compared to 2.7 months for those who received paclitaxel",174.0
RGNX,14.57,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD) ,Phase 1/2,02/07/2024,"Phase 1/2 dose 2 levels completed; additionally, the company reported interim safety and efficacy data where the third patient at dose level 1 demonstrates the largest increase in microdystrophin expr",50.0
VRPX,3.81,Probudur,Post-operative pain ,Phase 2,02/07/2024,"Phase 2 initial data reported that two doses of Probudur showed reduction in incision-induced pain behaviors, noted February 7, 2023.",1.0
BCTX,3.94,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,02/07/2024,"Additional Phase 2 data reported a disease control rate of 50%, noted February 7, 2024.",1.0
ALEC,6.4,Latozinemab (AL001) - (INFRONT-3),Frontotemporal Dementia ,Phase 3,02/07/2024,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",101.0
GSK,41.27,Latozinemab (AL001) - (INFRONT-3),Frontotemporal Dementia ,Phase 3,02/07/2024,"Breakthrough Therapy Designation granted by the FDA, noted February 7, 2024",
SAVA,25.4,Simufilam (PTI-125) - (RETHINK-ALZ),Alzheimer’s disease ,Phase 3,02/07/2024,"Phase 3 24-month data reported that treated patients scores declined by an average of 1.04 points on ADAS-Cog11, noted February 7, 2024.",48.0
RGNX,14.57,clemidsogene lanparvovec (RGX-121) - (CAMPSIITE),MPS II (Hunter Syndrome) ,Phase 3,02/07/2024,"Phase 3 topline data reported that trial met primary endpoint, noted February 7, 2024.",50.0
DNLI,16.95,DNL126,MPS IIIA (Sanfilippo syndrome Type A) ,Preclinical,02/07/2024,"Preclinical mouse-model data shared at the WORLDSymposium reported that ETV:SGSH lowered substrate accumulation in the CNS and improved cognitive deficits, noted February 7, 2024.",146.0
DNLI,16.95,Tividenofusp alfa (DNL310) - (COMPASS),Hunter syndrome MPS II ,Phase 1/2,02/07/2024,"Phase 1/2 data at WORLDSymposium showed additional improvement and stabilization in clinical outcomes in MPS II with 104 weeks of tividenofusp alfa (DNL310) treatment in the open-label, single-arm stu",146.0
ALEC,6.25,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD) ,Phase 2,02/08/2024,"Phase 2 dosing initiated, noted February 8, 2024.",101.0
GSK,41.08,AL101/GSK4527226 - (PROGRESS-AD),Early Alzheimer's disease (AD) ,Phase 2,02/08/2024,"Phase 2 dosing initiated, noted February 8, 2024.",
ADVM,19.7,"Ixo-vec (ixoberogene soroparvovec, ADVM-022) - (ARTEMIS)",Wet age-related macular degeneration (AMD) ,Phase 2,02/08/2024,"Phase 2 data presented at the Macula Society Annual Meeting on the 2E11 and 6E10 doses demonstrated maintenance of visual and anatomic outcomes, noted February 8, 2024.",20.0
AIM,0.38,Ampligen (AMP-518),Post-COVID conditions ,Phase 2,02/08/2024,ase 2 efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions. Safety results showed Ampligen is generally well tolerated in the treatment o,2.0
BDRX,1.3,MTX110 - (MAGIC-G1),Recurrent Glioblastoma (GBM) ,Phase 1,02/08/2024,"Phase 1 PFS data reported that one patient had a survival rate of 12 months from the start of treatment, while 3 patients remain in the study, noted February 8, 2024.",
AMLX,15.46,AMX0035 - (HELIOS),Wolfram Syndrome ,Phase 2,02/08/2024,"Phase 2 enrollment completed, noted February 8, 2024.",89.0
ATHA,3.17,ATH-1105,Amyotrophic Lateral Sclerosis (ALS) ,Preclinical,02/08/2024,"Preclinical data reported that ATH-1105 treatment results in significant, consistent beneficial effects both in cell culture and in vivo models of ALS, noted February 8, 2024.",3.0
TAK,13.95,Oveporexton (TAK-861-2001),Narcolepsy type 1 (NT1) ,Phase 2b,02/09/2024,"Phase 2b trial met its primary and secondary endpoints, noted February 9, 2024.",
CNTA,9.26,SerpinPC - (PRESent-3),Hemophilia B ,Phase 2a,02/09/2024,"Phase 2a data presented at EAHAD reinforce confidence in SerpinPC's novel mechanism of action as we continue to advance the registrational studies, noted February 9, 2024.",134.0
OKYO,1.71,Urcosimod (OK-101),Neuropathic corneal pain (NCP) ,IND-Enabling,02/09/2024,"IND cleared by the FDA, noted February 9, 2024.",33.0
NRXP,5.12,NRX-101,Bipolar Depression and Suicidal Ideation ,Phase 2/3,02/09/2024,"hase 2b/3 enrollment completed, noted February 9, 2024.",19.0
IRON,68.29,MWTX-003 - (DISC-3405),Polycythemia vera (PV) ,Phase 1,02/09/2024,"Orphan drug designation granted by the FDA on February 9, 2024",34.0
ANTX,5.1,EBO-301,Treatment-Refractory MAC Lung Disease ,Phase 2/3,02/12/2024,"Phase 2/3 enrollment voluntary pause enables time to evaluate study data further and for the independent DSMB to conduct an unblinded assessment and recommend next steps, which could include changes t",27.0
CSLLY,94.17,CSL112 -(AEGIS-II),Acute myocardial infarction (AMI) ,Phase 3,02/12/2024,"Phase 3 study did not meet its primary endpoint, noted February 12, 2024.",968.0
LRMR,7.83,Nomlabofusp (CTI-1601),Friedreich’s ataxia (FA) ,Phase 2,02/12/2024,"Phase 2 study showed that treatment was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events, noted February 12, 2",85.0
BTAI,1.95,BXCL701 and KEYTRUDA (pembrolizumab),Neuroendocrine Prostate Cancer (NEPC) ,Phase 2a,02/12/2024,"Fast Track designation granted by the FDA on February 12, 2024.",14.0
PYPD,6.84,D-PLEX100 - (SHIELD II),Surgical Site Infection ,Phase 3,02/12/2024,"Phase 3 trial 100th patient enrollment, noted February 12, 2024.",10.0
NUVL,83.55,Neladalkib (NVL-655) - (ALKove-1),ALK non-small cell lung cancer (NSCLC) ,Phase 1/2,02/12/2024,"Phase 1/2 trial initiated, noted February 12, 2024.",72.0
TAK,14.02,EOHILIA (budesonide oral suspension),People 11 years and older with eosinophilic esophagitis (EoE) ,Approved,02/12/2024,"FDA approved on February 12, 2024.",
JAGX,5.36,Mytesi (crofelemer),Moderate-to-severe diarrhea including Vibrio cholerae ,Phase 1,02/12/2024,"Orphan Drug Designation (ODD) submited to the FDA, noted February 12, 2024.",2.0
SGMO,0.81,Civaparvovec (ST-920) - (STAAR),Fabry disease ,Phase 1/2,02/12/2024,"Type-D meeting with the FDA agreed in a that data from a single, adequate, and well-controlled study may form the primary basis of approval of a BLA for isaralgagene civaparvovec, noted February 12, 2",301.0
TNXP,11.84,TNX-102 SL - (OASIS),"Acute stress reaction (ASR), acute stress disorder (ASD), and posttraumatic stress disorder (PTSD) ",Phase 2,02/12/2024,"FDA Cleared IND on February 12, 2024.",8.0
ANIX,4.46,Chimeric endocrine receptor T-cell (CER-T),Ovarian Cancer ,Phase 1,02/12/2024,"Phase 1 2nd cohort dosing initiated, noted February 12, 2024.",32.0
KTRA,0.12,REM-001,Cutaneous Metastatic Breast Cancer (CMBC) ,Phase 3,02/12/2024,"Phase 3 was initiated, noted February 12, 2024.",55.0
FDMT,27.85,4D-310 - (INGLAXA),Fabry Disease ,Phase 1/2,02/12/2024,"Phase 1/2 interim data presented at the WORLDSymposium 2024 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiop",46.0
PHRRF,0.13,KETARX (ketamine),Surgical pain management ,ANDA Filing,02/12/2024,"ANDA continues to be under review by the FDA and has provided preliminary thoughts on possible deficiencies identified by Quality, noted February 12, 2024.",91.0
BMRN,88.18,Valoctocogene roxaparvovec (BMN 270-303) - (GENEr8-3),Hemophilia A ,Phase 3,02/12/2024,"Phase 3 trial data presented at EAHAD after liver biopsy analysis suggests efficient hepatocyte transduction occurred, noted February 9, 2024.",192.0
KRYS,108.73,KB707 - (KYANITE-1),Solid Tumors ,IND-Enabling,02/13/2024,"The FDA cleared IND and granted fast-track designation on February 13, 2024.",28.0
KALV,14.85,EKTERLY (sebetralstat),Hereditary Angioedema (HAE) ,Phase 3,02/13/2024,"Phase 3 clinical trial met all primary and key secondary endpoints and demonstrated a favorable safety profile, noted February 13, 2024.",50.0
CADL,1.8,CAN-3110,Glioma ,Phase 1,02/13/2024,"Fast track designation granted by the FDA on February 13, 2024.",54.0
LCTX,1.02,AST-OPC1 SCiSTAR - (DOSED),Cervical spinal cord injury ,IND-Enabling,02/13/2024,"INDa cleared by the FDA on February 13, 2024.",228.0
RCKT,28.97,KRESLADI (marnetegragene autotemcel),Leukocyte Adhesion Deficiency-I (LAD-I) ,PDUFA,02/13/2024,"PDUFA date extended by 3 months to June 30, 2024.",107.0
CALC,5.23,Auxora - (KOURAGE),Acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) ,IND-Enabling,02/13/2024,"IND cleared by the FDA, noted February 13, 2024.",13.0
ROIV,10.8,RVT-2001,Transfusion-Dependent Anemia in Patients with Lower-Risk MDS ,Phase 1/2,02/13/2024,Phase 1/2 development discontinued after interim data analysis.,682.0
PTIX,0.97,PT00114,Major Depressive Disorder (MDD) / Generalized Anxiety Disorder (GAD) / Post-Traumatic Stress Disorder (PTSD) ,Phase 1/2,02/13/2024,"Phase 1/2 demonstrated safety at a low dose of 125 micrograms in the initial cohort of patients, with zero reported adverse reactions among subjects, noted February 13, 2024.",
PBYI,6.21,Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1),Small Cell Lung Cancer (SCLC) ,Phase 2,02/13/2024,"Phase 2 was initiated, noted on February 13, 2024.",50.0
OCUL,5.62,AXPAXLI (OTX-TKI) - (SOL-1),Wet Age-related Macular Degeneration (AMD) ,Phase 3,02/13/2024,"Phase 3 first three subjects have been screened and dosed with first aflibercept injection, noted February 13, 2024.",174.0
MACK,7.51,Onivyde (NALIRIFOX),Pancreatic cancer ,Approved,02/13/2024,"FDA Approved on February 13, 2024.",14.0
IPSEY,27.94,Onivyde (NALIRIFOX),Pancreatic cancer ,Approved,02/13/2024,"FDA Approved on February 13, 2024.",328.0
TAK,14.05,Eohilia (formerly TAK-721),Eosinophilic esophagitis ,Approved,02/13/2024,"Approved February 13, 2024.",
OPT,2.92,Sozinibercept (OPT-302) with Aflibercept - (COAST),Age-related macular degeneration (AMD) ,Phase 3,02/14/2024,"Phase 3 patient enrollment completed, noted February 14, 2024.",171.0
KRBP,2.56,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,02/14/2024,"Phase 1 initiated, noted February 14, 2024.",1.0
DTIL,11.99,PBGENE-HBV - (ELIMINATE-B),Chronic Hepatitis B Virus (HBV) ,Preclinical,02/14/2024,"Pre-IND meeting with FDA provided feedback on overall design for the proposed first-in-human clinical study as well as feedback on the toxicology and specificity assessments, noted February 14, 2024.",11.0
GLSI,10.2,GP2 (GLSI-100) - (FLAMINGO-01),HER2 positive breast cancer ,Phase 3,02/14/2024,"DSMB recommended to continue the study as is without modification. No serious adverse events related to GLSI-100 have been reported to date, noted February 14 2024.",13.0
ARVN,49.37,Vepdegestrant (ARV-471) - (TACTIVE-U),Solid Tumors ,Phase 1b,02/14/2024,"Phase 1b umbrella trial combination to be initiated in other arms, noted February 14, 2024.",73.0
AZN,60.73,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,02/14/2024,"Phase 1b/2 dosing commenced on February 14, 2024.",
AIM,0.41,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,02/14/2024,"Phase 1b/2 dosing commenced on February 14, 2024.",2.0
ATRA,19.26,ATA3219,"B-cell non-Hodgkin's lymphoma (NHL), Lupus Nephritis ",Preclinical,02/14/2024,"IND submitted to the FDA, noted February 14, 2024.",7.0
ANVS,10.37,Buntanetap (ANVS401),Alzheimer’s disease (AD) ,Phase 2/3,02/14/2024,"Phase 2/3 last patient completed, noted February 14, 2024.",19.0
SILO,1.69,SP-26,Fibromyalgia / Chornic pain ,Preclinical,02/14/2024,"The preclinical study demonstrated successful drug delivery, noted February 14, 2024.",9.0
INKT,1,"Botensilimab plus balstilimab, agenT-797",Gastric cancer ,Phase 2,02/14/2024,"Phase 2 trial initiated, noted February 14, 2024.",4.0
AMPE,1.82,OA-201,Osteoarthritis ,Preclinical,02/14/2024,Preclinical efficacy results from recently completed pre-IND enabling studies with OA-201 reported that the efficacy results of these studies do not support an Investigational New Drug (IND) submissio,1.0
MESO,1.93,Revascor (Rexlemestrocel-L) - (DREAM-HF),Heart failure ,Phase 3,02/14/2024,"Orphan drug designation was granted on February 14, 2024.",128.0
RPTX,6.95,RP-1664 - (LIONS),Adult and adolescent with TRIM37-high tumor cells to treat Solid Tumors ,Phase 1,02/15/2024,"Phase 1 dosing initiated, noted February 15, 2024.",42.0
APLT,3.75,govorestat (AT-007) - (INSPIRE),Sorbitol Dehydrogenase Deficiency (SORD Deficiency) ,Phase 3,02/15/2024,"Phase 3 study met the interim primary endpoint, noted February 15, 2024.",144.0
IONS,45.28,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS) ,Phase 3,02/15/2024,"Orphan Drug Designation granted by the FDA, noted February 15, 2024.",159.0
CRDL,1.48,CardiolRx - (MAvERIC-Pilot),Recurrent Pericarditis ,Phase 2,02/15/2024,"FDA has granted Orphan Drug Designation (ODD), noted February 15, 2024.",83.0
ONCY,1.16,Pelareorep and mFOLFIRINOX with and without atezolizumab - (GOBLET),Colorectal and advanced anal cancers ,Phase 1,02/15/2024,"Phase 1 Stage 1 data showed a near tripling of Objective Response Rate compared to checkpoint inhibitor monotherapy, including a Complete Response, and supports expansion, additionally an enrollment e",100.0
MNKD,3.71,Afrezza (Technosphere Insulin) - (INHALE-1),Pediatric type 1/2 diabetes ,Phase 3,02/15/2024,"Phase 3 enrollment goal reached, noted February 15, 2024.",306.0
AUPH,6.02,Aritinercept (AUR200),BAFF/APRIL (B-Cell Activating Factor) ,Phase 1,02/15/2024,"Phase 1 was discontinued due to resource allocation, noted February 15, 2024.",135.0
AUPH,6.02,AUR300,M2 Macrophage ,IND-Enabling,02/15/2024,"The trial was discontinued due to resource allocation, noted on February 15, 2024.",135.0
ENSC,0.89,PF614-102,Severe pain ,Phase 3,02/15/2024,"Phase 3 additional results from the two-part PF614‑102 study are very significant as we believe they demonstrate a clear dose relationship between PF614 and oxycodone, which is the foundation for the",2.0
FBIO,1.86,Triplex - (COLT),Cytomegalovirus (CMV) ,Phase 1,02/16/2024,Phase 1 data results demonstrated the potential benefit of vaccinating donors with dose to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transpla,29.0
CASI,5.8,FOLOTYN (Pralatrexate Injection) - (PROPEL),Peripheral T-cell lymphoma ,Phase 1,02/16/2024,"Phase 1 dosing initiated in China, noted February 16, 2024.",15.0
RHHBY,31.01,XOLAIR (omalizumab) - (OUtMATCH),Food allergy ,Approved,02/16/2024,"FDA Approved on February 16, 2024.",
IOVA,9.15,AMTAGVI (Lifileucel (LN-144)) - (TILVANCE-301),Refractory metastatic melanoma ,Approved,02/16/2024,"FDA Approved on February 16, 2024.",361.0
AZN,63.3,TAGRISSO (Osimertinib) - (FLAURA2),Non-small cell lung cancer (NSCLC) ,Approved,02/17/2024,"Approved February 17, 2024.",
AZN,64.06,TAGRISSO (osimertinib) - (LAURA),"Unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) ",Phase 3,02/19/2024,"Phase 3 data reported that the trial showed statistically significant and highly clinically meaningful improvement in progression-free survival (PFS), noted February 19, 2024.",
RAPT,6.87,Zelnecirnon (RPT193),Asthma ,Phase 2a,02/20/2024,"Phase 2a trial initiated March 29, 2023. Phase 2a trial placed on clinical hold February 20, 2024.",16.0
RAPT,6.87,Zelnecirnon (RPT193),Atopic dermatitis ,Phase 2a,02/20/2024,"Phase 2b trial initiated May 23, 2022. Phase 2b trial placed on hold February 20, 2024.",16.0
IMRX,6.76,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanoma ",Phase 1,02/20/2024,"Fast Track Designation granted by the FDA on February 20, 2024.",36.0
IRON,66.42,DISC-0974,Patients with non-dialysis dependent chronic kidney disease (NDD-CKD) and anemia ,Phase 1/2,02/20/2024,"Phase 1b/2 ongoing. FDA granted Fast Track designation, noted February 20, 2024.",34.0
SNY,44.97,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD) ,Phase 2b,02/20/2024,"PK data reported rapid and sustained suppression of free TL1A, noted February 20, 2024.",
TEVA,13.07,Duvakitug (TEV-'574/SAR447189) - (RELIEVE UCCD),Moderate-to-severe inflammatory bowel disease (IBD); this includes ulcerative colitis (UC) and Crohn's disease (CD) ,Phase 2b,02/20/2024,"PK data reported rapid and sustained suppression of free TL1A, noted February 20, 2024.",
ARVN,50.6,ARV-102,Parkinson's Disease in Healthy Volunteers ,Phase 1,02/20/2024,"Phase 1 dosing commenced, noted February 20, 2024.",73.0
SPRY,7.52,Neffy (epinephrine nasal spray),Allergic reactions (type I) including anaphylaxis ,Phase 3,02/20/2024,Phase 3 topline data showed that Repeated doses of neffy under nasal allergen challenge demonstrated a pharmacokinetic profile greater than or similar to injection and a pharmacodynamic profile greate,98.0
JNJ,156.58,TECVAYLI (teclistamab),Relapsed or refractory (R/R) multiple myeloma. ,Approved,02/20/2024,"Supplemental approval granted by the FDA, noted February 20, 2024.",
GSK,41.19,Cabenuva (cabotegravir + rilpivirine) - (LATITUDE),HIV ,Phase 3,02/21/2024,"Phase 3 interim data reported that demonstrated superior efficacy in maintaining viral load suppression compared to daily oral therapy in individuals with a history of ART adherence challenges, noted",
KZIA,0.32,Paxalisib (GDC-0084) with radiotherapy,Brain Metastases ,Phase 1,02/21/2024,"Phase 1 trial met its primary endpoint, noted February 21, 2024.",1.0
ENLV,3.22,Allocetra,Sepsis ,Phase 2,02/21/2024,"Phase 2 enrollment completed, noted February 21, 2024.",23.0
NRSN,1.25,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,02/21/2024,"Additional Phase 2b 6 month data reported a reduction of the risk of ALS disease complications or death by up to 53%, noted February 21, 2024.",23.0
MNPR,1.12,MNPR-101-Zr (uPAR),Solid tumors ,Preclinical,02/22/2024,"Preclinical data to date demonstrated compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes, noted February 22, 2024.",6.0
ELEV,2.7,EO-3021 (SYSA1801) with ramucirumab + dostarlimab,Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2 ,Phase 1,02/22/2024,"Phase 1 first patient dosed in Japan, noted February 22, 2024.",59.0
TARS,31.54,TP-05 - (Carpo),Lyme disease ,Phase 2a,02/22/2024,"Phase 2a data demonstrated a statistically significant benefit in killing ticks compared to placebo, noted February 22, 2024.",42.0
ATXI,10.67,BAER-101,Absence epilepsy ,Preclinical,02/22/2024,"Preclinical data reported full suppression of seizure activity with a minimal effective dose (MED) of 0.3 mg/kg, noted February 22, 2024.",3.0
PHVS,27.78,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic use ,Phase 2,02/22/2024,Phase 2 data reported that deucrictibant significantly reduced the monthly attack rate by 84.5% (p=0.0008) in participants dosed at 40 mg/day and 79.3% (p=0.0009) in participants dosed at 20 mg/day co,54.0
ATNM,6.74,Iomab-B - (SIERRA),Acute myeloid leukemia (AML) ,Phase 3,02/22/2024,"Phase 3 data shared at ASTCT reported that a median overall survival of 5.49 months versus 1.66 months, noted February 22, 2023.",31.0
GMDA,0.36,NAM-NK (GDA-201),Follicular and diffuse large B cell lymphomas ,Phase 1/2,02/22/2024,"Phase 1/2 results presented at the Tandem Meetings, Transplantation & Cellular Therapy (TCT) Meetings reported that EAP data for omidubicel are consistent with Phase 3 trial results, noted February 2",154.0
VTYX,5.77,Tamuzimod (VTX002),Ulcerative Colitis (UC) ,Phase 2,02/22/2024,"Phase 2 open-label extension data reported that both both doses of VTX002 achieved nominal statistical significance for all key secondary endpoints, noted February 22, 2024.",71.0
REGN,981.2,Dupixent (dupilumab) - (NOTUS),Chronic obstructive pulmonary disease (COPD) ,PDUFA priority review,02/23/2024,"PDUFA Priority Review date June 27, 2024.",105.0
BDRX,1.49,Tolimidone,Type 2 diabetes ,Preclinical,02/23/2024,"Preclinical data reported inconclusive data, noted February 23, 2024.",
COGT,7.44,Bezuclastinib - (SUMMIT),Non-Advanced Systemic Mastocytosis ,Phase 1b,02/23/2024,"Additional Part 1b data from AAAAI reported that 51% week 12 mean change in Total Symptom Score (TSS), including 70% of patients achieving ≥50% reduction in TSS at week 12, noted February 23, 2024.",139.0
CMND,1.88,CMND-100,Alcohol use disorder (AUD) ,Phase 1/2,02/23/2024,"Phase 1/2a approval to commence dosing, noted February 23, 2024.",5.0
BDRX,1.49,MTX110 - (PNOC015),Diffuse Midline Glioma (DMG) ,Phase 1,02/23/2024,"Phase 1 results reported that the median overall survival (OS) of patients in the study was 16.5 months, noted February 23, 2024.",
TEVA,12.89,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseases ,Approved,02/23/2024,"Approved February 23, 2024.",
ALVO,16.03,SIMLANDI (adalimumab-ryvk) - (Humira biosimilar),Inflammatory diseases ,Approved,02/23/2024,"Approved February 23, 2024.",301.0
CLDX,37.75,Barzolvolimab (CDX-0159),Chronic spontaneous urticaria (CSU) ,Phase 2,02/24/2024,"Phase 2 data presented at AAAAI reported that treatment demonstrated strong improvement in UAS7 independent of omalizumab status at Week 12, noted February 24, 2024.",66.0
KALV,13.69,EKTERLY (sebetralstat),Hereditary Angioedema (HAE) ,Phase 3,02/25/2024,"Phase 3 additional data presented at AAAAI reported that 94% of attacks required only one dose to achieve primary endpoint, noted February 25, 2024.",50.0
GSK,41.99,Blujepa (Gepotidacin) - (EAGLE 2/3),Uncomplicated urinary tract infection (uUTI) ,Phase 3,02/26/2024,"EAGLE-1 trial met its primary endpoint, noted February 26, 2024.",
ALLK,1.46,AK006,Prurigo nodularis ,Preclinical,02/26/2024,"Preclinical data presented at AAAAI showed evidence of MRGPRX2 mast cell activation and activated macrophages on skin lesions, noted February 26, 2024.",90.0
KRYS,157,KB407 - (CORAL-1),Cystic Fibrosis ,Phase 1,02/26/2024,"Phase 1 data reported that no severe or serious adverse events were observed in patients treated in Cohort 1, noted February 26, 2024.",28.0
TNYA,5.69,TN-301,Heart Failure with Preserved Ejection Fraction ,Preclinical,02/26/2024,"Preclinical data reported that treatment achieved comparable or superior efficacy and was shown to have a distinctive multi-modal mechanism of action versus empagliflozin, noted February 26, 2024.",162.0
BGNE,160.26,BRUKINSA (zanubrutinib) + Obinutuzumab - (ROSEWOOD),Follicular Non-Hodgkin Lymphoma ,Approved,02/26/2024,"Approval noted February 26, 2024.",106.0
ONC,—,BRUKINSA (zanubrutinib) + Obinutuzumab - (ROSEWOOD),Follicular Non-Hodgkin Lymphoma ,Approved,02/26/2024,"Approval noted February 26, 2024.",110.0
TCRX,6.79,"TSC-100, TSC-101 - (ALLOHA)",Hematologic malignancies ,Phase 1,02/26/2024,"Phase 1 presented at Tandem Meetings showed that all eight (100%) treatment-arm patients are relapse-free and have achieved and maintained complete donor chimerism following treatment, noted February",56.0
MTNB,0.27,Oral amphotericin b (MAT2203) - (EnACT),Cryptococcal meningitis ,Phase 3,02/26/2024,"Phase 3 update from ongoing Compassionate/Expanded use access of the 19 patients enrolled in the program, 15 have available follow-up and 4 recently initiated or will soon commence treatment with MAT2",5.0
JANX,15.1,PSMA-TRACTr (JANX007) - (ENGAGER-PSMA-01),Metastatic castration-resistant prostate cancer (mCPRC) ,Phase 1,02/26/2024,"Phase 1 updated clinical data at KOL illustrated a potential best-in-class profile: promising efficacy with favorable safety profile in heavily pretreated subjects with late-stage mCRPC, noted Februar",60.0
JANX,15.1,EGFR-TRACTr (JANX008),"Metastatic colorectal cancer (mCRC), squamous cell carcinoma of the head and neck (SCCHN) and non-small cell lung cancer (NSCLC) ",Phase 1,02/26/2024,"Phase 1 data at KOL display differentiated safety and encouraging signs of efficacy in heavily pretreated subjects with different solid tumor types, noted February 26, 2024.",60.0
GILD,71.36,Biktarvy,HIV ,Approved,02/26/2024,"Approved for expanded indication to treat people with HIV (PWH) who have suppressed viral loads with known or suspected M184V/I resistance, noted February 26, 2024.",
NERV,2.8,Roluperidone (MIN-101),Schizophrenia ,CRL,02/27/2024,"CRL issued by the FDA, noted February 27, 2024.",6.0
VKTX,85.05,VK2735 - (VENTURE),Obesity ,Phase 2,02/27/2024,"Phase 2 study met primary and all secondary endpoints, demonstrating reductions in body weight, noted February 27, 2024.",113.0
TARS,39.22,TP-04 - (Galatea),Rosacea ,Phase 2a,02/27/2024,Phase 2a topline data reported statistically significant improvements (p<0.05) in inflammatory lesions and Investigator's Global Assessment (IGA) score compared to vehicle at Week 12 TP-04 was genera,42.0
ACXP,3.13,Ibezapolstat,C. difficile Infection ,Phase 2b,02/27/2024,"Phase 2b FDA confirmed that trial adequate information was submitted for EoP2 meeting, noted February 27, 2024.",1.0
CGON,46.35,cretostimogene - (PIVOT-006) (EAP),Non-Muscle Invasive Bladder Cancer (NMIBC) ,Phase 3,02/27/2024,"Phase 3 dosing initiated, noted February 27, 2024.",76.0
PPBT,0.67,NT219 in combination with cetuximab,Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) ,Phase 1,02/27/2024,"Phase 2 was well tolerated with anti-tumor activity at relevant higher dose levels observed with 29% Objective Response Rate (ORR) and 71% Disease Control Rate (DCR), noted February 27, 2024.",2.0
GANX,4.63,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Phase 1,02/27/2024,"Phase 1 dosing initiated, noted February 27, 2024.",35.0
PTN,2.45,PL9643 - (MELODY-1),Dry eye disease (DED) ,Phase 3,02/28/2024,"Phase 3 final results reported met the first co-primary endpoint in the Intent-to-Treat Analysis, however did not meet the co-primary endpoint showing superiority over vehicle, noted February 28, 2024. read less",46.0
IXHL,6.27,PSX-001 (Psilocybin treatment) - (PsiGAD2),Generalized anxiety disorder (GAD) ,Phase 2,02/28/2024,"Phase 2 topline data reported that the trial met its primary endpoint, noted February 28, 2024.",347.0
CMPX,1.74,CTX-8371,Solid Tumors ,Preclinical,02/28/2024,"Preclinical data reported that CTX-8371 demonstrates enhanced anti-tumor activity relative to approved anti-PD-1 blockers and anti-PD-L1 blockers in a series of in vitro and in vivo experimental settings, noted February 28, 2024. read less",138.0
SILO,1.62,SPC-15,Post-traumatic stress disorder (PTSD) ,Preclinical,02/28/2024,"Preclinical data reported rapid absorption of SPC-15 with good exposure over a 24-hour period, suggesting a once-per-day human intranasal dosing regimen would be optimal, noted February 28, 2024.",9.0
HCM,15.21,Amdizalisib (HMPL-689),Follicular Lymphoma and Marginal Zone Lymphoma ,Phase 2,02/28/2024,"Phase 2 topline FL results reported that the trial met its primary endpoint, noted February 28, 2024.",174.0
SNSE,0.84,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancer ,Phase 1,02/28/2024,"Phase 1 initial safety data reported that in the monotherapy dose escalation arm, 13/16 patients (81%) experienced at least one treatment-emergent adverse event (TEAE), with the majority of adverse events (AEs) Grade 1 or 2. In the combination dose escalation arm, 10/17 patients (59%) experienced at least one TEAE, with the majority of AEs Grade 1 or 2, noted February 28, 2024. read less",1.0
REGN,987.61,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancer ,Phase 1,02/28/2024,"Phase 1 initial safety data reported that in the monotherapy dose escalation arm, 13/16 patients (81%) experienced at least one treatment-emergent adverse event (TEAE), with the majority of adverse events (AEs) Grade 1 or 2. In the combination dose escalation arm, 10/17 patients (59%) experienced at least one TEAE, with the majority of AEs Grade 1 or 2, noted February 28, 2024. read less",105.0
VANI,3.74,NPM-115 (exenatide implant) - (LIBERATE-1),Subdermal implants in development for chronic weight management ,Preclinical,02/28/2024,"Preclinical data showed that implant generated significant weight loss comparable to injectable semaglutide (Ozempic/Wegovy) from a single administration with expected twice-yearly dosing, noted February 28, 2024. read less",59.0
AVIR,4.37,Bemnifosbuvir and ruzasvir (RZR) - (C-FORWARD),Hepatitis C Virus (HCV) ,Phase 2,02/28/2024,"Phase 2 final data from the 60-patient lead-in cohort reported that the SVR4 rate exceeded the protocol-defined efficacy criterion of ≥90% SVR4 for continuing the study, noted February 28, 2024.",79.0
BLRX,1.32,"Motixafortide (BL-8040), gemcitabine, nab-paclitaxel and LIBTAYO (cemiplimab) - (Columbia University trial) - (CheMo4METPANC)",First-line pancreatic ductal adenocarcinoma (PDAC) ,Phase 2,02/28/2024,"Phase 2 trial initiated, noted February 28, 2024.",3.0
KANT,—,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumors ,Phase 1/2,02/29/2024,"Phase 1/2 initial data reported a partial Response in 1 patient with a PD-L1 negative mucoepidermoid carcinoma and a 54% reduction in target lesions and a complete response in non-target lesions, noted March 12, 2024. Phase 1/2 new enrollment terminated, noted February 29, 2024. read less",13.0
IMUX,1.47,IMU-838 - (CALLIPER),Progressive Multiple Sclerosis ,Phase 2,02/29/2024,"Phase 2 interim data presented at ACTRIMS reported that serum NfL was decreased in the treatment group by 22.4%, noted February 29, 2024.",98.0
IMUX,1.47,IMU-838 - (CALVID-1),COVID-19 ,Phase 2,02/29/2024,"Additional Phase 2 data reported that 80% of patients who received placebo reported fatigue, compared to 50% who received 45 mg vidofludimus calcium, noted February 29, 2024.",98.0
IRWD,9.43,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF) ,Phase 3,02/29/2024,"Phase 3 top-line data reported that the trial met its primary endpoint, however two key secondary endpoints were specific to colon-in-continuity patients in assessing at least one day/week off PS versus baseline and reaching enteral autonomy at week 48, both of which were not achieved, noted February 29, 2024. read less",162.0
CLNN,8.05,CNM-Au8 - (VISIONARY-MS),Multiple Sclerosis ,Phase 2,02/29/2024,"Phase 2 full clinical results presented at ACTRIMS Forum reported that treatment demonstrated significant improvement of vision as measured by low contrast letter acuity (LCLA) through 35 months from randomization, noted February 29, 2024. read less",9.0
IMNN,1.14,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5 ,Preclinical,02/29/2024,"Challenge study data reported that a single dose produced IgG neutralizing antibody and T-cell responses, noted February 29, 2024.",2.0
CUE,2.08,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancer ,Phase 1,02/29/2024,"Phase 1 data reported from the Multi-disciplinary Head and Neck Cancers Symposium that overall response rate (ORR) of 47% in first line (1L) patients treated with CUE-101 and pembrolizumab, compared to the historical ORR of 19% reported in the KEYNOTE-48 trial, noted February 29, 2024. read less",76.0
CRDF,1.77,"Onvansertib, FOLFIRI and AVASTIN (bevacizumab) - (ONSEMBLE)",KRAS-Mutated Colorectal Cancer ,Phase 2,02/29/2024,"Phase 2 data reported a 50% ORR rate in Bev Naive patients and 0% ORR in Bev Exposed patients, noted February 29, 2024.",66.0
TGTX,17.22,BRIUMVI (ublituximab-xiiy) - (ENHANCE),Relapsing forms of Multiple Sclerosis (RMS) ,Phase 3,02/29/2024,"Phase 3b data presented at ACTRIMS reported that 18 (86%) of participants completed the infusion without interruption or slowing, with a median infusion duration of 60 min, noted February 29, 2024.",158.0
RYTM,43.42,Setmelanotide - (DAYBREAK),Variants in one of 31 additional genes with MC4R pathway relevance ,Phase 2,02/29/2024,"Phase 2 data showed that nearly 97% of followed patients were relapse-free at 90 days post Zeposia discontinuation; patients that did relapse showed no evidence of rebound effect, noted February 29, 2024. read less",66.0
ATRA,19.45,ATA3219,"B-cell non-Hodgkin's lymphoma (NHL), Lupus Nephritis ",IND-Enabling,02/29/2024,"IND cleared by the FDA, noted February 29, 2024",7.0
CGEM,18.51,CLN-619 - (MICB),Relapsed or Refractory Multiple Myeloma ,IND-Enabling,03/01/2024,"IND Clearaed by the FDA, noted March 1, 2024.",59.0
BIVI,1.89,NE3107,Parkinson's disease ,Phase 2a,03/01/2024,"Additional Phase 2a data reported significant improvement of -2.4 points for the sleep/fatigue domain of the Non-Motor Symptom Scale (NMSS) in Parkinson's Disease, whereas placebo patients experienced a worsening of +1.0 points, noted March 1, 2024 read less",7.0
BIVI,1.89,NE3107,Alzheimer’s disease ,Phase 3,03/01/2024,"Additional Phase 3 data reported that due to the exclusion of data from so many sites the trial missed statistical significance but showed promising directional data on cognitive and functional measures. NE3107-treated patients saw an advantage compared to placebo of -0.95 (68% slowing of decline) on CDR-SB, -0.94 (26%) on ADAS-COG-12, -0.43 (139%) on ADAS-CGIC, -0.03 (27%) on ADCOMS, +1.02 (40%) on MMSE, and +3.08 (47%) on ADCS-ADL, noted March 1, 2024. read less",7.0
KRBP,2.36,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,03/01/2024,"Phase 1 third patient enrolled completed treatment, noted March 1, 2024",1.0
LEXX,2.92,HYPER-H23-1 (DehydraTECH-CBD),Hypertension ,IND-Enabling,03/01/2024,"IND Cleared by the FDA, noted March 1, 2024",19.0
SLS,1,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Phase 1,03/01/2024,"Phase 1 dose-escalation topline data for the heavily pretreated AML patients showed evidence of anti-tumor activity increasing with higher dose levels and no significant safety issues. Treatment with SLS009 resulted in a complete remission (CR) with no minimal residual disease (MRD) after three cycles as a monotherapy in an AML patient who had failed prior venetoclax plus azacytidine (aza/ven) therapy. The CR lasted eight months with the patient achieving one year survival at the latest assessment. This is the first time that a relapsed/refractory (r/r) AML patient achieved a CR with CDK9 inhibition monotherapy. Notably, the median survival for patients relapsed after aza/ven therapy is approximately 2.5 months. All key study objectives were met regarding pharmacokinetic (PK), pharmacodynamic (PD), safety, and clinical activity, noted March 1, 2024. read less",105.0
JNJ,160.8,RYBREVANT (amivantamab) - (PAPILLON),Non-small cell lung cancer ,Approved,03/01/2024,"FDA approved on March 1, 2024.",
WHWK,—,Nab-sirolimus - (AMPECT),Malignant PEComa (Perivascular epithelioid cell tumour) ,Phase 2,03/01/2024,"Phase 2 long-term efficacy and safety results demonstrated 40 months median duration of response and median survival >53 months, noted March 1, 2024.",47.0
RNA,18.86,Delpacibart etedesiran (del-desiran) - (MARINA-OLE),Myotonic dystrophy type 1 (DM1) ,Phase 2,03/04/2024,"Phase 2 preliminary data anticipated at the MDA conference showed reversal of disease progression in multiple functional measures, noted March 4, 2024.",128.0
NVO,—,Efruxifermin - (HARMONY),Nonalcoholic Steatohepatitis ,Phase 2b,03/04/2024,"Phase 2b 96-week results reported that the 50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%), noted March 4, 2024. read less",
AKRO,31.07,Efruxifermin - (HARMONY),Nonalcoholic Steatohepatitis ,Phase 2b,03/04/2024,"Phase 2b 96-week results reported that the 50mg (75%, p<0.001) and 28mg (46%, p=0.07) EFX groups demonstrated ≥1 stage improvement in fibrosis without worsening of MASH, approximately three- and two-fold the placebo rate (24%), noted March 4, 2024. read less",79.0
CLRB,4.24,CLR 131 (iopofosine) in combination with external beam radiation (EBRT),Head & neck cancer ,Phase 1,03/04/2024,"Phase 1 data reported the complete remission was achieved in 64% of patients, with an ORR of 73%, noted March 4, 2024.",3.0
NVS,98.29,Zolgensma (onasemnogene abeparvovec) - (SMART),Spinal muscular atrophy (SMA) ,Phase 3,03/04/2024,"Phase 3b data reported that nearly all patients treated maintained or improved motor milestones after 52 weeks, with most switching to the one-time gene therapy from another chronically administered disease-modifying therapy, noted March 4, 2024. read less",
INDP,2.36,Decoy-20 - (INDP-D101),Advanced/metastatic solid tumors ,Phase 1,03/04/2024,"Phase 1 data following completion of second cohort trial of Decoy 20 leads the independent Safety Review Committee to recommend initiating a multi-dosing cohort, noted March 4, 2024. Single dose cohort data expected to be published at a scientific conference in 2024 read less",1.0
BCDA,6.83,CardiAMP (BCDA-01),Ischemic Heart Failure ,Phase 3,03/04/2024,"Phase 3 data reported that patients had 37% relative risk reduction in heart death equivalent and 9% relative risk reduction in non-fatal major adverse cardiac and cerebrovascular events (MACCE) at mean 20-month follow-up compared to control patients on guideline-directed heart medications alone, noted March 4, 2024. read less",5.0
VTVT,14.01,Cadisegliatin (TTP399),Type 1 Diabetes ,Phase 3,03/04/2024,"Phase 3 announced the submission of the study protocol to the FDA to initiate the trial, noted March 4, 2024.",3.0
LNTH,65.36,DEFINITY (Perflutren Lipid Microsphere),Ultrasound enhancing agent for use in pediatric patients with suboptimal echocardiograms ,Approved,03/04/2024,"FDA approved on March 4, 2024.",67.0
MTEM,3.85,MT-6402,Solid tumors ,Phase 1,03/04/2024,"Phase 1 dose-escalation data showed that treatment appears generally well-tolerated at the 63 and 83 mcg/kg doses with no Grade 4 or Grade 5 adverse events and no instances of CLS seen at any dose, noted March 4, 2024. read less",6.0
NRXP,5.2,NRX-101,Bipolar Depression and Suicidal Ideation ,Phase 2/3,03/04/2024,"Phase 2/3 last patient dosed, noted March 4, 2024.",19.0
PCVX,71.55,VAX-24,Pneumococcal Disease in infants ,Phase 2,03/04/2024,"Phase 2 enrollment completed, noted March 4, 2024.",129.0
BCDA,6.83,Allogeneic CardiALLO,Heart failure ,Phase 1/2,03/04/2024,"Data presented at the Technology and Heart Failure Therapeutics Conference (THT) reported that first patient has been enrolled and treated in the low dose group and is doing well clinically, noted March 4, 2024. read less",5.0
GSK,42.09,"Cabenuva (cabotegravir, rilpivirine) - (CAB-ULA)",HIV treatment and prevention dosed at intervals of at least four months ,Phase 1,03/04/2024,"Phase 1 data show for the first time a new ultra-long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval, noted March 4, 2024.",
PFE,25.51,"Cabenuva (cabotegravir, rilpivirine) - (CAB-ULA)",HIV treatment and prevention dosed at intervals of at least four months ,Phase 1,03/04/2024,"Phase 1 data show for the first time a new ultra-long-acting cabotegravir formulation (CAB-ULA) that doubles the current dosing interval, noted March 4, 2024.",
APGE,59.3,APG777 - (APEX),"Healthy volunteers, Atopic dermatitis (AD) ",Phase 1,03/05/2024,"Phase 1 interim data reported a half-life of approximately 75 days across doses tested and Pharmacodynamic (PD) data showed deep and sustained inhibition of key AD biomarkers pSTAT6 and TARC for ~3 months, noted March 5, 2024. read less",59.0
GSK,42.25,Cabotegravir ultra long-acting (CAB-ULA) - (4 month dosing),HIV ,Phase 1,03/05/2024,"Phase 1 data reported that intramuscular dosing of CAB-ULA has a safety and pharmacokinetic (PK) profile that supports a longer dose interval, noted March 5, 2024.",
NVO,123.76,Semaglutide - (FLOW),Renal impairment in people with type 2 diabetes and chronic kidney disease (CKD) ,Phase 3,03/05/2024,"Phase 3 trial stopped early due to efficacy, based on a recommendation from an Independent Data Monitoring Committee. The trial achieved its primary endpoint by demonstrating a statistically significant and superior reduction in kidney disease progression, major adverse cardiovascular events (MACE) and death of 24% for people treated with semaglutide 1.0 mg compared to placebo, noted March 5, 2024. read less",
CASI,5.66,BI-1206 with rituximab - (China trial),Non-Hodgkin's Lymphoma (NHL) ,Phase 1,03/05/2024,"Phase 1 initial data showed promising responses including a long-lasting complete response for patients with difficult-to-treat disease, noted March 5, 2024.",15.0
MNPR,1.06,MNPR-101-Zr (uPAR),Solid tumors ,Preclinical,03/05/2024,"Addtional preclinical data demonstrated highly preferential uptake in the tumor. The new imaging data released today support the tumor-targeting ability of MNPR-101, noted March 5, 2024.",6.0
ALNY,149.68,Zilebesiran - (KARDIA-2),Hypertension ,Phase 2,03/05/2024,"Phase 2 trial met the primary endpoint, noted March 5, 2024.",131.0
RGNX,24.61,RGX-202 - (AFFINITY DUCHENNE),Duchenne Muscular Dystrophy (DMD) ,Phase 1/2,03/05/2024,"Phase 1/2 new three-month assessment in first patient at dose level 2 demonstrates robust microdystrophin expression. Patient aged 12 years at dosing had expression level at 75.7% of control, noted March 5, 2024. read less",50.0
CRVO,13,Neflamapimod - (AscenD-LB),Dementia with Lewy bodies (DLB) ,Phase 2a,03/05/2024,"Phase 2a data presented at AD/PD reported that there was a mean 3.7 pg/mL increase GFAP levels in placebo vs. mean 12.3 pg/mL reduction with neflamapimod, noted March 5, 2024.",9.0
GANX,4.66,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Preclinical,03/05/2024,"Preclinical data presented at AD/PD reported that GT-02287, through its interaction with glucocerebrosidase (GCase) in the endoplasmic reticulum (ER), aids correct GCase folding, preventing ER retention, ER stress, and ER-associated degradation of mutated GCase enzyme, noted March 5, 2024. read less",35.0
IMMP,2.61,Eftilagimod Alpha with weekly paclitaxel - (AIPAC-003),Metastatic breast cancer (MBC) ,Phase 2/3,03/05/2024,"Phase 2/3 90mg data reported a 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate overall, noted March 5, 2024.",145.0
LLY,776.31,Rezpegaldesleukin (LY3471851) - (REZOLVE-AA),Severe to very severe alopecia areata (AA) ,Phase 2b,03/05/2024,https://www.biopharmcatalyst.com/company/NKTR/news/189917,946.0
NKTR,0.88,Rezpegaldesleukin (LY3471851) - (REZOLVE-AA),Severe to very severe alopecia areata (AA) ,Phase 2b,03/05/2024,https://www.biopharmcatalyst.com/company/NKTR/news/189917,19.0
ONCY,1.03,mFOLFIRINOX +/- atezolizumab and pelareorep - (PanCAN),Pancreatic Ductal Adenocarcinoma (PDAC) ,Phase 1/2,03/05/2024,"Company submitted an amendment to GOBLET to initiate a new Phase 1/2 cohort, noted March 5, 2024.",100.0
LIPO,0.81,LP-410,Graft-Versus-Host Disease (GVHD) ,IND-Enabling,03/05/2024,"IND cleared by the FDA noted, March 5, 2024.",4.0
IBRX,4.82,Anktiva (N-803),HIV ,Phase 1,03/05/2024,"Phase 1 pilot study experienced a marked decrease in the burden of infection, and the procedures were found to be safe and well tolerated, noted March 5, 2024.",945.0
OPK,0.93,SAR441236,human immunodeficiency virus (HIV) ,Phase 1,03/05/2024,"Phase 1 study delivers first clinical safety and pharmacokinetic data as proof of concept for the use of multispecific antibodies in humans, noted March 5, 2024.",793.0
GILD,71.4,Bictegravir and Lenacapavir - (ARTISTRY-1),HIV ,Phase 2/3,03/05/2024,"Phase 2/3 data reported that all three treatment groups had robust virologic suppression at six months, with consistently low viral loads throughout the study, noted March 5, 2024.",
NVS,98.42,Wyost (denosumab-bddz) and Jubbonti (denosumab-bddz) interchangeable,multiple myeloma and in patients with bone metastases from solid tumors ,Approved,03/05/2024,"FDA biosimilar of Xgeva (denosumab) and Prolia (denosumab) approved on March 5, 2024.",
BTAI,2.96,BXCL501 - (SERENITY III),Agitation associated with bipolar I or II disorder or schizophrenia ,Phase 3,03/06/2024,"A Type C meeting with FDA feedback resulted in an amended Phase 3 trial planned for the at-home setting, noted March 6, 2024.",14.0
VNDA,3.91,HETLIOZ (tasimelteon),Insomnia ,CRL,03/06/2024,"CRL issued by FDA on March 6, 2024.",59.0
BMEA,15.8,Icovamenib (BMF-219) - (COVALENT-111),"Healthy volunteers, type 2 diabetes ",Phase 1/2,03/06/2024,"Phase 1/2 data presented at ATTD reported that across 100mg QD, 200mg QD, and 100mg BID cohorts, 38% of patients had ≥0.5% HbA1c reduction, and 23% of patients had ≥1.0% HbA1c reduction at Week 26, noted March 6, 2024. read less",59.0
XOMA,25,RZ358 - (sunRIZE),"Congenital hyperinsulinism (HI), non-islet cell tumors (NICTs) that have uncontrolled hypoglycemia ",Preclinical,03/06/2024,"Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024. read less",12.0
RZLT,1.8,RZ358 - (sunRIZE),"Congenital hyperinsulinism (HI), non-islet cell tumors (NICTs) that have uncontrolled hypoglycemia ",Preclinical,03/06/2024,"Preclinical data reported that data demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans, noted March 6, 2024. read less",90.0
KURA,22.7,KO-2806 and adagrasib in combination with cabozantinib - (FIT-001),Clear cell renal cell carcinoma (ccRCC) ,Phase 1,03/06/2024,"Phase 1 dosing initiated, noted March 6, 2024.",86.0
BMY,51.98,KO-2806 and adagrasib in combination with cabozantinib - (FIT-001),Clear cell renal cell carcinoma (ccRCC) ,Phase 1,03/06/2024,"Phase 1 dosing initiated, noted March 6, 2024.",
ASLN,5.35,eblasakimab versus dupilumab,human tissue model of chronic obstructive pulmonary disease (COPD) ,Preclinical,03/06/2024,"Preclinical new translational data from a head-to-head study of eblasakimab and dupilumab in a human tissue model of COPD shows eblasakimab performed better than dupilumab in improving airway function and enhancing bronchodilation at the same concentrations, noted March 6, 2024. read less",2.0
COYA,9.67,COYA 302,Frontotemporal dementia (FTD) ,Preclinical,03/06/2024,"Preclinical biomarker data shared at the AD/PD 2024 Conference clearly depicts a compromised peripheral immune environment present in patients with FTD that, we believe, contributes to the pathophysiology of the disease process, noted March 5, 2024. IND filing intended later in 2024 and Phase 2 initiation, noted March 6, 2024. read less",16.0
BHC,9.23,RELISTOR (methylnaltrexone bromide: MNTX),Resectable head and neck squamous cell carcinoma ,Phase 2,03/06/2024,"Phase 2 initiated sponsored by Salix Pharmaceuticals, noted March 6, 2024.",369.0
REGN,972.1,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,03/06/2024,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024",105.0
MAIA,1.47,Ateganosine (THIO-101),Non-small cell lung cancer (NSCLC) ,Phase 2,03/06/2024,"Phase 2 third-line ombination THIO 180mg + cemiplimab achieved 38% overall response rate (ORR) in difficult-to-treat, noted March 6, 2024",32.0
GILD,71.04,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV) ,Phase 2,03/06/2024,"Phase 2 data reported that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of more than 50 copies/mL at Week 24; the participant later suppressed on islatravir and lenacapavir at Week 30. No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24, noted March 6, 2024. read less",
MRK,122.23,Islatravir (MK-8591D) and Lenacapavir - (ISLEND),Human immunodeficiency virus (HIV) ,Phase 2,03/06/2024,"Phase 2 data reported that one participant (1.9%) treated with islatravir and lenacapavir had a viral load of more than 50 copies/mL at Week 24; the participant later suppressed on islatravir and lenacapavir at Week 30. No participants in the Biktarvy group had a viral load of more than 50 copies/mL at Week 24, noted March 6, 2024. read less",
GSK,42.27,Cabenuva (cabotegravir + rilpivirine) - (LATITUDE),HIV ,Phase 3,03/06/2024,"Phase 3 data reported that 24.1% of participants on LA-ART experienced regimen failure compared to 38.5% on SOC, noted March 6, 2024.",
ZLAB,19.8,ZEJULA (niraparib) - (NORA),Platinum-Sensitive Recurrent Ovarian Cancer (PSROC) ,Phase 3,03/06/2024,"Phase 3 data reported that treatment demonstrated a favorable OS trend versus placebo in this disease setting, regardless of BRCA-gene mutation status. No new safety signals were identified during the long-term follow up period subsequent to the primary analysis, noted March 6, 2024. read less",109.0
GILD,71.04,Biktarvy - (ALLIANCE),HIV/HBV Coinfection ,Phase 3,03/06/2024,"Phase 3 data reported that 97% percent (71/73) of participants treated with Biktarvy achieved viral suppression (HIV-1 RNA < 50 copies /ml) as did 97% (36/37) of participants treated with the DTG-based regimen, noted March 6, 2024. read less",
DYN,26.78,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD) ,Phase 1/2,03/06/2024,"Phase 1/2 initial data show levels of exon skipping, dystrophin, and PDPF increased at 6 months vs. baseline, noted March 6, 2024.",142.0
BMY,51.88,Opdivo (nivolumab) plus Yervoy (ipilimumab),Urothelial carcinoma ,Approved,03/07/2024,"Approved March 7, 2024.",
MNMD,9,MM-120 (LSD),Generalized Anxiety Disorder (GAD) ,Phase 2b,03/07/2024,"Phase 2b data 12-week data reported that the trial met its key secondary endpoint and maintained a clinically and statistically significant HAM-A reductions compared to placebo at 12 weeks with a 65% clinical response rate and 48% clinical remission rate, noted March 7, 2024. read less",75.0
FBIO,2.07,MB-101 - (City of Hope),High-Grade Glioma ,Phase 1,03/07/2024,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.",29.0
MBIO,1.39,MB-101 - (City of Hope),High-Grade Glioma ,Phase 1,03/07/2024,"Phase 1 data reported well-tolerated and 50% of patients achieved stable disease or better with two partial responses and two complete responses lasting 7.5 and 66+ months, noted March 7, 2024.",7.0
GSK,43.22,BLENREP (belantamab mafodotin) and POMALYST (Pomalidomide) and Dexamethasone - (DREAMM-8),Multiple Myeloma ,Phase 3,03/07/2024,"Phase 3 trial met its primary endpoint, noted March 7, 2024",
IMRN,4.55,Travelan - (CHIM),Enterotoxigenic Escherichia coli (ETEC) ,Phase 2,03/07/2024,"Phase 2 interim data reported that the intended attack rate for this study was approximately 70%. The attack rate for the Placebo group of this study was only 37%, noted March 7, 2024.",6.0
TELO,8.7,Telomir-1,Age-related conditions ,Preclinical,03/07/2024,"Preclinical data reported that Telomir-1 was observed to cause cell cytotoxicity at a concentration of 500 M in both MRC-5 and HUVEC cells, noted March 7, 2024.",32.0
APVO,6.6,ALG.APV-527,Solid tumors ,Phase 1,03/07/2024,"Phase 1 data reported 2 stable disease responses, noted March 7, 2024.",3.0
ATHA,3.58,Fosgonimeton (ATH-1017) - (SHAPE),Parkinson’s disease dementia ,Phase 2,03/08/2024,"Phase 2 data presented at AD/PD reported that changes in ADAS-Cog13 observed in the fosgonimeton 40 mg dose arm were suggestive of a pro-cognitive effect, noted March 8, 2024.",3.0
AMLX,3.36,AMX0035 - (A35-004 PHOENIX),Amyotrophic Lateral Sclerosis (AML) ,Phase 3,03/08/2024,"Phase 3 topline results did not meet the primary endpoint, noted March 8, 2024.",89.0
KYTX,28.67,KYV-101,Non-relapsing and progressive forms of multiple sclerosis ,Phase 1,03/08/2024,"Phase 1 trial with Stanford University commenced, noted March 8, 2024.",43.0
NVO,132.12,Wegovy (Semaglutide),Cardiovascular risk reduction in adults with obesity ,Approved,03/08/2024,"Approved March 8, 2024.",
ABOS,4.37,Sabirnetug (ACU193) - (INTERCEPT-AD),Alzheimer’s disease (AD) ,Phase 1,03/08/2024,"Phase 1 biomarker results presented at PD/AD support sabirnetug's downstream pharmacological effects in the brain in early AD, noted March 8, 2024.",60.0
MNKD,5.27,Afrezza Combined With Insulin Degludec - (INHALE-3),Type 1 Diabetes ,Phase 3,03/08/2024,"Phase 4 data presented at ATTD reported that post-meal hyperglycemia was significantly reduced by 20% with inhaled insulin compared with rapid-acting insulin delivered through MDI or insulin pumps, noted March 8, 2024. read less",306.0
TLSA,0.49,Foralumab (Intranasal),Alzheimer’s Disease ,Phase 1,03/08/2024,"IND clearance by FDA, noted August 15, 2023. Phase 1 data presented at the AD/PD Conference on March 8, 2024.",111.0
ARQT,11.15,Roflumilast Cream (ARQ-151) - (DERMIS-1),Plaque psoriasis ,Phase 3,03/09/2024,"Additional data shared at AAD reported a clinically meaningful response in >70% of patients, noted March 9, 2024.",119.0
MLTX,47.05,Nanobody sonelokimab - (IZAR),Active psoriatic arthritis (PsA) ,Phase 2b,03/10/2024,"Phase 2b 24-week data reported that 52% of patients achieved ACR50+PASI100 and up to 61% of patients achieved Minimal Disease Activity (MDA), noted March 10, 2024.",64.0
ARQT,10.04,ZORYVE (roflumilast) Cream 0.05%,Atopic Dermatitis - ages of 2-5 years old ,Phase 3,03/10/2024,"Phase 3 data to be shared at late-breaking presentation at AAD reported significant improvements in atopic dermatitis across multiple efficacy endpoints and all timepoints, noted March 10, 2024.",119.0
LXRX,2.81,Zynquista (sotagliflozin),Type 1 Diabetes and chronic kidney disease (CKD) ,NDA Filing,03/11/2024,"After public Notice of Opportunity for Hearing (NOOH) proceeding in late 2023, the FDA issued feedback for sotagliflozin resbmisssion, noted March 11, 2024.",363.0
AMGN,273.41,Otezla - (SPROUT),Plaque psoriasis in pediatric patients ,Phase 3,03/11/2024,"Phase 3 results data presented at AAD reported that 56.3% of patients who received Otezla through week 52 achieved static Physician Global Assessment (sPGA) response, noted March 11, 2024.",538.0
INCY,60.79,Ruxolitinib Cream (Opzelura),Adults with hidradenitis suppurativa (HS) ,Phase 2,03/11/2024,"Phase 2 additional data reported that more than three quarters (79.2%) of on-treatment patients achieved at least a 50% reduction in AN count (AN50), 54.2% achieved a 75% reduction (AN75), 20.8% achieved 90% reduction (AN90), and 20.8% achieved complete clearance (100% reduction, AN100), surpassing the 56.3%, 25.0%, 12.5% and 12.5% reductions, respectively, in the vehicle control group, noted March 11, 2024. read less",195.0
INCY,60.79,Povorcitinib (INCB54707),Prurigo Nodularis ,Phase 2,03/11/2024,"Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.",195.0
ASLN,13.04,Eblasakimab (ASLAN004) - (TREK-DX),Atopic dermatitis (AD) ,Phase 2b,03/11/2024,"Phase 2b preliminary review of blinded data from 22 patients treated to date, 45% (10/22) of patients saw at least a 90% reduction in their EASI score (EASI-90) and 50% (11/22) of patients achieved a vIGA score of 0 or 1 (clear or almost clear skin) after 16 weeks, noted March 11, 2024. read less",2.0
NRIX,14.13,NX-2127,"B-cell malignancies, chronic lymphocytic leukemia (CLL) ",Phase 1b,03/11/2024,"Phase 1a/1b clinical hold lifted by the FDA, noted March 11, 2024.",76.0
SONN,2.07,SON-080 - (SB211),Chemotherapy Induced Peripheral Neuropathy (CIPN) ,Phase 1/2,03/11/2024,"Phase 1b/2a cleared after review by the independent DSMB, noted March 11, 2024.",6.0
APRE,6.77,APR-1051 - (ACESOT-1051),Solid tumors ,IND-Enabling,03/11/2024,"IND cleared by the FDA, noted March 11, 2024.",5.0
LLY,733.16,Lebrikizumab,Moderate-to-severe atopic dermatitis ,Phase 3,03/11/2024,"Phase 3 data reported that 68% of people experienced significant improvement of at least 75% in disease extent and severity (EASI-75), noted March 11, 2024.",946.0
VTYX,8.04,VTX3232,Parkinson's disease ,Phase 1,03/11/2024,"Phase 1 clinical update presented at virtual investor event showed that treatment was well-tolerated with no dose-limiting toxicities identified. All treatment-emergent adverse events were graded mild or moderate, noted March 11, 2024. read less",71.0
VTYX,8.04,VTX2735,"Healthy volunteers, cryopyrin-associated periodic syndrome (CAPS) ",Phase 2,03/11/2024,"Phase 2 trial ongoing, with clinical update presented at virtual investor event showed that treatment demonstrated clinically meaningful improvements in disease activity, including an 85% mean reduction in the Key Symptom Score during Treatment Period 1, noted March 11, 2024. read less",71.0
VTYX,8.04,Tamuzimod (VTX002),Ulcerative Colitis (UC) ,Phase 2,03/11/2024,"Phase 2 OLE clinical update presented at the virtual investor event data continues to support the potentially differentiated profile of VTX002 in ulcerative colitis, with robust rates of clinical remission and endoscopic remission observed among participants completing 52 weeks of treatment with VTX002, noted March 11, 2024. read less",71.0
NVCR,15.99,Tumor Treating Fields (TTFields) - (INNOVATE-3),Ovarian cancer ,Phase 3,03/11/2024,"Phase 3 exploratory subgroup analysis finds that pegylated liposomal doxorubicin (PLD) -naïve patients randomized to receive TTFields therapy and paclitaxel had a median overall survival of 16.0 months compared to 11.7 months in PLD-naïve patients treated with paclitaxel alone, noted March 11, 2024. read less",111.0
TVTX,7.99,FILSPARI (sparsentan),IgA nephropathy (IgAN) ,sNDA Filing,03/11/2024,"sNDA submitted to the FDA, noted March 11, 2024.",89.0
LGND,72.25,FILSPARI (sparsentan),IgA nephropathy (IgAN) ,sNDA Filing,03/11/2024,"sNDA submitted to the FDA, noted March 11, 2024.",19.0
JNJ,159.92,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasis ,Phase 2b,03/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024 read less",
PTGX,30.12,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasis ,Phase 2b,03/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024 read less",62.0
JNJ,159.92,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasis ,Phase 2b,03/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024. read less",
PTGX,30.12,PN-235 (JNJ-77242113) - (FRONTIER 1),Plaque psoriasis ,Phase 2b,03/11/2024,"Phase 2b data presented at AAD reported that response rates were maintained from Week 16 to Week 52 with the highest PASI 75 response observed in the 100 mg twice daily group (78.6% at 16 weeks and 76.2% at 52 weeks), noted March 11, 2024. read less",62.0
ALMS,—,Izokibep,Hidradenitis Suppurativa (HS) ,Phase 2b,03/11/2024,"Phase 2b long-term data reported that data demonstrated no evidence of increased safety liability with longer-term treatment and increased duration of therapy was associated with further clinical improvements over time, noted March 11, 2024. read less",104.0
ALMS,—,Izokibep,Psoriatic arthritis (PsA) ,Phase 2,03/11/2024,"Phase 2 data reported that the trial met its primary endpoint, noted March 11, 2024.",104.0
VTRS,11.84,Glatiramer (GA Depot),Primary Progressive Multiple Sclerosis (PPMS) ,CRL,03/11/2024,"CRL announced March 11, 2024.",
ACAD,24.13,NUPLAZID (pimavanserin) - (Advance-2),Adjunctive treatment in patients with negative symptoms of schizophrenia ,Phase 3,03/11/2024,"Phase 3 study did not meet its primary endpoint, noted March 11, 2024.",168.0
TERN,7.43,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML) ,Phase 1,03/11/2024,"Orphan drug designation grated by the FDA, noted March 11, 2024",87.0
LRMR,8.63,Nomlabofusp (CTI-1601),Friedreich’s ataxia (FA) ,Phase 2,03/11/2024,"Phase 2 OLE dosing initiated, noted March 11, 2024.",85.0
PSTV,1.61,REYOBIQ (rhenium Re186 obisbemeda) - (ReSPECT-LM),Leptomeningeal metastases (LM) ,Phase 1,03/11/2024,"Phase 1 Cohort 5 dosing completed, noted March 11, 2024.",99.0
NVS,—,Farabursen (RGLS8429) (MAD),Autosomal Dominant Polycystic Kidney Disease (ADPKD) ,Phase 1b,03/12/2024,"Phase 1b MAD data from the second cohort, reported that a mechanistic dose response was observed at a 2mg/kg dose level based on urinary biomarker analyses, noted March 12, 2024.",
PFE,27.23,ADCETRIS (brentuximab vedotin) with lenalidomide and rituximab - (ECHELON-3),Relapsed/refractory diffuse large B-cell lymphoma (DLBCL) ,Phase 3,03/12/2024,"Phase 3 data reported a statistically significant and clinically meaningful improvement in overall survival (OS) compared to lenalidomide and rituximab plus placebo, noted March 12, 2024.",
KANT,—,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumors ,Phase 1/2,03/12/2024,"Phase 1/2 initial data reported a partial Response in 1 patient with a PD-L1 negative mucoepidermoid carcinoma and a 54% reduction in target lesions and a complete response in non-target lesions, note",13.0
CRNX,40.75,Paltusotine,Carcinoid syndrome associated with neuroendocrine tumors (NETs) ,Phase 2,03/12/2024,"Phase data from treatment demonstrated rapid and sustained reductions in the frequency and severity of flushing episodes and bowel movements. Results confirm initial positive data previously reported,",94.0
CYBN,0.42,CYB003 - (EXTEND and EMBRACE),Major Depressive Disorder (MDD) and Alcohol use disorder (AUD) ,Phase 2,03/13/2024,"Additional Phase 2 durability data reported with significant improvement in depression symptoms at four months with 75% of patients in remission from depression after two doses, noted March 13, 2024.",23.0
SLN,25.61,Zerlasiran (formerly SLN360) - (ALPACAR-360),Cardiovascular diseases and Polycythemia vera ,Phase 2,03/13/2024,"Phase 2 study met its primary endpoint, noted March 13, 2024.",46.0
PRTC,25.81,LYT-200,Relapsed/refractory AML and MDS ,Phase 1b,03/13/2024,"Phase 1b orphan drug designation granted by FDA, noted March 13, 2024.",24.0
SGMO,0.79,STAC-BBB,Neurological diseases ,Preclinical,03/13/2024,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024. read less",301.0
LLY,—,STAC-BBB,Neurological diseases ,Preclinical,03/13/2024,"Preclinical data reported robust penetration of the BBB and widespread transgene expression throughout the brain, and the treatment was well tolerated in NHPs, with no notable treatment related pathological findings in brain, spinal cord or peripheral tissues, noted March 13, 2024. read less",946.0
XOMA,25.61,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune Thrombocytopenia ,Phase 2,03/13/2024,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.",12.0
TAK,14.13,Mezagitamab (TAK-079) - (TAK-079-1004),Primary Immune Thrombocytopenia ,Phase 2,03/13/2024,"Phase 2 topline data reported that treatment was safe and well tolerated, with all mezagitamab doses tested demonstrated a higher platelet response rate than placebo, noted March 13, 2024.",
PHIO,9.18,PH-762,Cutaneous Squamous Cell Carcinoma ,Phase 1b,03/13/2024,"Phase 1b new trial sites opened, noted March 13, 2024.",5.0
SPRB,5.19,Tildacerfont - (CAHmelia-203),Congenital Adrenal Hyperplasia (poor disease control) ,Phase 2b,03/13/2024,"Phase 2b top-line data reported that trial did not meet its primary endpoint, noted March 13, 2024.",
SPRB,5.19,Tildacerfont - (CAHptain-205),Pediatric Classic Congenital Adrenal Hyperplasia ,Phase 2,03/13/2024,"Phase 2 top-line data reported that 73% of all patients (22 of 30 patients) met the efficacy endpoint of A4 or GC reduction from baseline at 12 weeks with no treatment-related SAEs reported, noted March 13, 2024. read less",
MIRM,27.77,LIVMARLI (maralixibat),Progressive Familial Intrahepatic Cholestasis (PFIC) ,Approved,03/13/2024,"Approval announced March 13, 2024.",50.0
CALC,4.34,Auxora - (KOURAGE),Acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) ,Preclinical,03/13/2024,"Preclinical data consistent with clinical observations made with Auxora, supporting the KOURAGE trial, noted March 13, 2024.",13.0
IMNN,0.87,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5 ,IND-Enabling,03/13/2024,"IND filed to FDA, noted March 13, 2024.",2.0
IONS,43.16,ION224,"metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH) ",Phase 2,03/13/2024,"Phase 2 achieved statistically significant liver histologic improvement as measured by at least a 2-point reduction in NAFLD Activity Score (NAS), noted March 13, 2024.",159.0
PCRX,30.29,PCRX-201 (enekinragene inzadenovec) - (ASCEND),Osteoarthritis of the knee ,Phase 1,03/13/2024,"Additional 104-week data presented at ACR reported MRI B-score change from baseline ranged from 2.3 to 5.4 in the not pretreated cohort and from 2.6 to 5.9 in the steroid pretreated cohort, noted November 17, 2024. RMAT designation granted March 13, 2024. read less",44.0
OCGN,1.04,OCU410 - (ArMaDa),Geographic Atrophy (GA) ,Phase 1/2,03/13/2024,"Phase 1/2 dosing initiated March 13, 2024.",292.0
IMRX,2.9,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanoma ",Phase 1,03/14/2024,"Phase 1 topline data reported that 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ctDNA and treated with IMM-1-104, with 53% of patients had ≥ 1 target lesion(s) regress when treated with IMM-1-104 at either 320mg or 240mg, noted March 14, 2024. read less",36.0
NVCT,9.15,NXP800,Ovarian Clear Cell Carcinoma ,Phase 1b,03/14/2024,"Phase 1b preliminary data reported that a 33% response rate and 100% disease control rate, defined as partial response (""PR"") plus stable disease (""SD""), in patients evaluated for efficacy, noted March 14, 2024. read less",25.0
GERN,1.75,RYTELO (imetelstat) - (IMerge),Myelodysplastic syndromes with transfusion-dependent (TD) anemia ,NDA Filing,03/14/2024,"Advisory committee voted 12 to 2 in favor, noted March 14, 2024.",638.0
MDGL,243.57,Rezdiffra (resmetirom),Non-alcoholic steatohepatitis (NASH) with liver fibrosis (also known as MASH) ,Approved,03/14/2024,"Approved on March 14, 2024.",22.0
BGNE,168.9,TEVIMBRA,Esophageal Squamous Cell Carcinoma (ESCC) ,Approved,03/14/2024,"Approved March 14, 2024.",106.0
ONC,—,TEVIMBRA,Esophageal Squamous Cell Carcinoma (ESCC) ,Approved,03/14/2024,"Approved March 14, 2024.",110.0
BMY,51.11,Breyanzi (lisocabtagene maraleucel),Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) ,Approved,03/14/2024,"Approved March 14, 2024.",
BGNE,168.9,Tislelizumab-jsgr (Tevimbra),Esophageal squamous cell carcinoma (ESCC) ,Approved,03/14/2024,"Approved March 14, 2024.",106.0
ONC,—,Tislelizumab-jsgr (Tevimbra),Esophageal squamous cell carcinoma (ESCC) ,Approved,03/14/2024,"Approved March 14, 2024.",110.0
AQST,6.09,Anaphylm (AQ-109)- (103),Anaphylaxis ,Phase 3,03/15/2024,"Phase 3 trial met all primary and secondary pharmacokinetic endpoints, noted March 15, 2024.",99.0
JSPR,25.08,Briquilimab (JSP191),Fanconi Anemia (FA) ,Phase 1/2,03/15/2024,"Additional Phase 1/2 data reported that all six patients with Fanconi Anemia treated with briquilimab achieved full donor engraftment and full blood count recovery and briquilimab was well tolerated, noted March 15, 2024. read less",16.0
JNJ,156.89,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple Myeloma ,BLA Filing,03/15/2024,"Adcom resulted votes 11 to 0 supporting favorable risk-benefit assessment, noted March 15, 2024.",
LEGN,64.02,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple Myeloma ,BLA Filing,03/15/2024,"Adcom resulted votes 11 to 0 supporting favorable risk-benefit assessment, noted March 15, 2024.",183.0
OPTN,1.88,XHANCE,Chronic sinusitis ,Approved,03/15/2024,"Approved March 15, 2024.",10.0
TSVT,4.01,Abecma (idecabtagene vicleucel; ide-cel),Multiple Myeloma ,BLA Filing,03/15/2024,"AdCom ODAC noted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients, noted March 15, 2024.",53.0
BMY,50.97,Abecma (idecabtagene vicleucel; ide-cel),Multiple Myeloma ,BLA Filing,03/15/2024,"AdCom ODAC noted positively (8-3) that Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients, noted March 15, 2024.",
PHVS,23.35,Deucrictibant (PHVS416) - (CHAPTER-3),Hereditary angioedema - prophylactic use ,Phase 2,03/15/2024,"Phase 2 full results presented at ITACA reported that treatment significantly reduced the monthly attack rate, noted March 15, 2024.",54.0
WHWK,—,Nab-sirolimus - (AMPECT),Malignant PEComa (Perivascular epithelioid cell tumour) ,Phase 2,03/18/2024,"Phase 2 data presented at SGO reported that the overall response rate to nab-sirolimus for the subgroup was 37.5% (6/16), noted March 18, 2024.",47.0
AZN,65.85,Imfinzi (durvalumab) in combination with carboplatin and paclitaxel,Endometrial cancer (EC) ,Phase 3,03/18/2024,"Additional Phase 3 data reported that treatment demonstrated an improvement in multiple key secondary efficacy endpoints, particularly in patients with mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer compared to chemotherapy alone, noted March 18, 2024. read less",
ALGS,0.92,ALG-055009 - (HERALD),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 2a,03/18/2024,"Phase 2a study initiated, noted March 18, 2024.",6.0
IVA,4.36,Lanifibranor in combination with empagliflozin (Jardiance1) - (LEGEND),"Metabolic dysfunction-associated steatohepatitis (MASH), and type 2 diabetes (T2D) ",Phase 2a,03/18/2024,"Phase 2a achieved its primary efficacy endpoint by significantly lowering HbA1c level in both the lanifibranor arm and in the lanifibranor with empagliflozin arm compared to placebo, noted March 18, 2",95.0
PMVP,1.67,Rezatapopt (PC14586) - (PYNNACLE),Solid tumors ,Phase 1/2,03/18/2024,"Phase 1/2 part 1 analysis showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients, noted March 18, 2024",52.0
MRK,120.71,Rezatapopt (PC14586) - (PYNNACLE),Solid tumors ,Phase 1/2,03/18/2024,"Phase 1/2 part 1 analysis showed promising efficacy of rezatapopt (PC14586) in heavily pre-treated patients, noted March 18, 2024",
PBM,1.25,Psilocybin,Adjustment Disorder due to a recent cancer diagnosis ,Preclinical,03/18/2024,"Recent study published in the journal Molecular Psychiatry, suggests that nature-derived psilocybin may be demonstrably more therapeutic than its synthetic analog, noted March 18, 2024.",1.0
JNJ,154.94,EDURANT (rilpivirine),HIV in pediatric patients (2-12 years) ,Approved,03/19/2024,"Approved March 19, 2024.",
CRNX,45.18,PALSONIFY (paltusotine),Acromegaly ,Phase 3,03/19/2024,"Phase 3 topline data reported that the trial met its primary endpoint, noted March 19, 2024.",94.0
DTIL,12,PBGENE-PMM,Primary mitochondrial myopathies ,Preclinical,03/19/2024,"Preclinical data presented at Mitochondrial Medicine Therapeutic Development (MMTD) annual conference demonstrated ARCUS' ability to efficiently eliminate mutant mitochondrial DNA without nuclear off-target editing, noted March 19, 2024. read less",11.0
AXSM,76.87,Sunosi (Solriamfetol) - (PARADIGM),Major depressive disorder (MDD) ,Phase 3,03/19/2024,"Phase 3 initiated, noted March 19, 2024.",49.0
CERS,2.04,INTERCEPT (ReCePI),Patients undergoing complex cardiac surgery procedures ,Phase 3,03/19/2024,"Phase 3 trial met the primary efficacy endpoint demonstrating non-inferiority of the incidence of acute kidney injury, noted March 19, 2024.",191.0
KRBP,2.83,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,03/19/2024,"Phase 1 results reported that stable disease status was confirmed, and the new onset metastatic disease, which completely resolved on repeat MRI imaging performed six weeks from the beginning of treat",1.0
SEEL,5.2,SLS-005 (IV trehalose) - (HEALEY ALS Platform Trial),Amyotrophic lateral sclerosis (ALS) ,Phase 2/3,03/19/2024,"Phase 2/3 trial did not meet the primary and secondary endpoint in the Full Analysis Set (FAS), noted March 19, 2024.",
HOTH,1.35,HT-ALZ,Alzheimer's Disease ,Preclinical,03/19/2024,"Preclinical data research presented compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheim",13.0
JSPR,26.24,Subcutaneous briquilimab - (SPOTLIGHT),Chronic inducible urticaria (CIndU) ,Phase 1/2,03/19/2024,"Phase 1b/2a patient enrollment commenced, noted March 19, 2024",16.0
ALIM,4.05,ILUVIEN - (New Day),Visual Acuity Loss due to Radiation Retinopathy ,Phase 1,03/19/2024,"Phase 1 first patient dosed, noted March 19, 2024.",54.0
LGND,72.21,V116 - (STRIDE-6),Pneumococcal Conjugate Vaccine ,Phase 3,03/19/2024,"Phase 3 extensive data reaffirms confidence in the potential clinical value V116 could provide to a range of adult populations, noted March 19, 2024.",19.0
MRK,121.47,V116 - (STRIDE-6),Pneumococcal Conjugate Vaccine ,Phase 3,03/19/2024,"Phase 3 extensive data reaffirms confidence in the potential clinical value V116 could provide to a range of adult populations, noted March 19, 2024.",
CVM,2.03,CEL-4000,Rheumatoid arthritis (RA) ,Preclinical,03/19/2024,"Preclinical data published at the scientific journal Frontiers in Immunology showed that treatment may deliver safe and effective therapy for RA by rebalancing the inflammatory response, without weak",6.0
TAK,14.12,ICLUSIG (ponatinib) - (PhALLCON),Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) ,Approved,03/19/2024,"FDA approved on March 19, 2024.",
TSHA,2.25,TSHA-102 - (REVEAL),Rett syndrome ,Phase 1/2,03/19/2024,Phase 1/2 clinical data from cohort one (low dose) showed that dosing was well-tolerated with no treatment-emergent SAEs as of 35-week assessment. Data from second adult patient showed TSHA-102 (low d,272.0
AEON,14.4,ABP-450 (prabotulinumtoxinA),Chronic Migraine (prophylaxis) ,Phase 2,03/19/2024,"FDA and AEON align on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine, noted March 19, 2024.",11.0
BMY,50.52,Opdivo (nivolumab) plus Yervoy (ipilimumab) - (CheckMate -9DW),Hepatocellular carcinoma (HCC) ,Phase 3,03/20/2024,"Phase 3 trial met primary endpoint, noted March 20, 2024.",
ALMS,—,Subcutaneous lonigutamab - (LONGITUDE),Thyroid eye disease (TED) ,Phase 1/2,03/20/2024,"Phase 1/2 proof of concept data exhibited rapid improvements demonstrated for proptosis, clinical activity scores, and diplopia versus placebo with a favorable safety profile, noted March 20, 2024.",104.0
ENTX,1.52,N-Tab (GLP-2 agonist),Short Bowel Syndrome ,Preclinical,03/20/2024,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",45.0
OPK,0.89,N-Tab (GLP-2 agonist),Short Bowel Syndrome ,Preclinical,03/20/2024,"PK data reported that the trial objective were met, with oral GLP-2 tablets exhibiting significant systemic exposure, noted March 20, 2024.",793.0
TFFP,7.95,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,03/20/2024,"Phase 2 data reported that eight out of eight patients have successfully transitioned from oral Tacrolimus to TFF TAC, with favorable safety results with no mortality or discontinuations due to advers",4.0
BNOX,1,BNC210 - (ATTUNE),Post-Traumatic Stress Disorder (PTSD) ,Phase 2b,03/21/2024,Phase 2b results reported that BNC210 led to statistically significant improvement (p<0.05) in the following secondary endpoints: depressive symptoms as measured by the Montgomery-Åsberg Depression Ra,2.0
MRK,122.88,KEYTRUDA + LYNPARZA - (KEYLYNK-006),Metastatic nonsquamous non-small cell lung cancer (NSCLC) ,Phase 3,03/21/2024,"Phase 3 data reported that the trial did not meet its dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted March 21, 2024.",
PHIO,7.56,INTASYL,Hematological malignancies ,Preclinical,03/21/2024,"Preclinical data presented at Immunotherapy of Cancer Conference (ITOC10) reported a consistent silencing of Cbl-b mRNA, which has been shown to limit NK cell activation, noted March 21, 2024.",5.0
VRTX,415.71,VX-407,"Autosomal Dominant Polycystic Kidney Disease (ADPKD), healthy volunteers ",IND-Enabling,03/21/2024,"IND cleared by the FDA, noted March 21, 2024.",256.0
ALPN,41.6,ALPN-303 - (DENALI),Systemic lupus erythematosus (SLE) ,Preclinical,03/21/2024,"Preclinical data presented at SLEuro demonstrated greater reductions in disease activity in a mouse model of lupus compared to WT TACI-Ig or B cell depletion, noted March 21, 2024.",68.0
NKTX,12.98,NKX101,Acute myeloid leukemia / myelodysplastic syndromes ,Phase 1,03/21/2024,"Phase 1 trial update reported that enrollment has been closed, with the aggregate CR/CRi rate (5 of 20 patients) was lower than what had been observed in the first 6 patients in the cohort, noted Marc",71.0
ABBV,175.15,Mirvetuximab - (MIRASOL),Cancer - ovarian cancer and relapsed endometrial cancer ,Approved,03/22/2024,"Approved March 22, 2024.",
OKYO,1.54,urcosimod (OK-101),Dry Eye Disease (DED) ,Phase 2,03/22/2024,"Phase 2 additional efficacy data showed a statistically significant and durable reduction in ocular pain statistically significant improvement in Tear Film Break-Up Time (TFBUT) throughout the study,",33.0
SMMT,3.37,Ivonescimab plus chemotherapy - (AK112-201),Non-small cell lung cancer (NSCLC) ,Phase 2,03/22/2024,Phase 2 combination data shared at the 2024 European Lung Cancer Congress (ELCC 2024) showed that patients experienced a median PFS of 11.1 months (95% CI: 9.5 – 16.3 months). The frequency of treatme,744.0
SMMT,3.37,ivonescimab (AK112-202),Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases ,Phase 2,03/22/2024,Phase 2 monotherapy data shared at the 2024 European Lung Cancer Congress (ELCC 2024) showed that treatment led to intracranial responses among 34% of patients with brain metastases at baseline – 23%,744.0
ABBV,175.15,ELAHERE (mirvetuximab soravtansine-gynx),Platinum-Resistant Ovarian Cancer ,Approved,03/22/2024,"Full approval announced March 22, 2024.",
IVVD,4.36,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 Prevention ,Approved,03/22/2024,"EUA approval announced March 22, 2024.",120.0
IVVD,4.36,PEMGARDA (VYD222 (pemivibart)) - (CANOPY),COVID-19 Prevention ,Phase 3,03/22/2024,"Additional Phase 3 data reported that only one patient (0.03%) was symptomatic after 90 days, noted March 22, 2024.",120.0
ESPR,2.29,NEXLETOL (bempedoic acid) - (CLEAR Outcomes),Cardiovascular Diseases ,Approved,03/22/2024,"Approved March 22, 2024.",201.0
TELO,6.49,Telomir-1,Age-related conditions ,Preclinical,03/22/2024,"Poster presentation delivers pre-clinical results that demonstrate that its lead development product, Telomir-1, elongates telomere caps on human normal embryonic fibroblast cells, noted March 22, 202",32.0
SLRX,4.96,Seclidemstat,Ewing's and other FET-rearranged sarcomas ,Phase 1/2,03/22/2024,"Phase 1/2 trial enrollment resumed, noted March 22, 2024.",
ZLAB,16.18,ZL-1310 (DLL3 ADC),"Solid tumors, relapsed and refractory second-line+ SCLC ",Preclinical,03/22/2024,"Preclinical data presented at ELCC reported strong and specific binding to DLL3 on the cell surface, leading to internalization, cell cycle arrest and the induction of apoptosis in tumor cells, noted",109.0
AXSM,77.35,Reboxetine (AXS-12) - (SYMPHONY),Narcolepsy ,Phase 3,03/25/2024,"Phase 3 trial met its primary endpoint, noted March 25, 2024.",49.0
AZN,65.46,ULTOMIRIS (ravulizumab-cwvz),Neuromyelitis Optica Spectrum Disorder (NMOSD) ,Approved,03/25/2024,"Approved March 25, 2024.",
AZN,65.46,ULTOMIRIS (ravulizumab-cwvz) - (CHAMPION-NMOSD),Neuromyelitis optica spectrum disorder (NMOSD) ,Approved,03/25/2024,"FDA Approved on March 25, 2024.",
ATXS,14.75,Navenibart (STAR-0215) - (ALPHA-ORBIT),"Hereditary angioedema (HAE), healthy volunteers ",Phase 1/2,03/25/2024,"Phase 1b/2 proof of concept data reported favorable safety and tolerability profile, mean monthly attack rate reduction of 90-96% for up to 6 months of follow up, noted March 25, 2024.",56.0
APGE,65,APG808,"Healthy volunteer, asthma, COPD ",Phase 1,03/25/2024,"Phase 1 dosing commenced and preclinical data demonstrated the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks",59.0
MBRX,5.25,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML) ,Phase 1/2,03/25/2024,"Phase 1/2 topline data reported a complete response composite (CRc) rate of 39% in all currently evaluable, intent to treat subjects (n= 18), noted March 25, 2024.",30.0
REGN,961.09,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL) ,CRL,03/25/2024,CRL issued by FDA on March 25 2024.,105.0
ZLAB,16.25,Odronextamab - (OLYMPIA),Non-Hodgkin Lymphoma (NHL) ,CRL,03/25/2024,CRL issued by FDA on March 25 2024.,109.0
ARWR,27.89,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),Hypertriglyceridemia ,Phase 2,03/25/2024,"Phase 2 expanded Access Program (EAP) initiated, noted March 25, 2024.",138.0
RYTM,39.65,RM-718,Hypothalamic Obesity ,Phase 1,03/25/2024,"Phase 1 trial dosing initiated, noted March 25, 2024.",66.0
MRK,124.56,Plinabulin with Pembrolizumab plus Etoposide/Platinum (EP),1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) ,Phase 2,03/25/2024,"Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.",
BYSI,3.47,Plinabulin with Pembrolizumab plus Etoposide/Platinum (EP),1L Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) ,Phase 2,03/25/2024,"Phase 2 investigator-initiated trial (IIT) dosing initiated, noted March 25, 2024.",40.0
SYRS,6.4,Tamibarotene (SY-1425) and VIDAZA (azaciditine) - (SELECT-MDS-1),Myelodysplastic Syndrome ,Phase 3,03/25/2024,"Phase 3 enrollment completed, noted March 25, 2024",26.0
MTNB,0.29,Docetaxel,Metastatic and unresectable tumors ,Preclinical,03/25/2024,"Preclinical in vivo data reported that an oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak wei",5.0
STOK,6.5,Zorevunersen (STK-001) - (EMPEROR),Dravet syndrome ,Phase 1/2,03/25/2024,"Phase 1/2a end of study data of 70mg doses demonstrated substantial and sustained reductions in convulsive seizure frequency on top of the best available anti-seizure medicines, noted March 25, 2024.",54.0
NKGN,2.16,Troculeucel (SNK01),Alzheimer's Disease ,Phase 1,03/25/2024,Phase 1 additional data suggested clinical activity regarding cognitive function in patients with advanced Alzheimer's disease in addition to previously disclosed positive effects on amyloid protein a,124.0
AMRX,5.91,ciprofloxacin and dexamethasone otic suspension,"Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult, and elderly patients due to staphylococcus aureus and pseudomonas aeruginosa. ",Approved,03/25/2024,"ANDA Approval from the FDA, noted March 25, 2024.",314.0
REGN,961.09,Odronextamab,Relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) ,CRL,03/25/2024,"CRL issued March 25, 2024.",105.0
ZLAB,16.25,Odronextamab,Relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL) ,CRL,03/25/2024,"CRL issued March 25, 2024.",109.0
PRAX,62.18,PRAX-628,Photo-Paroxysmal Response (PPR) ,Phase 2,03/26/2024,"Phase 2 data reported a 100% complete response rate in the 45 mg cohort, and in the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response, noted March 26, 2024",21.0
SLS,1.06,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Phase 1/2,03/26/2024,"Phase 1b/2 topline data reported a 10% response rate in the 45 mg QW safety cohort , 20% response rate in the 60 mg QW cohort, and 50% response rate in the 60 mg, 2 x 30 mg BIW cohort, noted March 26,",105.0
TECX,—,TX45,Group 2 Pulmonary Hypertension ,Phase 1a,03/26/2024,"Phase 1a clinical program advancing on track based on promising initial data, noted March 26, 2024.",18.0
VKTX,80.83,VK2735,Metabolic and endocrine disorders (GLP-1) ,Phase 1,03/26/2024,Phase 1 data was shown to be safe and well-tolerated in the 28-day study with low rates of GI-related adverse events. Up to 3.3% placebo-adjusted mean weight loss (5.3% from baseline) observed after 2,113.0
CERS,1.74,INTERCEPT,Platelets ,Approved,03/26/2024,"FDA has granted approval of 12-month shelf life for INTERCEPT Platelet Processing Sets, from the date of manufacture, effective immediately, noted March 26, 2024.",191.0
LITS,—,Voruciclib plus Venclexta (venetoclax),B-Cell Malignancies or Acute Myeloid Leukemia (AML) ,Phase 1,03/26/2024,"Additional Phase 1 data observed anti-leukemic activity in multiple heavily pretreated patients in the dose escalation cohorts, including responses, anticipated decreases in myeloid leukemia cell diff",35.0
MEIP,3.86,Voruciclib plus Venclexta (venetoclax),B-Cell Malignancies or Acute Myeloid Leukemia (AML) ,Phase 1,03/26/2024,"Additional Phase 1 data observed anti-leukemic activity in multiple heavily pretreated patients in the dose escalation cohorts, including responses, anticipated decreases in myeloid leukemia cell diff",6.0
STOK,10.29,Zorevunersen (STK-001),Dravet Syndrome ,Phase 1/2,03/26/2024,Phase 1/2 data demonstrated durable reductions in seizures and clinically meaningful improvements in multiple measures of cognition and behavior were maintained over 12 months with continued dosing at,54.0
ATNM,8.12,Iomab-ACT,Targeted conditioning prior to CD19 CAR T-cell therapy ,Phase 1,03/26/2024,"Phase 1 trial has commenced enrollment, noted March 26, 2024.",31.0
ZVRA,5.72,Serdexmethylphenidate (SDX) - (KP1077),Idiopathic hypersomnia (IH) ,Phase 2,03/26/2024,"Phase 2 topline data demonstrated clinically meaningful impact and encouraging outcomes on both clinical safety and efficacy, noted March 26, 2024.",56.0
MRK,124.77,WINREVAIR (sotatercept-csrk),Pulmonary arterial hypertension (PAH) ,Approved,03/26/2024,"Approved March 26, 2024.",
ARGX,398.59,Efgartigimod - (RHO),Primary Sjogren's syndrome ,Phase 2,03/27/2024,"Phase 2 trial data reported safety and tolerability profile that was consistent with other clinical trials, and a treatment effect across multiple clinical endpoints, noted March 27, 2024.",60.0
MRNA,110.59,mRNA-1283 - (NEXTCove),COVID-19 ,Phase 3,03/27/2024,"Phase 3 data reported a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, noted March 27, 2024.",389.0
MRNA,110.59,mRNA-1283 - (NEXTCove),COVID-19 ,Phase 3,03/27/2024,"Phase 3 data reported a higher immune response against both the Omicron BA.4/BA.5 and original virus strains of SARS-CoV-2 compared to mRNA-1273.222, noted March 27, 2024.",389.0
NVCR,14.64,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung Cancer ,Phase 3,03/27/2024,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie",111.0
ZLAB,16.19,Tumor Treating Fields (TTFields) - (METIS),Brain Metastases Originating from Non-Small Cell Lung Cancer ,Phase 3,03/27/2024,"Phase 3 final data clinical trial met its primary endpoint, demonstrating a statistically significant improvement in time to intracranial progression for adult patients treated with Tumor Treating Fie",109.0
ATAI,1.79,BPL-003,Resistant Depression ,Phase 2a,03/27/2024,"Phase 2a initial results demonstrated that a single 10mg dose of BPL-003 was well-tolerated and resulted in a rapid onset and durable antidepressant effect in patients living with TRD, noted March 27,",214.0
ALT,8.89,Pemvidutide - (MOMENTUM),"Non-alcoholic steatohepatitis (NASH)/ (MASH) - Healthy, Overweight and Obese Volunteers ",Phase 2,03/27/2024,"Phase 2 body composition study showed lean mass preservation, with only 25.5% of weight loss derived from lean mass, noted March 27, 2024.",88.0
ALT,8.89,HepTCell,Hepatitis B ,Phase 2,03/27/2024,"Phase 2 clinical trial evaluating the efficacy has been completed. The overall response in the trial was deemed to be insufficient to warrant further advancement. As a result, any further development",88.0
AVTX,4.75,AVTX-009 (anti-IL-1β mAb) - (LOTUS),Hidradenitis suppurativa (HS) ,Phase 2,03/27/2024,"Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc, noted March 27 , 2024. Phase 2 topline results from trial planned expected in 2026.",13.0
TFFP,6.59,Voriconazole Inhalation Powder - (VORI),Invasive Pulmonary Aspergillosis (IPA) ,Phase 2,03/27/2024,"Phase 2 data continue to demonstrate antifungal activity and a favorable safety and tolerability profile, noted March 27, 2024.",4.0
TFFP,6.59,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,03/27/2024,"Phase 2 8/8 patients successfully transitioned from oral tacrolimus to TFF TAC with no sign of acute rejection at reduced systemic exposures, noted March 27, 2024.",4.0
GMDA,0.06,NAM-NK (GDA-201),Follicular and diffuse large B cell lymphomas ,Phase 1,03/27/2024,"Gamida Cell does not plan to conduct further development of GDA-201 at this time, as noted on March 27, 2024.",154.0
REGN,966.3,Pexa-Vec in combination with cemiplimab - (REN026),Metastatic or unresectable renal cell carcinoma (RCC). ,Phase 1/2,03/27/2024,"Phase 1b/2a study demonstrated an acceptable safety profile and encouraging efficacy of the combination therapy of Pexa-Vec, an engineered oncolytic vaccinia virus, and Libtayo (cemiplimab), anti-PD-1",105.0
RARE,46.82,Setrusumab (BPS-804) - (ORBIT),Osteogenesis Imperfecta ,Phase 2/3,03/27/2024,Phase 3 enrollment to be completed around the end of 1Q 2024/1H 2024.,96.0
MREO,3,Setrusumab (BPS-804) - (ORBIT),Osteogenesis Imperfecta ,Phase 2/3,03/27/2024,Phase 3 enrollment to be completed around the end of 1Q 2024/1H 2024.,155.0
AKBA,2.24,Vafseo (vadadustat),Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis ,Approved,03/27/2024,"Approved March 28, 2024.",265.0
CSLLY,93.88,Vafseo (vadadustat),Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis ,Approved,03/27/2024,"Approved March 28, 2024.",968.0
RVPH,3.9,Brilaroxazine - (RECOVER),Schizophrenia ,Phase 3,03/27/2024,"Phase 3 safety and efficacy shared at ASCPT reported that the 50 mg dose provided a significant decrease in primary (Total PANSS) with a discontinuation rate lower than 6%, noted March 27, 2024.",68.0
PTIX,1.82,PT00114,Major Depressive Disorder (MDD) / Generalized Anxiety Disorder (GAD) / Post-Traumatic Stress Disorder (PTSD) ,Phase 1,03/27/2024,Phase 1 single-dose results demonstrated safety at a medium dose of 500 micrograms administered subcutaneously in the third of five planned cohorts of subjects in the single dose portion of the Phase,
MIST,1.79,CARDAMYST (etripamil) - (RAPID),Paroxysmal supraventricular tachycardia (PSVT) ,NDA Filing,03/28/2024,"NDA resubmitted to FDA, noted March 28, 2024.",84.0
IRWD,8.71,Apraglutide - (STARGAZE),Acute Graft-Versus-Host Disease ,Phase 2,03/28/2024,"Phase 2 initial data reported that treatment was well-tolerated with an acceptable safety profile, noted March 28, 2024.",162.0
LPCN,5.2,LPCN 1148,"Liver cirrhosis, specifically prevention of OHE recurrence and treatment of sarcopenia ",Phase 2,03/28/2024,"Phase 2 data reported that that participants who received LPCN 1148 during Stage 1 had a significant increase in L3-SMI of 4.1 cm2/m2 (8.8%) at Week 24, noted March 28, 2024.",5.0
GILD,72.39,Efarindodekin Alfa (XTX301),Solid tumors ,Phase 1,03/28/2024,"Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.",
XLO,1.08,Efarindodekin Alfa (XTX301),Solid tumors ,Phase 1,03/28/2024,"Xilio granted Gilead an exclusive global license to develop and commercialize XTX301, Xilio's tumor-activated IL-12, noted March 28, 2024.",51.0
SNDX,23.8,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemias ,Phase 2,03/28/2024,"Phase 2 enrollment completed, noted March 28, 2024.",86.0
OCEA,3.79,VRON-0200,Hepatitis B ,Phase 1b,03/28/2024,"Phase 1b preliminary data reported that VRON-0200 was safe and well tolerated, with no clinical or laboratory changes of concern, noted March 28, 2024.",232.0
PPBT,0.67,NT219 in combination with cetuximab,Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) ,Phase 1/2,03/28/2024,"Phase 1/2 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence, noted March 28, 2024.",2.0
GRTX,0.14,Rucosopasem (GC4711) - (GRECO-1),Non-Small Cell Lung Cancer (NSCLC) ,Phase 1/2,03/28/2024,"Trial discontinued, noted March 28, 2024.",75.0
GRTX,0.14,Rucosopasem (GC4711) - (GRECO-2),Pancreatic Cancer ,Phase 2b,03/28/2024,"Trial discontinued, noted March 28, 2024.",75.0
APLT,6.8,Govorestat (AT-007) - (ACTION-Galactosemia kids),Galactosemia ,PDUFA priority review,03/28/2024,"PDUFA PR date of August 28, 2024. The FDA has set a new PDUFA target action date of November 28, 2024.",144.0
NBIX,137.92,NBI-1065890,CNS Indications ,Phase 1,03/28/2024,"Phase 1 initiated, noted March 28, 2024.",99.0
CADL,1.58,CAN-3110,Glioma ,Phase 1b,03/28/2024,"Phase 1b showed that serial procedures were well tolerated without observed dose-limiting toxicity in first cohort, noted March 28, 2024.",54.0
BMY,52.81,KRAZATI (adagrasib) and Taxotere (Docetaxel) - (KRYSTAL-12),Non-small cell lung cancer (NSCLC) ,Phase 3,03/28/2024,"Phase 3 trial met its primary endpoints, noted March 28, 2024.",
CNTX,1.38,CTIM-76,Various cancers ,IND-Enabling,03/28/2024,"IND submitted on March 28, 2024.",89.0
EQ,2.11,Itolizumab (EQ001) - (EQUALISE),Systemic lupus erythematosus (SLE) and lupus nephritis (LN) ,Phase 1b,04/01/2024,"Phase 1b topline data continues to show clinically meaningful response in highly proteinuric subjects. More than 80% of subjects achieved >50% reduction in urine protein creatinine ratio (UPCR), noted",59.0
GRTS,2.35,GRANITE-CRC-1L,1L Microsatellite-Stable Colorectal Cancer (MSS-CRC) ,Phase 2/3,04/01/2024,"Phase 2/3 preliminary data reported that the PFS trends favor GRANITE recipients with hazard ratios of 0.82 in the overall population and 0.52 in a high-risk group, noted April 1, 2024.",118.0
NVCR,15.49,Tumor Treating Fields (TTFields) with pembrolizumab and temozolomide - (TIGER),Glioblastoma (GBM) ,Phase 2,04/01/2024,"Phase 2 long-term data presented at ASCO reported that the median OS and PFS were 19.6 months (95% CI, 17.9–22.4) and 10.2 months, noted April 1, 2024.",111.0
LQDA,14.92,YUTREPIA,Interstitial lung disease (PH-ILD) ,PDUFA,04/01/2024,"A District Court set aside the injunction and the FDA is no longer enjoined from issuing final approval of Liquidia's New Drug Application (NDA) for YUTREPIA (treprostinil) inhalation powder, noted Ap",86.0
AZN,66.84,VOYDEYA (danicopan) add-on to SoC with ULTOMIRIS (ravulizumab-cwvz) or SOLIRIS (eculizumab)- (ALPHA),Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS) ,Approved,04/01/2024,"FDA Approved on April 1, 2024.",
AXSM,76.99,Sunosi (Solriamfetol) - (ENGAGE),Binge eating disorder ,Phase 3,04/01/2024,"Phase 3 initiated, noted April 1, 2024.",49.0
VRTX,420.48,inaxaplin (VX-147) - (AMPLITUDE),Proteinuric kidney disease with two mutations in the APOL1 gene (AMKD) ,Phase 2/3,04/01/2024,Phase 2/3 trial part 3 dosing initiated with expanded access to include adolescents with AMKD ages 10 to 17 years. An Independent Data Monitoring Committee (IDMC) reviewed Phase 2 safety and efficacy,256.0
IRON,34.21,Bitopertin - (APOLLO),Erythropoietic Protoporphyria (EPP) ,Phase 2,04/01/2024,"Phase 2 study met its primary endpoint. Despite improved measures of light tolerance, including the key secondary endpoint, in both 20 mg and 60 mg dose groups, but it did not meet statistical signifi",34.0
VTGN,5.4,PH94B - (PALISADE-3),Social Anxiety Disorder (SAD) ,Phase 3,04/01/2024,"PALISADE-3 initiated, noted April 1, 2024.",30.0
SRZN,10.1,SZN-043,Severe alcohol associated hepatitis ,Phase 1a,04/01/2024,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",8.0
ATNM,8.56,Iomab-B - (SIERRA),Acute myeloid leukemia (AML) ,Phase 3,04/01/2024,"Phase 3 results demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis, noted April 1, 20",31.0
CORT,25.74,Relacorilant - (GRADIENT),Cushing’s syndrome ,Phase 3,04/01/2024,"Phase 3 enrollment completed, noted April 1, 2024.",105.0
BMEA,12.8,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D) ,Phase 2,04/02/2024,"Phase 2 was initiated, noted January 8, 2024. Phase 2 data reported that in patient one, fasting C-peptide increased by 80% compared to baseline. In patient two, fasting C-peptide increased by 16% com",59.0
LLY,761.64,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 1b,04/02/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,946.0
VERV,8.32,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 1b,04/02/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,89.0
VTGN,$5.40 ,PH94B - (PALISADE-3),Social Anxiety Disorder (SAD) ,Phase 3,04/01/2024,"PALISADE-3 initiated, noted April 1, 2024.",30.0
SRZN,$10.10 ,SZN-043,Severe alcohol associated hepatitis ,Phase 1a,04/01/2024,"Phase 1a demonstrated acceptable safety and tolerability with no reported serious adverse events, noted April 1, 2024.",8.0
ATNM,$8.56 ,Iomab-B - (SIERRA),Acute myeloid leukemia (AML) ,Phase 3,04/01/2024,"Phase 3 results demonstrated Iomab-B's ability to overcome the negative impact of a TP53 mutation in patients who otherwise would have limited treatment options and dismal prognosis, noted April 1, 20",31.0
CORT,$25.74 ,Relacorilant - (GRADIENT),Cushing’s syndrome ,Phase 3,04/01/2024,"Phase 3 enrollment completed, noted April 1, 2024.",105.0
BMEA,$12.80 ,Icovamenib (BMF-219) - (COVALENT-112),Type 1 diabetes (T1D) ,Phase 2,04/02/2024,"Phase 2 was initiated, noted January 8, 2024. Phase 2 data reported that in patient one, fasting C-peptide increased by 80% compared to baseline. In patient two, fasting C-peptide increased by 16% com",59.0
LLY,$761.64 ,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 1b,04/02/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,946.0
VERV,$8.32 ,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 1b,04/02/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,89.0
ZLDPF,$94.49 ,VERVE-101 - (Heart-1),Heterozygous familial hypercholesterolemia (HeFH) ,Phase 1b,04/02/2024,Phase 1b clinical trial demonstrated LDL-C reduction of up to 73% at 0.45 mg/kg. Company to pause enrollment in Heart-1 clinical trial following asymptomatic Grade 3 transient ALT elevation and thromb,70.0
ROIV,$10.92 ,Brepocitinib - (NEPTUNE),Non-infectious uveitis (NIU) ,Phase 2,04/02/2024,"Phase 2 topline data showed the strongest efficacy data in NIU observed to date. The Treatment Failure rate from disease activity (discontinuations censored) was 18% in the brepocitinib 45 mg arm, n",682.0
GNPX,$2.84 ,Oncoprex,Anti-PD1 resistant non-small cell lung cancer (NSCLC) ,Preclinical,04/02/2024,"Preclinical data from mouse model reported that NPRL2 treatment reduced lung metastases significantly, whereas pembrolizumab was ineffective. The antitumor effect was greater in humanized than non-hum",
KNSA,$18.73 ,Abiprubart (KPL-404),Rheumatoid arthritis ,Phase 2,04/02/2024,"Phase 2 cohort 4 data reported a a statistically significant reduction of approximately 40% in Rheumatoid Factor in the abiprubart group, noted April 2, 2024.",74.0
KRBP,$3.00 ,Deltacel-01 - (KB-GDT-01),Stage 4 Metastatic Non-Small Cell Lung Cancer ,Phase 1,04/02/2024,"Phase 1 data from third patient after reviewing safety and efficacy findings from the first cohort, the Safety Monitoring Committee (SMC) recommended not to escalate the cell dose level and instead t",1.0
CRBP,$37.46 ,CRB-701 (SYS6002) with Pembrolizumab,"Solid tumors, Locally advanced or metastatic urothelial carcinoma ",Phase 1,04/02/2024,"Phase 1 US dosing initiated, noted April 2, 2024.",12.0
SGHT,$5.44 ,TearCare - (SAHARA RCT),Dry Eye Disease ,Phase 1,04/02/2024,"Phase 1 clinical results demonstrate long-term efficacy of the OMNI Surgical System for primary open-angle glaucoma and support use of TearCare technology as a primary treatment for dry eye disease, n",52.0
VNDA,$3.91 ,FANAPT (iloperidone),Bipolar Disorder ,Approved,04/02/2024,"Approved April 2, 2024.",59.0
FGEN,$1.47 ,FG-3246 (FOR46) in combination with enzalutamide - (Investigator-sponsored trial),Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 1,04/03/2024,"Phase 1 topline data reported a PSA50 response in 36% of patients, a confirmed radiographic objective response rate of 20%, with a median duration of response of 7.5 months, noted April 3, 2024.",4.0
LENZ,$21.22 ,VIZZ (aceclidine ophthalmic solution),Presbyopia ,Phase 3,04/03/2024,Phase 3 primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours. Rapid onset and long duration shown with 71% of participants achiev,28.0
MRK,$129.12 ,"Raludotatug deruxtecan (DS-6000, R-DXd) - (REJOICE-Ovarian01)",Ovarian cancer ,Phase 2/3,04/03/2024,"Phase 2/3 trial portion 2 initiated, noted April 3, 2024.",
DSNKY,$31.22 ,"Raludotatug deruxtecan (DS-6000, R-DXd) - (REJOICE-Ovarian01)",Ovarian cancer ,Phase 2/3,04/03/2024,"Phase 2/3 trial portion 2 initiated, noted April 3, 2024.",
PRFX,$1.77 ,PRF-110,Bunionectomy ,Phase 3,04/03/2024,"Phase 3 enrollment target reached 50%, noted April 2, 2024.",1.0
NBTX,$6.13 ,NBTXR3 - (MD Anderson Study 2020-0123),Non-small cell lung cancer (NSCLC) ,Phase 1,04/03/2024,"Phase 1 dose escalation study completed, noted April 2, 2024.",47.0
SPRY,$9.40 ,Neffy (epinephrine nasal spray),Allergic reactions (type I) including anaphylaxis ,CRL,04/03/2024,The Company submitted its response to the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for neffy® (epinephrine nasal spray) for the treatment of Type I allergic reactions,98.0
MRNA,$101.21 ,mRNA-3927 (Paramount),Propionic Acidemia ,Phase 1/2,04/03/2024,"Phase 1/2 has been well tolerated in participants at the doses administered, with no dose-limiting toxicities observed. Fifteen participants reported treatment-emergent adverse events (TEAEs), while n",389.0
MGNX,$13.67 ,MGC018 - (TAMARACK),Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 2,04/03/2024,"Phase 2 preliminary safety data suggested that reducing the dose and frequency of cobra duo improves its safety and tolerability in men with mCRPC, noted April 3, 2024.",63.0
ACHL,$0.90 ,ATL001 - (CHIRON),Non-Small Cell Lung Cancer (NSCLC) ,Phase 1/2,04/04/2024,"Phase 1/2 data reported that 25% of higher dose (>100M cNeT) patients demonstrated stable disease with some reduction in tumor volume, noted April 4, 2024.",41.0
ACHL,$0.90 ,ATL001 - (THETIS),Melanoma ,Phase 1/2,04/04/2024,"Phase 1/2a data reported that 3 of 12 patients demonstrated stable disease with some reduction in tumor volume, noted April 4, 2024.",41.0
CVAC,$2.96 ,Flu-SV-mRNA,Multivalent seasonal flu vaccine ,Phase 2,04/04/2024,"Phase 2 interim data reported that the vaccine boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose, noted April 4",224.0
GSK,$40.15 ,Flu-SV-mRNA,Multivalent seasonal flu vaccine ,Phase 2,04/04/2024,"Phase 2 interim data reported that the vaccine boosted antibody titers against all encoded flu strains and across all age groups and tested dose levels, including the lowest tested dose, noted April 4",
ADCT,$4.71 ,ZYNLONTA (Loncastuximab Tesirine-Ipyl) - (LOTIS-7),B-cell non-Hodgkin lymphoma ,Phase 1b,04/04/2024,"Phase 1b dose escalation trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients a",112.0
AMLX,$2.61 ,RELYVRIO (sodium phenylbutyrate and taurursodiol),Amyotrophic lateral sclerosis (ALS) ,Phase 3,04/04/2024,Company has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA (sodium phenylbutyrate and taurursodiol [also known as ursodo,89.0
AMLX,$2.61 ,AMX0035 - (A35-004 PHOENIX),Amyotrophic Lateral Sclerosis (AML) ,Phase 3,04/04/2024,"Based on Phase 3 previous results, the company has started a process with the FDA and Health Canada to voluntarily discontinue the marketing authorizations for RELYVRIO/ALBRIOZA (sodium phenylbutyrate",89.0
CADL,$6.40 ,CAN-2409 plus valacyclovir (prodrug),"Non-Metastatic Pancreatic Cancer, Pancreatic ductal adenocarcinoma (PDAC) ",Phase 2,04/04/2024,"Phase 2 interim data reported that at 24 months, survival rate was 71.4% in CAN-2409 treated patients versus only 16.7% in the control group after chemoradiation, noted April 4, 2024.",54.0
EFTR,$2.96 ,Tomivosertib (MNK1/2) - (KICKSTART),Non-small cell lung cancer (NSCLC) ,Phase 2b,04/04/2024,"Phase 2b study did not meet the pre-specified threshold of p≤0.2. The median PFS was 13.0 weeks in the tomivosertib plus pembrolizumab arm and 11.7 weeks in the placebo plus pembrolizumab arm, respect",4.0
GOVX,$2.01 ,GEO-CM04S1- (COH04S1),COVID-19 in immunocompromised patients ,Preclinical,04/04/2024,"Preclinical data presented at the Annual World Vaccine showed that vaccine-induced immunity protects against infections, serious disease symptoms, and death against the original Wuhan variant as well",25.0
DTIL,$14.34 ,ECUR-506 - (OTC-HOPE),Ornithine Transcarbamylase (OTC) Deficiency ,IND-Enabling,04/04/2024,"IND Cleared by the FDA, noted April 4, 2024.",11.0
CRBU,$4.54 ,CB-010 - (GALLOP),"Lupus nephritis (LN), extrarenal lupus (ERL) ",IND-Enabling,04/04/2024,"IND Clearance by FDA, noted April 4, 2024. Phase 1 trial planned by year end 2024.",93.0
HCM,$16.36 ,HMPL-295,Solid tumors ,Preclinical,04/05/2024,Preclinical data from AACR reported that HMPL-295 significantly improved the anti-tumor activity of standard-of-care chemotherapy as well as targeted agents in KRAS- or BRAF-mutant tumor models both,174.0
HCM,$16.36 ,HMPL-506,Leukemia ,Preclinical,04/05/2024,Preclinical data from AACR reported that in In vivo studies demonstrated the dose- and exposure- dependent target regulation of MEIS1 and anti-tumor efficacy following HMPL-506 treatment in multiple t,174.0
HCM,$16.36 ,HMPL-A067 (HMA800067),B-cell malignancies ,Preclinical,04/05/2024,"Preclinical data reported that an intravenous injection of HMA800067 at 10 mg/kg single dose induced complete tumor regression in all the animals within 10 days of administration, noted April 5, 2024.",174.0
AZN,$67.04 ,IMFINZI (Durvalumab) - (ADRIATIC),Small cell lung cancer (SCLC) limited disease ,Phase 3,04/05/2024,"Phase 3 trial met the the dual primary endpoints of overall survival (OS) and progression-free survival (PFS), noted April 5, 2024.",
CYTK,$72.71 ,Aficamten - (FOREST-HCM) (OLE),Non-obstructive hypertrophic cardiomyopathy (HCM) ,Phase 3,04/05/2024,Phase 3 first cohort efficacy and safety datacompleting 1-year follow-up data from ACC.24 reported that treatment with aficamten for 48 weeks resulted in substantial and sustained reductions in averag,119.0
OCGN,$1.83 ,OCU410 - (ArMaDa),Geographic Atrophy (GA) ,Phase 1/2,04/05/2024,"Phase 1/2 Data and Safety Monitoring Board (DSMB) convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study, noted April 5, 2024.",292.0
IGXT,$0.19 ,Buprenorphine Buccal Film - (Belbuca Biosimilar),Pain ,CRL,04/05/2024,"In an Amendment Acknowledgement received from the FDA by the company, the FDA granted priority review with a Generic Drug User Fee Act (GDUFA) date for review of the Amendment of March 8, 2024, unless",174.0
TARA,$3.63 ,TARA-002 - (ADVANCED-1),Non-muscle invasive bladder cancer (NMIBC) ,Phase 1b,04/05/2024,"Phase 1b data reported a complete response rate of 43% at three months, noted April 5, 2024.",38.0
TSVT,$4.92 ,Abecma (idecabtagene vicleucel; ide-cel),Multiple Myeloma ,Approved,04/05/2024,"Approved April 5, 2024.",53.0
BMY,$50.56 ,Abecma (idecabtagene vicleucel; ide-cel),Multiple Myeloma ,Approved,04/05/2024,"Approved April 5, 2024.",
CDTX,$23.20 ,CCR5-001,Colorectal cancer ,Preclinical,04/05/2024,"Preclinical data shared at the AACR conference demonstrated potent efficacy in colorectal cancer mouse model, noted April 5 2024.",25.0
CDTX,$23.20 ,CBO421,Tumor immune evasion prevention ,Preclinical,04/05/2024,"Preclinical data shared at AACR data demonstrated improved efficacy compared to oleclumab in human triple-negative breast cancer cell lines, noted April 5, 2024.",25.0
HOWL,$5.92 ,WTX-518,Solid tumors ,Preclinical,04/05/2024,"Preclinical data presented at AACR reported complete tumor regression in the MC38 mouse tumor model, noted April 5, 2024.",45.0
HOWL,$5.92 ,WTX-712,Solid tumors ,Preclinical,04/05/2024,"Preclinical data presented at AACR reported that treatment demonstrated inducibility and antitumor activity with regressions in the MC38 mouse tumor model, noted April 5, 2024.",45.0
JNJ,$152.39 ,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple Myeloma ,Approved,04/05/2024,"FDA Approval on April 5, 2024.",
LEGN,$54.93 ,CARVYKTI (ciltacabtagene autoleucel) - (CARTITUDE-4),Multiple Myeloma ,Approved,04/05/2024,"FDA Approval on April 5, 2024.",183.0
AZN,$67.04 ,Trastuzumab deruxtecan - (DESTINY-CRC02),HER2-overexpressing/amplified (HER2+) metastatic colorectal cancer (mCRC) ,Phase 2,04/05/2024,"Phase 2 data showed a confirmed ORR of 51.4% and a median DoR range of 19.4 months, noted April 5, 2024.",
AMRN,$1.05 ,VASCEPA (icosapent ethyl) - (REDUCE-IT),Cardiovascular disease ,Phase 1,04/06/2024,Phase 1 data presented at the American College of Cardiology's Annual Scientific Session & Expo show that findings presented on VASCEPA/VAZKEPA utility in REDUCE-IT patient subgroups by baseline High/,20.0
XLO,$1.47 ,XTX501,Solid Tumors ,Preclinical,04/07/2024,"Preclinical data shared at AACR reported superior PK profile compared to non-masked PD1/IL2 in mice, akin to PD1 antibodies, projected to achieve >95% PD-1 RO with once every 3 weeks (Q3W) dosing, no",51.0
REPL,$7.12 ,RP1 (vusolimogene oderparepvec) - (ARTACUS),Liver and kidney transplant recipients with recurrent Cutaneous squamous cell carcinoma ,Phase 1/2,04/07/2024,"Phase 1/2 open-label data presented at AACR reported an overall response rate (ORR) of 34.8 percent (8 of 23 evaluable patients, including 5 complete responses and 3 partial responses) with most respo",78.0
ALNY,$156.04 ,Zilebesiran - (KARDIA-2),Hypertension ,Phase 2,04/07/2024,"Phase 2 full data shared at the American College of Cardiology Scientific Sessions reported that zilebesiran demonstrated clinically significant and sustained placebo-adjusted, time-adjusted reduction",131.0
ARWR,$25.70 ,Plozasiran (ARO-APOC3-2001) - (SHASTA-2),Hypertriglyceridemia ,Phase 2,04/07/2024,"Phase 2 clinical data presented at ACC.24 reported a dose-dependent placebo-adjusted reductions in triglycerides, with Significant and durable triglyceride and APOC3 reductions to week 48, noted April",138.0
BNTX,$89.31 ,Cevumeran (BNT122),Resected pancreatic ductal adenocarcinoma (PDAC) ,Phase 1,04/07/2024,"Phase 1 data presented at AACR reported that in 8 of 16 patients, autogene cevumeran elicited high-magnitude T cells specific to the encoded neoantigens. 98% of the T cells targeting individual neoant",239.0
IONS,$42.24 ,TRYNGOLZA (olezarsen),Familial Chylomicronemia Syndrome (FCS) ,Phase 3,04/07/2024,"Phase 3 trial met her primary endpoint, noted April 7, 2024.",159.0
ITOS,$12.22 ,EOS-984 - (APT-008),Adenosine on T and B cells ,Preclinical,04/07/2024,"Preclinical data presented at AACR reported a blockade of intracellular adenosine accumulation by EOS-984 enabled proliferation of memory T cells and TILs despite high adenosine concentrations, result",44.0
INO,$11.34 ,GT-30,Cancer Vaccine in advanced hepatocellular carcinoma ,Phase 1/2,04/07/2024,"Phase 1/2 trial has met primary endpoints of safety and immunogenicity and secondary endpoint for efficacy based on response rate, noted April 7, 2024.",53.0
EWTX,$16.88 ,EDG-7500 - (CIRRUS-HCM),Hypertrophic Cardiomyopathy (HCM) ,Preclinical,04/07/2024,Preclinical data presented at ACC blunted the HCM-mediated progressive slowing of LV diastolic relaxation; additionally the candidate preserved myocardial distensibility and maintained cardiac reserve,105.0
SNDX,$22.81 ,Revuforj (revumenib) - (AUGMENT-101),Relapsed/refractory (R/R) acute leukemias ,Phase 2,04/08/2024,"Phase 2 data reported a complete remission (CR) or CR with partial hematological recovery (CRh) rate was 23%, and the overall response rate was 46%, noted April 8, 2024.",86.0
ZYME,$9.62 ,ZW191,"Non-small cell lung cancer, endometrial cancer, and triple-negative breast cancer ",Preclinical,04/08/2024,"Preclinical data reported superior internalization, payload delivery, and spheroid penetration to other FRα-targeted multi-specific antibodies, noted April 8, 2024.",75.0
BMRN,—,BMN 401 (INZ-701) - (adults trial),ENPP1 deficiency ,Phase 1/2,04/08/2024,"Phase 2 topline data showed avorable safety, immunogenicity and clinical outcome data were maintained through 48 weeks in Cohorts 1-3 in ENPP1 Deficiency; Data from Cohort 4 support once weekly dosing",192.0
MIST,$1.82 ,Etripamil - (NODE-303),Paroxysmal supraventricular tachycardia (PSVT) ,Phase 3,04/08/2024,Phase 3 data shared at ACC24 demonstrated that symptom-prompted treatment with etripamil was effective at restoring sinus rhythm as compared to placebo with a median time-to-conversion of 17.0 minutes,84.0
PSTX,$2.97 ,P-BCMA-ALLO1,Multiple myeloma ,Phase 1,04/08/2024,Phase 1 clinical early update presented at AACR suggests patients with relapsed/refractory multiple myeloma who progressed after prior BCMA-targeted therapy achieved clinical responses with P-BCMA-AL,97.0
KANT,—,KVA12123 with KEYTRUDA (pembrolizumab) - (VISTA-101),Solid tumors ,Phase 1/2,04/08/2024,"Phase 1/2 data presented at AACR showed a partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts, noted April 8, 2024.",13.0
VINC,$4.78 ,VIP236,Solid tumors ,Phase 1,04/08/2024,"Phase 1 initial data presented at AACR demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid",5.0
CRDF,$5.88 ,"Onvansertib, FOLFIRI and AVASTIN (bevacizumab) - (ONSEMBLE)",KRAS-Mutated Colorectal Cancer ,Phase 1/2,04/08/2024,Phase 1/2 data presented at AACR showed enhanced clinical efficacy signal in bev naïve patients is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-li,66.0
NUVL,$68.44 ,Zidesamtinib - (NVL-330) - (HEROEX-1),HER2-mutant tumors ,Preclinical,04/08/2024,"Preclinical data presented at AACR continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-type EGFR, and differentiated brain-penetrant profile , Zidesa",72.0
MRUS,$44.01 ,Zenocutuzumab (Zeno) in combination with Trastuzumab and Vinorelbine,Metastatic breast cancer ,Preclinical,04/08/2024,"Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2",75.0
GMAB,—,Zenocutuzumab (Zeno) in combination with Trastuzumab and Vinorelbine,Metastatic breast cancer ,Preclinical,04/08/2024,"Phase 2 data presented at AACR data show that Zeno is effective in tumor cell killing in vitro and in vivo in high NRG1 expressing cancer models representing multiple different tumor types, April 8, 2",661.0
INKT,$1.32 ,FAP-CAR-IL-15 iNKT (MiNK-215),Non-small cell lung cancer (NSCLC) ,Preclinical,04/08/2024,Preclinical data shared at AACR exhibits potent anti-tumor activity through multiple mechanisms including immune activation and eliminated MSS colorectal cancer liver metastases in human organoid mode,4.0
CADL,$6.43 ,Alpha 201-macro-1 (enLIGHTEN Discovery Platform),"Solid tumors, breast cancer ",Preclinical,04/08/2024,"Preclinical data shared at AACR reported that treatment was shown to induce tertiary lymphoid structure formation, inhibit tumor growth, and improve response to immune checkpoint inhibitor therapy in",54.0
COGT,$6.52 ,CGT4255 - (ErbB2),Solid tumors ,Preclinical,04/08/2024,Preclinical data presented at AACR showed that data further demonstrate Cogent's capability to discover and advance potential best-in-class novel therapies for rare disease populations with high unmet,139.0
AGEN,$9.31 ,BMS-986442 (AGEN1777),Solid tumors ,Preclinical,04/08/2024,"Preclinical data presented at AACR reported that treatment demonstrated superior immune activation as monotherapy and in combination with PD-(L)1 blockade compared to conventional anti-TIGIT mAb, note",31.0
ADCT,$5.09 ,ADCT-601 (mipasetamab uzoptirine),"Soft tissue sarcomas, pancreatic cancer and AXL-expressing non-small cell lung cancer (NSCLC) ",Phase 1b,04/08/2024,"Phase 1b additional data presented at AACR reported that due to the incidence of TEAE judged related to Mipa and the preliminary activity observed, 15mg was selected as the highest dose to be tested i",112.0
ALXO,$12.14 ,ALX148 and Vidaza (azacitidine) - (ASPEN-02),Myelodysplastic syndromes (MDS) ,Phase 1,04/08/2024,"Phase 1 data presented at AACR reported that the combination results in high CR rates in patients with relapsed refractory iNHL, noted April 8, 2024.",53.0
PYXS,$5.58 ,PYX-106,Solid Tumors ,Preclinical,04/08/2024,Additional preclinical data shared at AACR reported that Siglec-15 and PD-L1 mRNA expression are not broadly mutually exclusive across cancer indications and instead expression of each gene varies bro,62.0
ELTX,$8.66 ,ELI-002 (AMPLIFY-201),Solid Tumors ,Phase 1,04/08/2024,Phase 1 trial data presented at AACR reported that a majority of patients who received ELI-002 booster immunizations maintained or increased mKRAS-specific T cell responses relative to baseline. Durab,16.0
RIGL,$12.60 ,REZLIDHIA (olutasidenib) - (CONNECT),High-grade glioma (HGG) harboring an isocitrate dehydrogenase-1 (IDH1) mutation ,Phase 2,04/08/2024,"Phase 2 showed induced durable composite complete remission in 43.8% of patients relapsed or refractory to prior venetoclax-based regimens, noted April 8, 2024.",17.0
PTN,$2.02 ,PL9643 - (MELODY-1),Dry eye disease (DED) ,Phase 3,04/08/2024,Phase 3 results presented at the ASCRS Conference 2024 included co-Primary symptom endpoint of pain met statistical significance and 7 of 11 secondary symptom endpoints met statistical significance (p,46.0
SUPN,$31.43 ,ONAPGO (apomorphine hydrochloride) injection (SPN-830),Motor fluctuations in Parkinson’s disease (PD) ,CRL,04/08/2024,"CRL announced April 8, 2024.",56.0
ORIC,$10.75 ,ORIC-944,Metastatic castration resistant prostate cancer (mCRPC) ,Preclinical,04/08/2024,"Preclinical data demonstrated that EED and EZH2 inhibitors act through the same mechanism of action, making prostate cancer cells more susceptible to AR inhibition, noted April 8, 2024.",97.0
PFE,$25.84 ,DOVATO (Dolutegravir and lamivudine) - (DANCE),HIV-1 infection in adolescents 12 years + and weighing at least 25 kg with no antiretroviral (ARV) treatment history ,Approved,04/08/2024,"FDA Approved on April 8, 2024.",
ENTX,$1.95 ,EB613,Osteoporosis ,Phase 2,04/08/2024,"Phase 2 publication in the Journal of Bone Mineral Research showed that despite the superior benefits of bone building (anabolic) agents and guidelines supporting their use, these medications are used",45.0
CHRS,$2.51 ,CHS-1000,Solid Tumors ,Preclinical,04/08/2024,"Preclinical studies showed a high affinity for human ILT4, reverses ILT4-mediated immunosuppressive functions, leading to activation of immune cells and increased cytokine secretion, noted April 8, 20",116.0
NVCT,$7.81 ,NXP900,Non-small cell lung cancer (NSCLC) ,Phase 1,04/08/2024,"Phase 1 data presented at AACR demonstrated that the combination reverses resistance to osimertinib versus osimertinib alone, noted April 8, 2024.",25.0
CCCC,$7.66 ,CFT1946,Solid tumors ,Preclinical,04/08/2024,"Preclinical data reported that a CFT1946 as a single agent and in combination with cetuximab demonstrates superior activity to the standard of care combination, BRAFi with cetuximab, in all CRC models",71.0
CORT,$24.23 ,Relacorilant plus ABRAXANE (nab-paclitaxel) - (ROSELLA),Ovarian cancer ,Phase 3,04/08/2024,"Phase 3 enrollment completed, noted April 8, 2024.",105.0
INMB,$10.36 ,INB03,MUC4 expressing cancer ,Phase 1,04/08/2024,Trial data reported that the increase in T cell infiltrate did not occur unless both anti-HER2 and INB03 immunotherapy were used in combination. Decreases in T cell and macrophage immune checkpoint p,26.0
BMRN,—,BMN 401 (INZ-701),ABCC6 deficiency ,Phase 1/2,04/08/2024,"Phase 1/2 topline data reported a reduction or stabilization of cIMT was observed across all dose cohorts, and increased choroidal thickness was observed across all dose cohorts, noted April 8, 2024.",192.0
MRKR,$4.71 ,Neldaleucel (MT-601) - (APOLLO),Lymphoma who have failed or are ineligible to receive anti-CD19 CAR T cell treatment ,Phase 1,04/08/2024,"Phase 1 data reported that the initial dose level was well tolerated and demonstrated durable objective responses after MT-601 treatment, noted April 8, 2024.",12.0
NVS,$95.48 ,Leqvio - (V-INITIATE),Low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD) ,Phase 3,04/08/2024,"Phase 3b data reported significant reductions in LDL-C compared to those receiving usual care (60% vs. 7%), noted April 8, 2024.",
NXTC,$2.05 ,LNCB74,B7-H4 expressing cancers ,Preclinical,04/08/2024,"Preclinical data reported durable tumor regression in multiple CDX and PDX tumor models, suggesting activity comparable or superior to competitor B7-H4 targeting ADCs, noted April 8, 2024.",2.0
OCS,$10.76 ,OCS-01 - (OPTIMIZE-2),Inflammation and pain following ocular surgery ,Phase 3,04/08/2024,"Phase 3 trial data reported that 57.2% of patients treated with OCS-01 were inflammation free (i.e. absence of anterior chamber cells) at Day 15, and 75.5% had absence of ocular pain at Day 4, noted A",43.0
CVKD,$6.13 ,tecarfarin - (ARIES-HM3),Thromboembolism and thrombosis ,Phase 2,04/09/2024,"FDA granted orphan drug designation, noted April 9, 2024.",2.0
ATOS,$1.84 ,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer ,Phase 2,04/09/2024,"Phase 2 data shared at AACR showed that a Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging (MRI) central review demonstrated target lesion decreases in all",129.0
LLY,$754.94 ,(Z)-endoxifen with abemaciclib (VERZENIO) - (EVANGELINE),Pre-menopausal women w/ early-stage estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 negative breast cancer ,Phase 2,04/09/2024,"Phase 2 data shared at AACR showed that a Among the six patients who were treated for a total of 24-weeks, magnetic resonance imaging (MRI) central review demonstrated target lesion decreases in all",946.0
IMRX,$2.19 ,Atebimetinib (IMM-1-104) + mGnP,"Solid tumors, pancreatic cancer, melanoma ",Preclinical,04/09/2024,Preclinical data presented at AACR demonstrated that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibiti,36.0
CMPX,$1.67 ,CTX-009 in combination with paclitaxel,Biliary Tract Cancer (cholangiocarcinoma) ,Preclinical,04/09/2024,Preclinical data presented at AACR suggest that the combination of CTX-009 and CTX-471 could re-establish anti-tumor immunity in patients whose tumors have either downregulated or lost MHC-I expressio,138.0
MTEM,$1.85 ,MT-6402,Solid tumors ,Phase 1,04/09/2024,"Phase 1 interim data presented at AACR showed that drug has been well tolerated with no drug-related Grade 4 or Grade 5 adverse events observed, noted April 9, 2024.",6.0
NRIX,$17.48 ,NX-5948,B-cell malignancies / graft-versus-host disease ,Phase 1a,04/09/2024,Additional data with higher dose levels and longer treatment duration were reported at AACR; The company presented new case studies demonstrating clinical responses in two patients with B cell maligna,76.0
IOBT,$1.61 ,IO102-IO103 - (IOB-032),Squamous cell carcinoma of the head and neck (SCCHN) ,Phase 1/2,04/09/2024,"Phase 1/2 early data presented at AACR demonstrated the mechanism. Based on these results the company hopes to confirm its ongoing Phase 3 pivotal study, noted April 9, 2024.",65.0
RAPT,$8.44 ,tivumecirnon (FLX475) in combination with pembrolizumab,Advanced Cancer ,Phase 2,04/09/2024,"Phase 2 data shared at AACR confirmed an objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status, noted April 9, 2024.",16.0
FHTX,$7.48 ,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC) ,Preclinical,04/09/2024,"Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.",56.0
LLY,$754.94 ,FHD-909 (LY4050784),Non-small cell lung cancer (NSCLC) ,Preclinical,04/09/2024,"Preclinical data presented at AACR demonstrated favorable tolerability and dose-dependent single agent activity in BRG1 mutated cancers preclinically, noted April 9, 2024.",946.0
INAB,$1.09 ,INB-300,Solid Tumors ,Preclinical,04/09/2024,"Preclinical data presented at AACR supports potential for proprietary nsCAR platform to selectively eliminate cancer cells while preserving healthy tissue, noted April 9, 2024.",4.0
TPST,$3.87 ,TPST-1120,renal cell carcinoma (RCC) ,Preclinical,04/09/2024,"Preclinical data shared at AACR showed that TPST-1120 increases infiltrating cytotoxic CD8+ T cells in the tumor microenvironment, consistent with modulation of the tumor microenvironment to a more im",4.0
AZN,$67.99 ,FPI-2265 - (AlphaBreak),Prostate cancer ,Phase 2,04/09/2024,"Phase 2 preliminary data presented at AACR demonstrate that FPI-2265 is active in heavily pretreated patients with progressive metastatic castration-resistant prostate cancer (mCRPC), including those",
PRLD,$4.99 ,PRT7732,lymphoid malignancies ,Preclinical,04/09/2024,"Preclinical data shared at AACR shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses, noted April 9, 2024.",56.0
PRLD,$4.99 ,PRT2527,Solid tumors and hematological malignancies ,Preclinical,04/09/2024,"Additional preclinical data shared at the AACR provides improved depth and duration of response in combination with BTK/BCL2 inhibition, noted April 9, 2024.",56.0
PRLD,$4.99 ,PRT3645,Cancer ,Preclinical,04/09/2024,"Preclinical data at AACR showed that drug is highly effective in combination with other targeted therapies in preclinical models of breast cancer, CRC and NSCLC, noted April 9, 2024.",56.0
CRVS,$1.63 ,Soquelitinib - (CPI-818),Peripheral T-cell lymphoma (PTCL) ,Phase 3,04/09/2024,"Phase 3 dosing initiated, noted April 9, 2024.",74.0
MCRB,$0.71 ,SER-155,"Gastrointestinal infections, bacteremia and graft versus host disease (GvHD) ",Phase 1b,04/09/2024,"Phase 1b cohort 2 patient enrollment completed, noted April 9, 2024.",8.0
QLGN,$0.40 ,QN-302,"Pancreatic cancer, Prostate cancer and other solid tumors ",Phase 1,04/09/2024,"Phase 1 results demonstrated that for the first five patients (three of whom were PDAC patients), QN-302 is overall well-tolerated (no SAE) and they have reported a ""good"" quality of life during the d",1.0
BCTX,$2.85 ,SV-BR-1-GM,Metastatic breast cancer ,Phase 2,04/09/2024,"Phase 2 efficacy and safety data shared at AACR shows that Bria-IMT provides prolonged progression-free survival and clinical benefits in heavily pre-treated, ADC resistant breast cancer patients comp",1.0
BCTX,$2.85 ,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,04/09/2024,Phase 2 data shared at AACR showed that Bria-IMT's tumor reductions observed in all breast cancer subtypes in patients with intracranial disease underlines its potential clinical effectiveness in mana,1.0
IPHA,$2.60 ,IPH45,Nectin-4 expressing tumors ,Preclinical,04/09/2024,"Preclinical data presented at AACR reported that treatment effectively inhibits Nectin-4 expressing tumor growth both in vitro and in vivo, including in Enfortumab Vedotin (EV) refractory models, note",92.0
ALXO,$12.34 ,ALX148 (evorpacept) + rituximab and lenalidomide,Non-Hodgkin lymphoma (NHL) ,Phase 1,04/09/2024,"Phase 1 trial data presented at AACR reported that the best ORR of 94% and a CRR of 83%, noted April 9, 2024.",53.0
GNPX,$3.07 ,REQORSA (GPX-001) with KEYTRUDA (pembrolizumab) - (Acclaim-2),Non-Small Cell Lung Cancer (NSCLC) ,Preclinical,04/09/2024,"Preclinical data presented at AACR reported that the NPRL2 treatment by itself led to a marked decrease in the size of lung metastases but pembrolizumab had no effect, noted April 9, 2024.",
CGEN,$2.36 ,COM503,Solid tumors ,Preclinical,04/09/2024,"Preclinical data shared at AACR found that COM503's activity is localized to the tumor microenvironment with the additional advantage of a wider therapeutic window than systemic IL-18 delivery, noted",93.0
GILD,$69.12 ,COM503,Solid tumors ,Preclinical,04/09/2024,"Preclinical data shared at AACR found that COM503's activity is localized to the tumor microenvironment with the additional advantage of a wider therapeutic window than systemic IL-18 delivery, noted",
NTBL,$1.41 ,Volasertib,Relapsed/refractory acute myeloid leukemia ,Preclinical,04/09/2024,"Preclinical data presented at AACR suggest a strong correlation between volasertib resistant fractions treated with 31.6 and 100 nM of volasertib and AUCs, which could represent a suitable metric to s",9.0
PFE,$26.03 ,ABRYSVO - (MONeT),Respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD) ,Phase 3,04/09/2024,"Phase 3 trial met its primary endpoint, noted April 9, 2024.",
BGNE,$154.02 ,Tislelizumab (anti-PD1) plus ociperlimab (anti-TIGIT) - (AdvanTIG-204),Small cell lung cancer (SCLC) ,Phase 2,04/09/2024,"Phase 2 data presented at AACR reported that in patients with untreated limited-stage SCLC, tislelizumab + cCRT yielded a trend of improvement in PFS and ORR vs cCRT; addition of ociperlimab did not s",106.0
ONC,—,Tislelizumab (anti-PD1) plus ociperlimab (anti-TIGIT) - (AdvanTIG-204),Small cell lung cancer (SCLC) ,Phase 2,04/09/2024,"Phase 2 data presented at AACR reported that in patients with untreated limited-stage SCLC, tislelizumab + cCRT yielded a trend of improvement in PFS and ORR vs cCRT; addition of ociperlimab did not s",110.0
BGNE,$154.02 ,BGB-10188,Solid tumors ,Phase 1a,04/09/2024,Phase 1a data presented at AACR reported that BGB‑10188 + tislelizumab showed preliminary antitumor activity and was generally safe and tolerable across doses in this heavily pretreated population of,106.0
ONC,—,BGB-10188,Solid tumors ,Phase 1a,04/09/2024,Phase 1a data presented at AACR reported that BGB‑10188 + tislelizumab showed preliminary antitumor activity and was generally safe and tolerable across doses in this heavily pretreated population of,110.0
CCCC,$7.97 ,CFT8634,Synovial sarcoma ,Phase 1,04/09/2024,"Phase 1 data presented at AACR reported that selective targeting of EP300 with targeted protein degradation is a safe and effective treatment strategy for advanced tumors, noted April 9, 2024.",71.0
BCYC,$23.07 ,BT7455,EphA2-expressing cancers ,Preclinical,04/09/2024,"Preclinical data shared at AACR reported that treatment engages EphA2 and CD137 with high affinity, resulting in potent EphA2-dependent activity in vitro and robust anti-tumor activity in vivo with in",69.0
APRE,$6.04 ,ATRN-119,Advanced solid tumors ,Phase 1/2,04/09/2024,Phase 1/2a trial shared at AACR reported that two of 12 patients achieved stable disease (SD): one patient from Dose level 1 (50 mg) who progressed on Day 112 and one patient from Dose level 3 (200 mg,5.0
YS,$0.90 ,PIKA Rabies Vaccine,Rabies ,Phase 3,04/10/2024,"Phase 3 trial met its primary endpoints, noted April 10, 2024.",93.0
WHWK,—,Nab-sirolimus in combination with fulvestrant,Breast Cancer ,Preclinical,04/10/2024,"Preclinical data presented at AACR reported that nab-sirolimus enhanced the cytotoxic effects of fulvestrant in HR+ breast cancer cells and PI3Ki in both HR+ and HR- breast cancer cells, noted April 1",47.0
BTAI,$2.63 ,Dexmedetomidine (BXCL501) - (TRANQUILITY III),Agitation associated with Alzheimer’s Disease ,Phase 3,04/10/2024,"Phase 3 expanded to In-Care study, trial planned to initiate soon following FDA meeting, noted April 10, 2024.",14.0
VSTM,$11.30 ,GFH375/VS-7375,Cancer KRAS G12D ,Preclinical,04/10/2024,"Preclinical data shared at AACR shown potent efficacy and safety of orally administered GFH375 in animal models, noted April 8, 2024.",61.0
GALT,$3.82 ,GR-MD-02 (belapectin) - (NAVIGATE),Non-alcoholic steatohepatitis (NASH) with cirrhosis ,Phase 2/3,04/10/2024,"5th DSMB recommends the continuation, without modifications, noted April 10, 2024.",64.0
ALKS,$26.14 ,ALKS 2680 - (Vibrance-1),Narcolepsy ,Phase 1,04/10/2024,Phase 1 demonstrated clinically meaningful and statistically significant improvements from baseline in mean sleep latency compared to placebo at all doses tested in both narcolepsy type 2 and idiopath,165.0
ACRV,$10.39 ,ACR-2316,"Dual WEE1 and PKMYT1 inhibitor, Solid tumors ",Preclinical,04/10/2024,"Preclinical data presented at AACR reported that treatment was highly potent across multiple human tumor cell lines and patient-derived ex vivo tumor models, noted April 10, 2024.",31.0
AIM,$0.56 ,"Ampligen, cisplatin and KEYTRUDA (pembrolizumab)",Ovarian cancer ,Phase 2,04/10/2024,"Phase 2 protocol planned interim results by leading the investigator to concluded that the combination therapy could be far more effective than pembrolizumab alone as a therapy for the disease, noted",2.0
BCTX,$2.73 ,Bria-Pros+,Prostate cancer ,Preclinical,04/10/2024,"Preclinical data reported that treatment engaged with multiple facets of the adaptive immune response, which may result in lasting anti-cancer effects in patients, noted April 10, 2024.",1.0
AMLX,$2.46 ,AMX0035 - (HELIOS),Wolfram Syndrome ,Phase 2,04/10/2024,"Phase 2 data demonstrated improvements in pancreatic function and glycemic control, as measured by C-peptide and other markers of glucose metabolism, rather than worsening typically expected with dise",89.0
REGN,$936.20 ,BNT116 and Libtayo - (LuCa-MERIT-1),Non-small cell lung cancer (NSCLC) ,Phase 1,04/10/2024,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs",105.0
BNTX,$88.65 ,BNT116 and Libtayo - (LuCa-MERIT-1),Non-small cell lung cancer (NSCLC) ,Phase 1,04/10/2024,"Phase 1 trial preliminary results presented at AACR reported that BNT116 + DTX shows encouraging antitumor activity, consistent induction of immune responses, a manageable safety profile, and no signs",239.0
APVO,$2.40 ,ALG.APV-527,Solid tumors ,Phase 1,04/10/2024,"Phase 1 Cohort 5 dosing imminent, trial more than 50% enrolled, noted April 10, 2024.",3.0
APVO,$2.40 ,mipletamig (APVO711),Solid tumors ,Preclinical,04/10/2024,"Preclinical studies ongoing, in vivo studies have confirmed that APVO711 reduces the size of PD-L1-expressing tumors, noted April 10, 2024.",3.0
CRBU,$4.35 ,CB-012,Acute Myeloid Leukemia (AML) ,Preclinical,04/10/2024,"Preclinical data presented at AACR reported that in robust tumor control, leading to significant prolongation of survival in AML xenograft models, noted April 10, 2024.",93.0
VRTX,$397.58 ,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathy ",Phase 2,04/10/2024,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we",256.0
ALPN,$47.04 ,Povetacicept (ALPN-303) - (RAINIER),"Lupus nephritis, IgA nephropathy ",Phase 2,04/10/2024,"Phase 1b/2a 240mg data presented at the World Congress of Nephrology showed that treatment continues to be well tolerated in IgA nephropathy, with UPCR reductions of greater than 60% observed at 36 we",68.0
KRYS,$175.70 ,KB707 - (KYANITE-1),Solid Tumors ,Preclinical,04/10/2024,"Preclinical data shared at AACR reported that KB703/KB704 treatment enhanced the frequency of IFNγ-expressing T cells both in the tumor and tumor-draining lymph node, leading to higher levels of circu",28.0
LPCN,$6.41 ,LPCN 2401,"Obesity, Chronic Weight Management ",Phase 2,04/11/2024,Phase 2 treatment resulted in statistically significant body composition improvement in men Increased lean mass (LM) by 4.4% and decreased fat mass (FM) by 6.7%. Reduced android fat (AF) by 4.1% and i,5.0
PRTC,$27.93 ,LYT-200,"Solid tumors, urothelial and head and neck cancers, acute myeloid leukemia (AML) ",Phase 1/2,04/11/2024,"Fast track designation granted by the FDA, noted April 11, 2024.",24.0
CLYM,—,Budoprutug (TNT119),Systemic lupus erythematosus ,Phase 2,04/11/2024,"Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67.0
CLYM,—,Budoprutug (TNT119),Immune thrombocytopenia ,Phase 2,04/11/2024,"Phase 2 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67.0
CLYM,—,Budoprutug (TNT119),Membranous nephropathy ,Phase 1,04/11/2024,"Phase 1 ongoing, acquired by Eliem from Tenet Medicines, noted April 11, 2024.",67.0
BOLD,$11.63 ,BBI-355/BBI-825 - (POTENTIATE),Resistance gene amplifications ,Phase 1/2,04/11/2024,"Phase 1/2 dosing commenced, noted April 11, 2024.",22.0
AZN,$69.02 ,FASENRA (benralizumab) - (TATE),Eosinophilic asthma aged 6 to 11 with an eosinophilic phenotype ,Approved,04/11/2024,"FDA approved on April 11, 2024.",
RARE,$42.87 ,GTX-102 - (Aspire),Angelman Syndrome ,Phase 1/2,04/15/2024,"Phase 1/2 data from expansion cohorts showed rapid, clinically meaningful improvement across multiple domains; improvements consistent or exceeding Dose-escalation Cohorts data at Day 170, noted April",96.0
LGND,$79.77 ,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE) ,Phase 3,04/15/2024,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,19.0
MRNS,$1.30 ,ZTALMY (ganaxolone) - (RAISE),Refractory status epilepticus (RSE) ,Phase 3,04/15/2024,Phase 3 did not meet pre-defined stopping criteria at the interim analysis; Marinus has completed RAISE enrollment at approximately 100 patients with topline results expected summer 2024.,55.0
TFFP,$3.52 ,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,04/15/2024,Phase 2 updates data to be presented at the upcoming ISHLT 2024 meeting provided strong biomarker evidence that treatment with TFF TAC results in normalization of rejection-related genes; the treatmen,4.0
VIRX,$0.78 ,Nanatinostat - (NAVAL-1),Epstein Barr Virus-associated cancers ,Phase 2,04/15/2024,Phase 2 Stage 1 data from patients in the Nana-val treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the int,39.0
RNAZ,$0.54 ,TTX-MC138,Metastatic solid tumors ,Phase 1/2,04/15/2024,"IND clearance by the FDA, noted April 15, 2024.",
ONVO,$1.35 ,FXR314,MASH & Primary Biliary Cholangitis ,Phase 2,04/15/2024,"Phase 2 16-week details study results demonstrated a statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo, noted April 15, 2024.",1.0
CORT,$23.15 ,Dazucorilant (DAZALS),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2,04/15/2024,"Phase 2 enrollment completed, noted April 15, 2024.",105.0
EWTX,$16.48 ,sevasemten (EDG-5506) - (ARCH),Becker muscular dystrophy (BMD) ,Phase 1b,04/15/2024,"Phase 1b 24-months topline data showed that significant decreases were observed in circulating levels of creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), biomarkers associated with sk",105.0
ORIC,$9.54 ,ORIC-114,"Tumors - EGFR/HER2 Exon 20 Inhibitor, 1L NSCLC ",Phase 1b,04/15/2024,"Phase 1b expansion cohorts initiated, noted April 15, 2024.",97.0
TELO,$8.84 ,Telomir-1,Age-related conditions ,Preclinical,04/15/2024,"Preclinical data confirmed our hypothesis that TELOMIR-1 affects telomere length, promoting its extension in primary cell strains including MRC-5, HUVEC, and MSCs (~40% increase), noted April 15, 2024",32.0
LBPH,$18.25 ,Bexicaserin (LP352) - (DEEp OCEAN),Adolescent and adult patients with developmental and epileptic encephalopathies (DEEs) ,Phase 1/2,04/15/2024,"Phase 1b/2a data presented at the AAN Annual Meeting reported that treatment with bexicaserin reduced seizures in all participant subgroups, including LGS and DEE Other, noted April 15, 2024.",39.0
NVS,$94.41 ,Fabhalta (iptacopan),IgA nephropathy (IgAN) ,Phase 3,04/15/2024,"Phase 3 data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo, noted April 15, 2024.",
HALO,$38.38 ,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP) ,Phase 3,04/16/2024,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",116.0
ARGX,$370.68 ,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP) ,Phase 3,04/16/2024,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",60.0
ZLAB,$14.42 ,Efgartigimod - (ADHERE),Chronic inflammatory demyelinating polyneuropathy (CIDP) ,Phase 3,04/16/2024,"Phase 3 data presented at AAN reported that 67% of patients treated with VYVGART Hytrulo demonstrated evidence of clinical improvement (ECI), including 40% who had achieved ECI by the earliest possibl",109.0
JNJ,—,CAPLYTA (lumateperone) - (Study 501),Major depressive disorder (MDD) ,Phase 3,04/16/2024,"Phase 3 topline results for the 42 mg Cohort achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints, noted April 16, 2024.",
PRTC,$25.48 ,Deupirfenidone (LYT-100) - (ELEVATE IPF),Idiopathic pulmonary fibrosis (IPF) ,Phase 2,04/16/2024,"Phase 2 enrollment completed, noted April 16, 2024.",24.0
CGEM,$17.32 ,CLN-978,Relapsed/refractory B-cell non-Hodgkin lymphoma ,Phase 1,04/16/2024,"The company has discontinued enrollment in its B-NHL study to focus ongoing development on autoimmune indications, noted April 16, 2024.",59.0
PALI,$5.93 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,04/16/2024,"Preclinical data completion of exvivo analysis, noted April 16, 2024.",9.0
CMPX,$1.57 ,CTX-8371,Solid Tumors ,Phase 1,04/16/2024,"Phase 1 dosing initiated, noted April 16, 2024.",138.0
ABOS,$3.50 ,Sabirnetug (ACU193) - (INTERCEPT-AD),Alzheimer’s disease (AD) ,Phase 1,04/16/2024,"Phase 1 additional data presented at AAN demonstrated a favorable safety and tolerability profile in participants with early AD with a relatively low incidence of ARIA-E, noted April 16, 2024.",60.0
LEXX,$2.31 ,DehydraTECH-GLP-1 - (GLP-1-H24-2),"Healthy volunteers, Diabetes-related control, weight loss ",Preclinical,04/16/2024,"Preclinical approval has been received from an independent third-party ethics review board, for human pilot study #2, noted April 16, 2024.",19.0
CLNN,$6.20 ,CNM-Au8 - (VISIONARY-MS),Multiple Sclerosis ,Phase 2,04/16/2024,"Phase 2 LTE emonstrated significant evidence of repair and remyelination across multiple paraclinical endpoints, noted April 16, 2024.",9.0
PXMD,$0.66 ,PAX-HAT-301,Stage 1 Trypanosoma Brucei Rhodesiense Human African Trypanosomiasis (Stage 1 TBR HAT) ,NDA Filing,04/16/2024,"NDA Company received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on by dwindling supplies",10.0
TEVA,$13.09 ,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. ,Approved,04/16/2024,"FDA approved on April 16, 2024.",
ALVO,$12.73 ,SELARSDI (ustekinumab-aekn) - (STELARA biosimilar),moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. ,Approved,04/16/2024,"FDA approved on April 16, 2024.",301.0
SAGE,$12.57 ,Dalzanemdor (SAGE-718) - (PRECEDENT),Mild cognitive impairment (MCI) ,Phase 2,04/17/2024,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.",62.0
SUPN,—,Dalzanemdor (SAGE-718) - (PRECEDENT),Mild cognitive impairment (MCI) ,Phase 2,04/17/2024,"Phase 2 data did not show statistically significant differences versus placebo on the primary endpoint , noted April 17, 2024.",56.0
LLY,$748.49 ,Zepbound (Tirzepatide) - (SURMOUNT-OSA),Obstructive Sleep Apnea (OSA) ,Phase 3,04/17/2024,"Phase 3 trial data showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints, noted April 17, 2024.",946.0
GSK,$38.91 ,Blujepa (Gepotidacin) - (EAGLE 2/3),Uncomplicated urinary tract infection (uUTI) ,Phase 3,04/17/2024,"Phase 3 EAGLE-1 data from ESCMID reported that gepotidacin (oral, two doses of 3,000mg) was non-inferior with 92.6% success rates when compared to 91.2% success rates for intramuscular (IM) ceftriaxon",
RHHBY,$30.08 ,Ocrevus Zunovo,Multiple sclerosis (MS) or primary progressive MS ,Phase 3,04/17/2024,Phase 3 data reported near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential be,
HALO,$38.02 ,Ocrevus Zunovo,Multiple sclerosis (MS) or primary progressive MS ,Phase 3,04/17/2024,Phase 3 data reported near-complete suppression of clinical relapses and brain lesions in people with relapsing or primary progressive multiple sclerosis (RMS or PPMS) which reinforce the potential be,116.0
NVS,$93.08 ,Kesimpta (ofatumumab) - (ALITHIOS),Relapsing Multiple Sclerosis ,Phase 3,04/17/2024,"Additional Phase 3 data reported that significant reductions in ARR (71.3%) and in MRI lesion activity (Gd+ T1: 98.5% reduction; neT2: 93% reduction), and rapid increase in rates of NEDA-3, noted Apri",
MTVA,—,DA-1726,NASH and obesity ,Phase 1a,04/17/2024,"Phase 1a dosing initiated, noted April 17, 2024.",24.0
VIGL,$2.92 ,iluzanebart (VGL101) - (IGNITE),Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) ,Phase 2,04/17/2024,"Phase 2 interim results shared at the 2024 American Academy of Neurology (AAN) Annual Meeting demonstrated iluzanebart (VGL101) as potential disease-modifying therapy for ALSP, noted April 17, 2024.",46.0
SNY,—,iluzanebart (VGL101) - (IGNITE),Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP) ,Phase 2,04/17/2024,"Phase 2 interim results shared at the 2024 American Academy of Neurology (AAN) Annual Meeting demonstrated iluzanebart (VGL101) as potential disease-modifying therapy for ALSP, noted April 17, 2024.",
VIGL,$2.92 ,VGL101 - (ILLUMINATE),Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) ,Phase 2,04/17/2024,"Phase 2 Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology, noted April 17, 2024.",46.0
SNY,—,VGL101 - (ILLUMINATE),Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) ,Phase 2,04/17/2024,"Phase 2 Natural History Study show that MRI and fluid biomarkers are emerging as key measures of ALSP pathophysiology, noted April 17, 2024.",
DMAC,$2.60 ,Rinvecalinase Alfa (DM199) - (ReMEDy2),Acute ischaemic stroke (AIS) ,Phase 2/3,04/17/2024,"Phase 2/3 resumed with dosing of first patient, noted April 17, 2024.",51.0
GLPG,$29.22 ,GLPG5101 - (ATALANTA-1),Relapsed/refractory Non-Hodgkin Lymphoma (rrNHL) ,Phase 1/2,04/17/2024,"Phase 1/2 preliminary data reported that six patients responded to treatment (ORR 86%), including four CRs (CRR 57%), noted April 17, 2024.",65.0
ATHA,$2.11 ,ATH-1020,"Healthy volunteers, Neuropsychiatric conditions ",Preclinical,04/17/2024,"Preclinical data presented at AAN reported that significantly enhanced neurite outgrowth, increased synaptic count, and promoted survival in primary neuron cultures, noted April 17, 2024.",3.0
GLPG,$29.22 ,GLPG5201 - (EUPLAGIA-1),"B-cell malignancies, Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL) ",Phase 1/2,04/17/2024,"Phase 1/2 data reported an ORR of 93% , noted April 17, 2024.",65.0
ABBV,$163.15 ,Tavapadon - (TEMPO-3),Late Parkinson’s disease ,Phase 3,04/18/2024,"Phase 3 trial met its primary endpoint, noted April 18, 2024.",
OCUL,$5.86 ,AXPAXLI (OTX-TKI) - (HELIOS),Non-proliferative diabetic retinopathy (NPDR) ,Phase 1,04/18/2024,"Phase 1 interim data showed that demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the AXPAXLI arm, compared to 0% in the control arm. No patient",174.0
BPTH,$4.20 ,BP1002,Acute Myeloid Leukemia (AML) ,Phase 1b,04/18/2024,"Phase 1/1b second dose cohort completed, noted April 18, 2024.",8.0
BNTC,$6.82 ,BB-301,Oculopharyngeal muscular dystrophy (OPMD) ,Phase 1/2,04/18/2024,"Phase 1b/2a interim safety and efficacy data reported that facilitated improvements across multiple measures of swallowing function in the first subject, as compared to pretreatment assessments conduc",26.0
PBLA,$0.49 ,Lvospemin (SBP-101),Ovarian cancer ,Phase 1,04/18/2024,"Phase 1 data presented at AACR results suggest that SBP-101 in combination with doxorubicin may have a role in the clinical management of ovarian cancer, in particular the difficult to treat platinum-",4.0
ATNM,$6.67 ,Iomab-B - (SIERRA),Acute myeloid leukemia (AML) ,Phase 3,04/18/2024,Phase 3 data presented at the Annual European Bone Marrow Transplant Society Meeting (EBMT) demonstrated that Iomab-B led bone marrow transplant produced high rates of complete remission and durable c,31.0
IMNN,$1.13 ,IMNN-101 - (IMUNON),SARS-CoV-2 variant XBB.1.5 ,IND-Enabling,04/18/2024,"IND Cleared by the FDA, noted April 18, 2024.",2.0
ABBV,$163.15 ,Upadacitinib (RINVOQ) - (SELECT-GCA),Giant cell arteritis (GCA) ,Phase 3,04/18/2024,"Phase 3 showed that upadacitinib (RINVOQ; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52, not",
NRSN,$1.52 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,04/18/2024,Phase 2b data presented at AAN reported that PrimeC met safety and tolerability measures as well as statistically significant slowing of disease progression as demonstrated by the ALSFRS-R by 37% (p=0,23.0
PHRRF,$0.17 ,KETARX (ketamine),Surgical pain management ,CRL,04/18/2024,"CRL issued by FDA, noted April 18, 2024.",91.0
RHHBY,$30.05 ,Alecensa(alectinib),Non-small cell lung cancer (NSCLC) ,Approved,04/18/2024,"FDA approved on April 18, 2024.",
MGTX,$5.01 ,AAV2-hAQP1 - (AQUAx2),Xerostomia ,Phase 1,04/18/2024,"Phase 1 data presented at AAOM resulted in no treatment-related serious adverse events or dose-limiting toxicities were reported, and all participants completed the study, noted April 18, 2024.",80.0
BRNS,$2.71 ,VTP-200 - (APOLLO),Human papillomavirus (HPV) ,Phase 1/2,04/18/2024,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.",40.0
CLYD,—,VTP-200 - (APOLLO),Human papillomavirus (HPV) ,Phase 1/2,04/18/2024,"Additional Phase 1/2a met its primary endpoint, noted April 18, 2024.",
TAK,$13.16 ,ENTYVIO (vedolizumab),Crohn's Disease ,Approved,04/18/2024,"FDA Approved by the FDA, noted April 18, 2024.",
TVGN,$1.85 ,TVGN 489 - (TCTL Study),Cytotoxic T Lymphocytes for the Treatment of Elderly and High-Risk Patients with Covid-19 ,Phase 1,04/19/2024,"Phase 1 study proof-of-concept clinical trial suggested the ability to target and eliminate a virus in high-risk population with multiple comorbidities, noted April 11, 2024.",196.0
OCGN,$1.32 ,OCU410 - (ArMaDa),Geographic Atrophy (GA) ,Phase 1/2,04/19/2024,"Phase 1/2 Cohort 2 dosing completed, noted April 19, 2024.",292.0
CNTA,$10.00 ,ORX750 - (CRYSTAL-1),Narcolepsy and other sleep-wake disorders ,IND-Enabling,04/22/2024,"IND cleared by the FDA, noted April 22, 2024",134.0
KRYS,$157.25 ,KB707 - (KYANITE-1),Solid Tumors ,Phase 1,04/22/2024,"Phase 1 dosing initiated, noted April 22, 2024.",28.0
ENLV,$1.27 ,Allocetra - (ENX-CL-05-001),Knee osteoarthritis (OA) ,Phase 2,04/22/2024,"Phase 2 trial initiated, noted April 22, 2024.",23.0
CORT,$22.30 ,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome) ,Phase 3,04/22/2024,"Phase 3 additional results exhibited clinically meaningful and statistically significant improvements in hypertension, hyperglycemia and other key secondary and exploratory endpoints, noted April 22,",105.0
ASLN,$3.64 ,Eblasakimab (ASLAN004) - (TREK-DX),Atopic dermatitis (AD) ,Phase 2b,04/22/2024,Phase 2b data reported that 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg,2.0
PHIO,$7.47 ,PH-762,Cutaneous Squamous Cell Carcinoma ,Preclinical,04/22/2024,Preclinical studies demonstrated PH-762 is rapidly taken up by cells and robustly silences PD-1 mRNA and protein in lymphocytes within the tumor microenvironment (TME) Intratumoral injection of murine,5.0
ABEO,$7.36 ,ZEVASKYN (prademagene zamikeracel),Recessive dystrophic epidermolysis bullosa (RDEB) ,CRL,04/22/2024,"CRL issued by the FDA, noted April 22, 2024.",51.0
AZTR,$5.85 ,ATR12-351,Netherton Syndrome ,Preclinical,04/22/2024,"Preclinical data suggests ATR-12 can significantly reduce IL-36g, a pro-inflammatory cytokine that drives Netherton syndrome, noted April 22, 2024.",3.0
TOVX,$10.28 ,VCN-01 (VIRAGE),Metastatic PDAC ,Preclinical,04/22/2024,"Preclinical data demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft, noted April 22, 2024.",9.0
ACET,$2.00 ,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC) ",Preclinical,04/22/2024,"Preclinical findings showed robust anti-tumor activity of ADI-270 in multiple CD70-positive solid and hematological cancer models, noted April 22, 2024",83.0
IBRX,$4.94 ,ANKTIVA,BCG-Unresponsive Non-Muscle Invasive Bladder Cancer ,Approved,04/22/2024,"Approved April 22, 2024.",945.0
TOVX,$9.42 ,VCN-01 (zabilugene almadenorepvec),Retinoblastoma ,Phase 1,04/23/2024,"Phase 1 topline data in collaboration with Sant Joan de Déu-Barcelona Children's Hospital (SJD) determined to have a positive outcome by the study Monitoring Committee, safety and clinical outcomes su",9.0
TLSA,$0.78 ,Foralumab (Intranasal),Secondary Progressive Multiple Sclerosis (SPMS) ,Phase 2a,04/23/2024,"Phase 2a FDA allowed its intranasal foralumab na-SPMS Expanded Access (EA) Program to expand from 10 patients to a total of 30 patients, noted April 23, 2024.",111.0
UBX,$1.49 ,UBX1325 - (ASPIRE),Diabetic macular edema (DME) ,Phase 2,04/23/2024,"Phase 2 study of UBX1325 has been extended from 24 to 36 weeks to assess potentially greater durability compared to aflibercept. In addition, the study is being upsized from 40 to 50 patients to incre",17.0
SILO,$1.78 ,SPC-15,Post-traumatic stress disorder (PTSD) ,Preclinical,04/23/2024,"Preclinical study of intranasal delivery showed rapid and effective drug exposure for PTSD Therapy, noted April 23, 2024.",9.0
NBIX,$140.09 ,Osavampator (NBI-1065845) - (SAVITRI),Major depressive disorder ,Phase 2,04/23/2024,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Åsb",99.0
TAK,$13.38 ,Osavampator (NBI-1065845) - (SAVITRI),Major depressive disorder ,Phase 2,04/23/2024,"Phase 2 study met its primary and key secondary endpoints, demonstrating that once-daily, oral administration of NBI-1065845 produced a statistically significant change from baseline in Montgomery Åsb",
ANRO,$13.88 ,ALTO-101,Schizophrenia ,Phase 1,04/23/2024,Phase 1 study in healthy volunteers demonstrated favorable tolerability and improved pharmacokinetics of ALTO-101 when administered via a transdermal delivery system (TDS) compared to oral administrat,27.0
HOWL,$6.44 ,IL-10 Indukine (PREDATOR Platform),Ulcerative Colitis (UC) ,Preclinical,04/23/2024,"Preclinical data in animal models supported unique conditionally active cytokine immunotherapy approach for the potential treatment, noted April 23, 2024.",45.0
INMB,$10.14 ,XPro1595 (pegipanermin) - (XPro),Neuroinflammation caused by Alzheimer’s disease ,Phase 2,04/23/2024,"Phase 3 preparation ongoing after 24-month validation data completed, noted April 23, 2024.",26.0
NVS,$97.28 ,LUTATHERA (lutetium Lu 177) - (NETTER-P),Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) ,Approved,04/23/2024,"FDA approved on April 23, 2024.",
DAWN,$16.64 ,OJEMDA (tovorafenib),Low-grade Glioma ,Approved,04/23/2024,"FDA Approved on April 23, 2024.",102.0
RHHBY,$30.54 ,HB-700,KRAS-mutated cancers ,IND-Enabling,04/24/2024,"IND cleared by the FDA, noted April 24, 2024.",
HOOK,$8.50 ,HB-700,KRAS-mutated cancers ,IND-Enabling,04/24/2024,"IND cleared by the FDA, noted April 24, 2024.",12.0
ALVO,$13.54 ,AVT05 (biosimilar to golimumab),Rheumatoid Arthritis ,Phase 3,04/24/2024,"Phase 3 trial met its primary endpoint, with results demonstrating therapeutic equivalence between AVT05 and Simponi. Additionally, no clinically meaningful differences in safety were observed through",301.0
IMMP,$2.59 ,Eftilagimod alpha (IMP321) and KEYTRUDA (pembrolizumab) - (TACTI-003),Head and neck squamous cell carcinoma (HNSCC) ,Phase 2b,04/24/2024,"Phase 2b enrollment completed, noted November 9, 2023. Phase 2b data from efti in combination in patients who do not express PD-L1 (TACTI-003, Cohort B) showed a preliminary 26.9% response rate, the p",145.0
ALKS,$24.65 ,ALKS 2680 - (Vibrance-1),Narcolepsy ,Phase 2,04/24/2024,"Phase 2 initiated, noted April 24, 2024.",165.0
ATAI,$1.87 ,BPL-003,Resistant Depression ,Phase 2a,04/24/2024,"Phase 2a OLE study initiated, noted April 24, 2024.",214.0
RDHL,$10.50 ,RHB-107 (upamostat) - (ACESO PROTECT),Early COVID-19 outpatient treatment ,Phase 2,04/24/2024,"Phase 2 dosing commenced, noted April 24, 2024.",3.0
AMRX,$6.05 ,Naloxone hydrochloride nasal spray - (generic Narcan),Opioid overdose ,Approved,04/24/2024,"FDA Approved, noted April 24, 2024.",314.0
CALC,$5.49 ,Auxora - (CARPO),Acute Pancreatitis ,Phase 2b,04/24/2024,"Phase 2b enrolment completed, noted April 24, 2024.",13.0
NVS,$98.35 ,Coartem (artemether-lumefantrine) - (CALINA),Malaria in babies <5 kg ,Phase 2/3,04/24/2024,"Phase 2/3 data reported that the new formulation has good efficacy and safety, and the data have been submitted for regulatory review, noted April 24, 2024.",
GANX,$3.19 ,"GT-02287, GT-02329",GBA1 and Idiopathic Parkinson's Disease ,Phase 1,04/24/2024,"Phase 1 data reported that treatment was generally well tolerated up to and including the highest planned dose level, and there were no serious adverse events, noted April 24, 2024.",35.0
ACRV,$9.50 ,ACR-368,"Platinum-resistant ovarian,(PROC) endometrial, and urothelial cancers ",Phase 2b,04/24/2024,"Phase 2b initial data demonstrated a 50% confirmed overall response rate observed with ACR-368 in OncoSignature-positive gynecological (ovarian and endometrial) cancers, noted April 24, 2024.",31.0
IBRX,$5.11 ,Anktiva (N-803) + various Checkpoint Inhibitors (QUILT-3.055),"NSCLC, Various tumors ",Phase 2,04/25/2024,"Phase 2 results reported significant prolongation of overall survival, noted April 25, 2024.",945.0
VTGN,$4.70 ,PH15,Psychomotor impairment caused by mental fatigue ,Phase 2a,04/25/2024,"Phase 2a data reported that treatment demonstrated a statistically significant improvement in reaction time compared to placebo and caffeine in sleep-deprived study participants, noted April 25, 2024.",30.0
BLCO,$14.76 ,LCD supplement capsule,Dry eyes ,Phase 1,04/25/2024,"Trial met both primary endpoints, noted April 25, 2024.",353.0
TLSA,$0.84 ,Foralumab,"Non-active, secondary-progressive multiple sclerosis (na-SPMS) ",Phase 2,04/25/2024,"Phase 2 data quantitative data showing improvement in White Matter Z-scores measured from PET images taken at 3 months in nasal foralumab, noted April 25, 2024.",111.0
BIVI,$4.89 ,Bezisterim (NE3107) - (Biomarker Trial),Alzheimer's disease ,Phase 2,04/25/2024,"Phase 2 data shared at the Annual Alzheimer's & Parkinson's Drug Development Summit shows how bezisterim may be restoring homeostasis via specific genes associated with dementia, metabolism, and infla",7.0
ROIV,$10.88 ,Namilumab - (RESOLVE-Lung),Sarcoidosis ,Phase 2,04/25/2024,"Phase 2 enrollment completed, noted April 25, 2024.",682.0
ALGS,$20.45 ,ALG-097558,COVID-19 ,Phase 1,04/25/2024,"Phase 1 data presented at ECCMID showed that single (up to 2000 mg) and multiple (up to 800 mg Q12 for 7 days) doses of this potent, pan-coronavirus protease inhibitor were well tolerated in healthy v",6.0
NKGN,$1.98 ,Troculeucel (SNK01),Alzheimer's Disease ,Phase 1,04/25/2024,Preclinical data to be presented at the Alzheimer's & Parkinson's Drug Development Summit shows a direct ability to phagocytose and digest amyloid and alpha-synuclein proteins while also secreting imm,124.0
PFE,$24.69 ,BEQVEZ (fidanacogene elaparvovec-dzkt),Hemophilia B ,Approved,04/26/2024,"Approval announced April 26, 2024.",
GILD,$64.06 ,Biktarvy,HIV ,Approved,04/26/2024,"Approved for updated label on (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) to treat pregnant people with HIV-1 (PWH) with suppressed viral loads, noted April 2",
CDTX,$12.63 ,JNJ-0953 (CD388) - (ANCHOR),Seasonal Influenza ,Phase 2a,04/26/2024,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe,25.0
JNJ,$143.86 ,JNJ-0953 (CD388) - (ANCHOR),Seasonal Influenza ,Phase 2a,04/26/2024,Phase 2a data presented at ESCMID reported that well tolerated and demonstrated statistically significant antiviral effects when administered as a single subcutaneous dose in healthy volunteers challe,
ENTA,$12.37 ,EDP-235 - (SPRINT),COVID-19 ,Phase 2,04/27/2024,"Phase 2 data presented at ESCMID reported that the EDP-235 400 mg arm achieved greater mean change in TSS compared with the placebo arm at all time points, noted April 27, 2024.",21.0
AZN,$75.02 ,Enhertu - (DESTINY-Breast06),"HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer ",Phase 3,04/29/2024,"Phase 3 data reported statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy, noted April 29, 2024",
DSNKY,$32.70 ,Enhertu - (DESTINY-Breast06),"HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer ",Phase 3,04/29/2024,"Phase 3 data reported statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy, noted April 29, 2024",
AQST,$3.74 ,Libervant (diazepam) - (pediatric),Acute treatment seizure activity ,Approved,04/29/2024,"FDA Approved on April 29, 2024.",99.0
XFOR,$1.09 ,XOLREMDI (mavorixafor),WHIM syndrome ,Approved,04/29/2024,"Approved April 29, 2024.",11.0
PRME,$4.86 ,PM359,Chronic Granulomatous Disease (CGD) ,IND-Enabling,04/29/2024,"IND cleared by the FDA, noted April 29, 2024.",134.0
ADXN,$7.54 ,ADX71149 (mGlu2 PAM) - (JNJ-40411813),Epilepsy ,Phase 2,04/29/2024,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.",1.0
JNJ,$144.53 ,ADX71149 (mGlu2 PAM) - (JNJ-40411813),Epilepsy ,Phase 2,04/29/2024,"Phase 2 trial did not meet its primary endpoint, noted April 29, 2024.",
ATHE,$2.20 ,ATH434,Parkinson's Disease ,Preclinical,04/29/2024,"Preclinical data presented at the World Orphan Drug Congress USA 2024 Indicated that ATH434 can function as an iron chaperone to redistribute iron, noted April 29, 2024.",15.0
ITRM,$1.54 ,ORLYNVAH (Oral Sulopenem),Uncomplicated urinary tract infections (uUTI) ,NDA Filing,04/29/2024,"NDA resubmitted to the FDA, noted April 29, 2024.",44.0
SLS,$1.21 ,Galinpepimut-S - (REGAL),Acute Myeloid Leukemia (AML) ,Phase 3,04/29/2024,"IDMC recommended the continuation of the trial, noted April 29, 2024.",105.0
AZN,$75.02 ,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,04/29/2024,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.",
AIM,$0.41 ,Ampligen (rintatolimod) with Imfinzi (durvalumab) - (DURIPANC),Pancreatic Cancer ,Phase 1/2,04/29/2024,"Phase 1b/2 first dose level is generally well tolerated, noted April 29, 2024.",2.0
LGND,$70.46 ,V116 - (STRIDE-10),Pneumococcal vaccine ,Phase 3,04/29/2024,"Phase 3 data presented at ESCMID Global showed that results build on the data supporting the clinical profile of V116 for adults, noted April 29, 2024.",19.0
MRK,$128.50 ,V116 - (STRIDE-10),Pneumococcal vaccine ,Phase 3,04/29/2024,"Phase 3 data presented at ESCMID Global showed that results build on the data supporting the clinical profile of V116 for adults, noted April 29, 2024.",
ANVS,$7.28 ,Buntanetap (ANVS401),Alzheimer’s disease (AD) ,Phase 2/3,04/29/2024,"Phase 2/3 AD study data reported a significantly higher improvement in ADAS-Cog 11 scores in each treatment dose relative to placebo for patients with mild AD (n=90), after unblinding the data to scre",19.0
TERN,$5.10 ,TERN-701 - (CARDINAL),Chronic myeloid leukemia (CML) ,Phase 1,04/29/2024,"Phase 1 interim data showed no clinically significant difference in exposure between fed and fasted dosing, noted April 29, 2024.",87.0
TFFP,$2.71 ,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,04/29/2024,"Phase 2 demonstrated that treatment with TFF TAC prevents Lung Transplant Rejection at only one-sixth of the dose of oral Tacrolimus and at Two-thirds of the oral Tacrolimus Systemic Trough Exposures,",4.0
PFE,$24.92 ,TIVDAK (tisotumab vedotin-tftv),Cervical Cancer with disease progression on or after first-line therapy ,Approved,04/29/2024,"Approved April 29, 2024.",
GMAB,$28.57 ,TIVDAK (tisotumab vedotin-tftv),Cervical Cancer with disease progression on or after first-line therapy ,Approved,04/29/2024,"Approved April 29, 2024.",661.0
MOLN,$3.70 ,MP0533,Acute myeloid leukemia (AML) ,Preclinical,04/29/2024,"Preclinical data of tetra-specific T cell engager MP0533 demonstrated preferential T cell mediated killing of AML cells, while sparing healthy cells, noted April 29 2024.",40.0
VERU,$1.35 ,Enobosarm with semaglutide (Wegovy) - (PLATEAU),Obesity ,Phase 2b,04/30/2024,"IND cleared February 6, 2024. Phase 2b first patient dosed April 30, 2024.",14.0
NBIX,$137.54 ,TAK-653 / NBI-1065845,Major Depressive Disorder (MDD) ,Phase 2,04/30/2024,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.",99.0
TAK,$13.08 ,TAK-653 / NBI-1065845,Major Depressive Disorder (MDD) ,Phase 2,04/30/2024,"Phase 2 study met its primary and key secondary endpoints, noted April 2024.",
AUPH,$5.09 ,LUPKYNIS (Voclosporin) - (updated label),Lupus Nephritis ,Approved,04/30/2024,"Updated label approved April 30, 2024.",135.0
VRPX,$2.65 ,Probudur,Pain Relief ,Preclinical,04/30/2024,"MTD data reported that all doses were well-tolerated, noted April 30, 2024.",1.0
SNTI,$3.60 ,SENTI-202,Acute Myeloid Leukemia (AML) ,Preclinical,04/30/2024,"Preclinical data reported that the engineered NK cells killed multiple AML subtypes while protecting primary hematopoietic stem cells (HSCs), noted April 30, 2024.",26.0
NRXP,$2.58 ,NRX-101,Bipolar Depression and Suicidal Ideation ,Phase 2/3,04/30/2024,"Phase 2/3 top line data reported that NRX-101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduc",19.0
VXRT,$0.71 ,Norovirus vaccine - (lactating mothers trial),Norovirus ,Phase 1,04/30/2024,"Phase 1 topline data reported no vaccine-related serious adverse events (SAEs) and no dose-limiting pharmacotoxicity, noted April 30, 2024.",228.0
INMB,$11.84 ,XPro1595 (pegipanermin) - (XPro),Neuroinflammation caused by Alzheimer’s disease ,Phase 1b,04/30/2024,"Phase 1b compassionate use data reported that treatment has been well-tolerated throughout the treatment period, with stable cognitive function observed in the patients. Furthermore, the patients expr",26.0
GRTS,$0.80 ,CORAL-CEPI,COVID-19 vaccine ,Phase 1,04/30/2024,"Additional data reported that all doses of the three samRNA vaccine candidates were well tolerated in both HIV-negative participants and PLWH participants irrespective of age, SARS-CoV-2 serostatus, o",118.0
SCYX,$1.69 ,SCY-247,Pulmonary mucormycosis ,Preclinical,04/30/2024,"Preclinical data shared at the ECCMID reported that SCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains of Candida and Aspergillus species, no",41.0
NBIX,$137.54 ,INGREZZA SPRINKLE (valbenazine) Capsules,Tardive dyskinesia (TD) ,Approved,04/30/2024,"Approved April 30, 2024.",99.0
ACXP,$2.20 ,Ibezapolstat,C. difficile Infection ,Phase 2b,04/30/2024,"Phase 2b data results shared at ESCMID einforced earlier findings related to the anti-recurrence properties, noted April 30, 2024.",1.0
MRK,$127.20 ,KEYTRUDA (pembrolizumab) in combination with trastuzumab - (KEYNOTE-811),HER2-positive gastric or Gastroesophageal junction (GEJ) adenocarcinoma ,Phase 3,05/01/2024,"Phase 3 trial met its dual primary endpoint of overall survival (OS), noted May 1, 2024.",
PALI,$7.08 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,05/01/2024,"Preclinical successful completion of its analysis to determine the effects of bioactivated PALI-2108 on TNF-α production in a whole blood (WB) assay, noted May 1, 2024.",9.0
SLS,$1.28 ,Tambiciclib (SLS009) (GFH009) with venetoclax,"Hematologic malignancies, acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and lymphoma ",Phase 2,05/01/2024,"Phase 2 30 mg cohort showed a 100% overall response rate in patients with ASXL1 mutation, treatment exhibited strong anti-leukemic activity in 62% of patients with a favorable safety profile across al",105.0
ALRN,$4.16 ,LTI-03 - (Caveolin-1),Idiopathic pulmonary fibrosis (IPF) ,Phase 1b,05/01/2024,Phase 1a low dose data showed a reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epit,21.0
COCP,$1.53 ,CC-42344,Influenza A ,Phase 2a,05/01/2024,"Phase 2a enrollment completed, noted May 1, 2024.",10.0
DNLI,$16.16 ,DNL343 - (HEALEY),Amyotrophic lateral sclerosis (ALS) ,Phase 2/3,05/01/2024,"Phase 2/3 trial enrollment completed noted May 1, 2024.",146.0
BCDA,$5.64 ,CardiAMP (BCDA-02),Chronic Myocardial Ischemia ,Phase 3,05/01/2024,"Phase 3 data reported that 100% of patients responded for the change in Angina Episodes per week, noted May 1, 2024.",5.0
KZIA,$0.30 ,EVT801,Renal cell carcinoma and soft-tissue sarcoma ,Phase 1,05/01/2024,"Phase 1 trial successful and complete, noted May 1, 2024.",1.0
GLTO,$17.00 ,GB1211 in combination with KEYTRUDA (pembrolizumab),Melanoma and head and neck squamous cell carcinoma (HNSCC) ,Phase 2,05/01/2024,"Phase 2 trial initiated, noted May 1, 2024.",1.0
AZN,$75.34 ,"Calquence (acalabrutinib) with chemoimmunotherapy, bendamustine and rituximab - (ECHO)",Mantle cell lymphoma (MCL) ,Phase 3,05/02/2024,"Phase 3 data reported a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care, noted May 2, 2024.",
CNTX,$1.75 ,CTIM-76,Various cancers ,IND-Enabling,05/02/2024,"IND Cleared by the FDA, noted May 2, 2024.",89.0
PTN,$2.05 ,Bremelanotide with Tirzepatide (GLP-1),Obesity ,IND-Enabling,05/02/2024,"IND clearance by the FDA, noted May 2, 2024.",46.0
ALLR,$36.90 ,Stenoparib,Advanced ovarian cancer (AOC) ,Phase 2,05/02/2024,"Phase 2 trial discontinued early due to clear clinical benefit, including tumor shrinkage and long-term disease stability, noted May 2, 2024.",14.0
ELAB,$0.71 ,EL-22 (BLS-M22),GLP-1 Weight Loss Drugs and Age-Related Sarcopenia ,Preclinical,05/02/2024,"Preclinical data reported statistically significant increase in anti-myostatin IgG antibody concentration, where myostatin is a key negative regulator of muscle growth, noted May 2, 2024.",
IMMP,$2.69 ,Eftilagimod alpha with pembrolizumab and radiotherapy - (EFTISARC-NEO),Soft tissue sarcoma ,Phase 2,05/02/2024,"Phase 2 trial is well tolerated and has led to encouraging initial efficacy data. Four of six patients treated have very good, near-complete pathologic responses (primary endpoint of study) that are r",145.0
AEON,$1.70 ,ABP-450 (prabotulinumtoxinA),Chronic Migraine (prophylaxis) ,Phase 2,05/03/2024,"Phase 2 trial did not meet its primary endpoint, noted May 3, 2024.",11.0
XOMA,$24.78 ,Seralutinib (GB002) - (TORREY/PROSERA),Pulmonary arterial hypertension (PAH) ,Phase 2,05/03/2024,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p,12.0
GOSS,$0.74 ,Seralutinib (GB002) - (TORREY/PROSERA),Pulmonary arterial hypertension (PAH) ,Phase 2,05/03/2024,Phase 2 data from TPRREY trail published at the Lancet Respiratory Medicine journal confirmed results demonstrating a statistically significant improvement for seralutinib compared to placebo in the p,227.0
CGON,$36.27 ,Cretostimogene - (BOND-003),BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) with Carcinoma in Situ ,Phase 3,05/03/2024,"Phase 3 data presented at AUA showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy. Although the median duration of response (DOR) was not rea",76.0
URGN,$14.30 ,UGN-102 - (ATLAS),Non-Muscle-Invasive Bladder Cancer ,Phase 3,05/04/2024,"Data from AUA 2024 reported that DOR at 12 months after achieving CR at 3 months was 87.5% and 69.1% in new and recurrent patients, respectively. Also, patients achieved similar probabilities of DFS r",46.0
MNMD,$10.00 ,MM120 ODT (Lysergide (LSD)) - (Emerge),Major Depressive Disorder (MDD) ,Phase 2,05/04/2024,"Phase 2 data at APA reported clinically and statistically significant efficacy compared to placebo at its primary week 4 and secondary week 12 timepoints, noted May 4, 2024.",75.0
IRD,—,APX3330 Oral Pill - (ZETA-1),Diabetic Retinopathy (DR) / Macular Edema (DME) ,Phase 2,05/05/2024,"Additional data shared at ARVO on May 5, 2024 reported that no participants in the APX3330 group had a ≥ 4-step worsening at week 24 compared to 15.2% in the placebo group, representing a 100% reducti",59.0
VTRS,$11.57 ,APX3330 Oral Pill - (ZETA-1),Diabetic Retinopathy (DR) / Macular Edema (DME) ,Phase 2,05/05/2024,"Additional data shared at ARVO on May 5, 2024 reported that no participants in the APX3330 group had a ≥ 4-step worsening at week 24 compared to 15.2% in the placebo group, representing a 100% reducti",
NNVC,$1.40 ,NV-387,"Influenza A viruses, Bird Flu H5N1 ",Preclinical,05/06/2024,"Preclinical data reported that in a lethal animal model of lung infection by Influenza A /H3N2 virus, NV-387 was found to have substantially superior antiviral effects compared to three approved anti-",17.0
EYPT,$11.20 ,DURAVYU ( EYP-1901 vorolanib intravitreal) - (PAVIA),Non-proliferative diabetic retinopathy (NPDR) ,Phase 2,05/06/2024,"Phase 2 trial did not meet the pre-specified primary endpoint, noted May 6, 2024.",68.0
GLYC,$0.32 ,Uproleselan (GMI-1271),Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer ,Phase 3,05/06/2024,"Phase 3 final analysis and topline results did not achieve a statistically significant improvement in overall survival in the intent to treat population versus chemotherapy alone, noted May 6, 2024.",13.0
APLM,$0.42 ,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ,Phase 3,05/06/2024,"Phase 3 data reported that median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the",1.0
GLYC,$0.32 ,Uproleselan,Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) ,Phase 3,05/06/2024,"Phase 3 data reported that median overall survival of 13 months, compared to 12.3 months in the placebo arm. Adverse events were consistent with known side effect profiles of chemotherapy used in the",13.0
ADCT,$4.45 ,ZYNLONTA (loncastuximab tesirine-lpyl),Relapsed/refractory (r/r) marginal zone lymphoma (MZL) ,Phase 2,05/06/2024,"Phase 2 data reported that treatment was generally well-tolerated and safety was consistent with the known profile, with two patient discontinuations, with both of these patients remain in CR at 10 an",112.0
VYNE,$2.71 ,VYN202,Moderate-to-severe plaque psoriasis ,IND-Enabling,05/06/2024,"IND Cleared by the FDA, noted April 6, 2024.",25.0
LYRA,$0.52 ,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitis ,Phase 3,05/06/2024,Phase 3 data reported that the trial did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symp,1.0
LIAN,$0.31 ,LYR-210 - (ENLIGHTEN I),Chronic rhinosinusitis ,Phase 3,05/06/2024,Phase 3 data reported that the trial did not meet its primary endpoint of demonstrating statistically significant improvement compared to sham control in the composite score of the three cardinal symp,108.0
BCAB,$3.17 ,BA3361 (CAB-Nectin-4),Multiple tumor types ,IND-Enabling,05/06/2024,"IND cleared by the FDA, noted May 6 2024.",58.0
DRTS,$2.46 ,Alpha DaRT,Pancreatic Cancer ,Preclinical,05/06/2024,"Preclinical data reported that a statistically significant (FDR adjusted p-value < 0.05) decline in secondary tumor growth rate was found at days 21, 25 and 29 in those mice that received Alpha DaRT",70.0
CALT,$20.13 ,Setanaxib with pembrolizumab,Squamous Cell Carcinoma of the Head and Neck (SCCHN) ,Phase 2,05/06/2024,"Phase 2 final data reported statistically significant improvements in key secondary endpoints, such as progression-free survival, (PFS median 5 months versus 2.9 months; Hazard ratio= 0.58) and statis",26.0
BLTE,$43.30 ,Tinlarebant (LBS-008) - (DRAGON),Adolescent Stargardt disease (STGD1) ,Phase 2/3,05/06/2024,"Phase 2/3 24-month data shared at ARVO 2024 provided further support for the potential of Tinlarebant to slow and potentially halt lesion growth, May 6, 2024.",32.0
NVS,—,RGSL8429,ADPKD ,Phase 1b,05/06/2024,"Phase 1b Cohort 4 advanced, noted May 6, 2024.",
LCTX,$1.30 ,RG6501 - (OpRegen),Geographic atrophy (GA) ,Phase 1/2,05/06/2024,"Additional Phase 1/2a data suggested that OpRegen may counteract RPE cell dysfunction and cell loss in GA by providing support to remaining retinal cells, with effects observed through at least 2 year",228.0
EWTX,$20.34 ,EDG-7500 - (CIRRUS-HCM),Hypertrophic Cardiomyopathy (HCM) ,Phase 2,05/06/2024,"Phase 2 initiated, noted May 6, 2024.",105.0
RYTM,$43.88 ,IMCIVREE (setmelanotide),"Obesity due to biallelic POMC, PCSK1, LEPR deficiency, or BBS (ages 2-6 years old) ",Phase 3,05/06/2024,"Phase 3 data showcased previously disclosed data that demonstrated that setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in 12 patients, noted May 6, 20",66.0
MRUS,$47.34 ,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancer ,BLA Filing,05/06/2024,"BLA accepted for priority review by the FDA, noted May 6, 2024.",75.0
GMAB,—,BIZENGRI (zenocutuzumab-zbco),Solid tumors - NRG1+ NSCLC and PDAC cancer ,BLA Filing,05/06/2024,"BLA accepted for priority review by the FDA, noted May 6, 2024.",661.0
DTIL,$10.57 ,ECUR-506 - (OTC-HOPE),Ornithine Transcarbamylase (OTC) Deficiency ,Phase 1/2,05/07/2024,"Fast track designation granted by the FDA, noted May 7, 2024.",11.0
ANNX,$4.73 ,ANX007 - (ARCHER-II),Geographic atrophy ,Phase 2,05/07/2024,"Phase 2 data presented at ARVO demonstrated significant, broad-based protection from vision loss in foveal and non-foveal patients, and in low light settings, noted May 7, 2024.",109.0
DNLI,$16.85 ,DNL788 (SAR443820) - (HIMALAYA),Amyotrophic lateral sclerosis (ALS) ,Phase 2,05/07/2024,"Phase 2 trial did not meet the primary endpoint, noted May 7, 2024.",146.0
ELDN,$2.26 ,Tegoprubart (AT-1501) - (BESTOW),Kidney transplant rejection ,Phase 1b,05/07/2024,"Phase 1b data reported that two subjects completed 12 months on therapy post-transplant and both demonstrated mean eGFRs above 90 mL/min/1.73m2 at one year, noted May 7, 2024.",59.0
ASLN,$3.30 ,Eblasakimab (ASLAN004) - (TREK-DX),Atopic dermatitis (AD) ,Phase 2,05/07/2024,"Additional Phase 2 data reported discontinuation rates were lower for patients treated with eblasakimab (13%, 2/15) compared to those on placebo, noted May 7, 2024.",2.0
MBRX,$5.09 ,"Annamycin (MB-106) in combination with Cytarabine - (Ara-C, MIRACLE)",Acute Myeloid Leukemia (AML) ,Phase 1/2,05/07/2024,"Phase 1/2 topline data reported a CRc rate of 45% and an overall remission rate (ORR) of 55% for all subjects, noted May 7, 2024.",30.0
NRSN,$1.29 ,PrimeC - (PARADIGM),Amyotrophic Lateral Sclerosis (ALS) ,Phase 2b,05/07/2024,"Additional Phase 2b data analysis reported a statistically significant slowing of disease progression in high-risk ALS patients treated with PrimeC by 43% (p=0.02), noted May 7, 2024.",23.0
REGN,$955.76 ,Otoferlin gene therapy (DB-OTO) - (CHORD),Genetic hearing loss ,Phase 1/2,05/08/2024,"Phase 1/2 data presented at ASGCT reported an average 84 dB improvement from baseline and one frequency measure reaching 10 dB in hearing level per PTA. Across all tested frequencies, an average 80 dB",105.0
VYGR,$8.57 ,TRACER (GBA1),Parkinson's Disease ,Preclinical,05/08/2024,"Preclinical data reported that showed further enhanced blood-brain barrier (BBB) penetrance, greater liver detargeting, and transduction of 50-75% of cells across diverse brain regions, with upwards o",55.0
ALDX,$4.07 ,Reproxalap (ADX-102) - (TRANQUILITY),Dry eye disease ,Phase 3,05/08/2024,"Phase 3 first patient enrollment, noted May 8, 2024.",59.0
CYTK,$65.27 ,CK-4021586 (CK-586) - (AMBER-HFpEF),Heart failure with preserved ejection fraction (HFpEF) ,Phase 1,05/08/2024,"Phase 1 trial met its primary and secondary objectives, noted May 8, 2024.",119.0
TEVA,$15.74 ,Olanzapine LAI (44749) - (SOLARIS),Schizophrenia ,Phase 3,05/08/2024,"Phase 3 trial data reported that the trial met its primary endpoint as measured by a change in the PANSS total score from baseline after 8 weeks compared to placebo, noted May 8, 2024.",
CYTK,$65.27 ,Aficamten - (CEDAR-HCM),obstructive HCM ,Phase 3,05/08/2024,"Phase 3 initiated, noted May 8, 2024.",119.0
PRME,$5.36 ,PM359,Chronic Granulomatous Disease (CGD) ,Preclinical,05/08/2024,"Preclinical data presented at ASGCT demonstrated the ability of PM359 to correct disease-causing mutation in CGD patient blood stem cells, leading to restored immune function in vivo with no off-targe",134.0
LLY,$772.64 ,VERVE-102 - (Heart-2),PCSK9 ,Phase 1b,05/08/2024,"Phase 1b dosing initiated, noted May 8, 2024.",946.0
VERV,$6.08 ,VERVE-102 - (Heart-2),PCSK9 ,Phase 1b,05/08/2024,"Phase 1b dosing initiated, noted May 8, 2024.",89.0
CVM,$1.39 ,Multikine - (IT-MATTERS),Head and Neck cancer ,Phase 3,05/08/2024,"Phase 3 Go-Ahead received by the FDA for its study, noted May 8, 2024.",6.0
LEXX,$3.54 ,DehydraTECH-GLP-1 - (GLP-1-H24-2),"Healthy volunteers, Diabetes-related control, weight loss ",Phase 1,05/08/2024,"Phase 1 dosing initiated, noted May 8, 2024.",19.0
PRQR,$2.00 ,AX-0810,"Healthy volunteers, deficiency of sodium taurocholate cotransporting polypeptide (NTCP), cholestatic diseases ",Preclinical,05/08/2024,"Preclinical data shared at the American Society of Gene & Cell Therapy (ASGCT) confirmed findings in in vitro models and showed translatability across models, noted May 8, 2024",105.0
CTMX,$4.19 ,CX-904,Advanced solid tumors ,Phase 1,05/08/2024,"Phase 1 data demonstrated a favorable safety profile with no cytokine release syndrome (CRS) of any grade observed in step-dosing cohorts and no grade >1 CRS observed overall, noted May 8, 2024.",164.0
OCS,$12.37 ,OCS-05 - (ACUITY),Acute optic neuritis ,Phase 2,05/08/2024,"Phase 2 enrollment completed, noted May 8, 2024.",43.0
MRK,$128.61 ,KEYTRUDA versus chemotherapy - (KEYNOTE-B21),High-Risk Endometrial Cancer ,Phase 3,05/09/2024,"Phase 3 study did not meet the study's pre-specified statistical criteria for DFS compared to placebo plus adjuvant chemotherapy, with or without radiotherapy, noted May 9, 2024.",
PRTC,$27.46 ,SPT-300 (Glyph allopregnanolone; formerly LYT-300),"Healthy volunteers, neurological and neuropsychological conditions ",Phase 2a,05/09/2024,"Phase 2a demonstrated nine times greater allopregnanolone exposure in humans dosed orally than published data for oral allopregnanolone, validating Glyph platform's ability to enhance oral bioavailabi",24.0
TCRX,$7.80 ,TSC-203-A0201 - (PRAME),Targeting PRAME Solid tumors ,Phase 1,05/09/2024,"Phase 1 dosing initiated, noted May 9, 2024.",56.0
ANVS,$6.03 ,Buntanetap,Parkinson's Disease (PD) ,Phase 3,05/09/2024,"The phase 3 study was completed, noted May 9, 2024.",19.0
PSTX,$2.71 ,P-KLKB1-101,Gene Therapy ,Preclinical,05/09/2024,"Preclinical early non-human primate (NHP) data for P-KLKB1-101 demonstrate successful liver gene editing approaching human therapeutic range with a favorable safety and tolerability profile, noted May",97.0
PSTX,$2.71 ,P-FVIII-101,Hemophilia A ,Preclinical,05/09/2024,"Preclinical data highlight sustained Hemophilia A correction following a single dose and support potential for repeat dosing and precise tuning of Factor VIII levels, noted May 9, 2024.",97.0
IKT,$1.36 ,IkT-001Pro,Pulmonary Arterial Hypertension (PAH) ,Preclinical,05/09/2024,Pre-IND meeting with FDA indicated IkT-001Pro can be considered a New Molecular Entity and is eligible for exclusivity designations in Pulmonary Arterial Hypertension. FDA agreed that the 505(b)(2) pa,74.0
FATE,$3.90 ,FT819,B-cell Leukemias and Lymphomas ,Phase 1b,05/09/2024,"Phase 1b translational data presented at ASGCT highlighted the scientific rationale and demonstrate key therapeutic mechanisms of activity for the treatment of B cell-mediated autoimmune disease, note",115.0
FATE,$3.90 ,FT819,B-cell Leukemias and Lymphomas ,Phase 1b,05/09/2024,"Phase 1b translational data presented at ASGCT highlighted the scientific rationale and demonstrate key therapeutic mechanisms of activity for the treatment of B cell-mediated autoimmune disease, note",115.0
FATE,$3.90 ,FT522,Lupus ,Preclinical,05/09/2024,"Preclinical data to be presented at ASGCT showed dose-dependent trafficking, infiltration, and residency in secondary and tertiary tissues without cytokine support at human dose equivalency levels of",115.0
RAPT,$4.66 ,Zelnecirnon (RPT193),Asthma ,Phase 2a,05/09/2024,"Trial closed due to clinical hold, noted May 9, 2024.",16.0
RAPT,$4.66 ,Zelnecirnon (RPT193),Atopic dermatitis ,Phase 2a,05/09/2024,"Trial closed due to clinical hold, noted May 9, 2024.",16.0
AZN,$77.13 ,FPI-2265 - (AlphaBreak),Prostate cancer ,Phase 2/3,05/09/2024,"Phase 2/3 trial AlphaBreak initiated, noted May 9, 2024.",
ANAB,$26.23 ,Imsidolimab (ANB019) - (GEMINI-1),Generalized pustular psoriasis ,Phase 3,05/09/2024,Phase 3 data showed that All 8 patients who responded to IV imsidolimab in GEMINI-1 and received monthly SC maintenance dosing in GEMINI-2 maintained clear/almost clear skin through 24 weeks with no f,28.0
PDSB,$3.83 ,PDS0101 + KEYTRUDA (pembrolizumab) - (VERSATILE-002),HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell cancer with low PD-L1 expression (CPS 1-19) ,Phase 2,05/09/2024,"Phase 2 data presented at a KOL showed a 30-month median overall survival (OS); median OS independent of patient CPS score; ORR 34% (CPS≥1); 48% (CPS≥20, noted May 9, 2024.",46.0
PHIO,$6.93 ,PH-762,Cutaneous Squamous Cell Carcinoma ,Preclinical,05/09/2024,"Preclinical data presented at ASCGT data demonstrates that intratumoral injection of PH-762 significantly inhibits tumor growth in murine cells and may generate memory-specific T cells, noted May 9, 2",5.0
FDMT,$25.64 ,4D-175 - (GAZE),Geographic Atrophy ,Preclinical,05/09/2024,Preclinical data presented at ARVO showed that intravitreal administration of 4D-175 to non-human primates (NHP) was safe and well tolerated and resulted in robust transgene expression in the retina a,46.0
FDMT,$25.64 ,4D-150 - (PRISM),Wet age-related macular degeneration (AMD) ,Phase 2,05/09/2024,"Phase 2 interim 24-week landmark data presented at ARVO demonstrated that a high dose of 4D-150 (3E10 vg/eye) resulted in robust reductions in overall treatment burden of 89%, percent of patients with",46.0
FRLN,—,FLT201 - (GALILEO-1),Gaucher disease ,Phase 1/2,05/09/2024,Phase 1/2 results shared at the ASGCT reported an early lyso-Gb1 data and reduction in BMB and fatigue suggest potential for meaningful improvements in clinical outcomes over existing standard of care,4.0
CELU,$3.05 ,CYNK-201,Solid Tumors ,Preclinical,05/09/2024,Preclinical data presented on at ASGCT reported that PT-CD16VS can be combined with various monoclonal antibodies to engage in anti-tumor antibody-dependent cellular cytotoxicity against diverse cance,26.0
INSM,$26.38 ,Treprostinil Palmitil Inhalation Powder (TPIP),Pulmonary hypertension associated with interstitial lung disease (PH-ILD) ,Phase 2,05/09/2024,"Phase 2 topline results reported that serious adverse events occurred in 20.7% of TPIP-treated patients and 40.0% of placebo-treated patients, noted May 9, 2024.",211.0
EWTX,$20.00 ,EDG-5506 - (DUNE),Becker muscular dystrophy (BMD) ,Phase 2,05/09/2024,Phase 2 data reported that sevasemten was well tolerated across all 21 participants and significantly reduced biomarkers of muscle damage associated with exercise with a mean post-exercise reduction o,105.0
CANF,$2.14 ,Namodenoson (CF102),Metabolic dysfunction-associated steatohepatitis (MASH) ,IND-Enabling,05/09/2024,"IND cleared by the FDA, noted May 9, 2024.",10.0
MRNA,$117.31 ,mRESVIA (mRNA-1345) - (ConquerRSV),Respiratory syncytial virus (RSV) vaccine ,PDUFA,05/10/2024,"PDUFA decision due on May 12, 2024. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by the PDUFA date of May 12, 2024, The FDA has",389.0
IPSC,$3.13 ,CNTY-101 - (CALiPSO-1),Systemic Lupus Erythematosus ,Preclinical,05/10/2024,"Preclinical data demonstrates the potential utility of using a synthetic ligand targeting CD300a as a universal strategy for preventing NK-mediated rejection in allogeneic cell therapies, as noted on",86.0
RCKT,$22.72 ,RP-L301,Pyruvate Kinase Deficiency (PKD) ,Phase 1,05/10/2024,"Phase 1 data reported robust and sustained efficacy in adults and the first pediatric patient infusion of RP-L301 was well tolerated, with engraftment achieved at day +15, noted May 19, 2023. Phase 1",107.0
AZTR,$6.48 ,ATR12-351,Netherton Syndrome ,Preclinical,05/10/2024,Preclinical data presented at ASGCT from In vitro data showed that LEKTI (lympho-epithelial Kazal-type-related inhibitor) protein secreted by ATR-12 has nanomolar inhibition of a key protease that dr,3.0
IMMX,$2.18 ,NXC-201 (HBI10101) - (NEXICART-1),relapsed/refractory multiple myeloma and relapsed/refractory AL amyloidosis ,Phase 1/2,05/10/2024,"Phase 1/2 data presented at ASGCT showed a 92% (12/13) overall response rate (ORR) for relapsed/refractory AL Amyloidosis. Best responder duration of response was 28.0 months with response ongoing, no",28.0
PLX,$1.10 ,PRX-115,Severe Gout ,Phase 1,05/10/2024,"Phase 1 initial data from the seven cohorts, and following the review and acceptance of the safety data from cohort 7 by the safety and monitoring committee for dose escalation for the FIH Study, the",79.0
MGNX,$3.31 ,MGC018 - (TAMARACK),Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 2,05/10/2024,"Phase 2 interim data showed PSA50 responses 43.9%/36.6%, ORR 17.8%/25% confirmed. Unfortunately, 5 deaths were found: 1 unrelated, 2 pneumonitis under investigation., noted May 10, 2024",63.0
BMY,$44.27 ,Opdivo (nivolumab) + Yervoy (ipilimumab) versus CCRT - (CheckMate-73L),Stage III non-small cell lung cancer (NSCLC) ,Phase 3,05/10/2024,"Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS), noted May 10, 2024.",
ACET,$1.47 ,ADI-270,"Solid tumors CAR T, relapsed/refractory renal cell carcinoma (RCC) ",Preclinical,05/10/2024,"Preclinical data featured at ASGCT data reported robust efficacy maintained across multiple relevant tumor models of varying stringency, noted May 10, 2024.",83.0
MRK,$127.68 ,KEYTRUDA (KeyVibe-010),Resected high-risk melanoma (Stage IIB-IV) ,Phase 3,05/13/2024,Phase 3 pre-planned analysis data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria. A higher rate of discontinuation of all adjuvant therapy b,
VALN,$7.61 ,VLA1553-321 - (Adolescents trial),Chikungunya Vaccine for adolecents ,Phase 3,05/13/2024,"Phase 3 day 180 results confirm the initial positive immunogenicity and safety data Valneva reported previously, noted May 13, 2024.",81.0
MRUS,$45.85 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,05/13/2024,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",75.0
GMAB,—,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,05/13/2024,"FDA Granted Breakthrough Therapy Designation (BTD) on May 13, 2024.",661.0
INAB,$1.02 ,INB-200,Glioblastoma ,Phase 1,05/13/2024,"Phase 1 data presented at ASGCT data provide additional insight into the complex gene-expression changes that occur throughout the manufacturing of our gamma-delta T cell products, which demonstrate a",4.0
CYTK,$57.89 ,Aficamten (CK-274) - (SEQUOIA-HCM),Hypertrophic cardiomyopathy (HCM) ,Phase 3,05/13/2024,"Phase 3 full results due presented at Heart Failure showed that treatment with aficamten for 24 weeks significantly improved exercise capacity compared to placebo, noted May 13, 2024.",119.0
EWTX,$17.48 ,Sevasemten (EDG-5506) - (CANYON),Becker Muscular Dystrophy (BMD) ,Phase 2,05/13/2024,"Phase 2 trial met primary endpoint, noted May 13, 2024.",105.0
PLRX,$14.14 ,Bexotegrast (PLN-74809) - (INTEGRIS-IPF),Idiopathic pulmonary fibrosis (IFP) ,Phase 2a,05/14/2024,"Phase 2a 12-week post-hoc analysis reported that bexotegrast-treated patients showed a reduction in SUV in the lung compared to an increase seen in placebo, noted May 14, 2024.",61.0
HCM,$21.40 ,SULANDA (surufatinib),Metastatic pancreatic ductal adenocarcinoma (PDAC) in China ,Phase 2/3,05/14/2024,"Phase 2/3 study initiated in China, noted May 14, 2024.",174.0
KOD,$3.84 ,Tarcocimab tedromer (KSI-301) - (GLOW2),Non-proliferative diabetic retinopathy ,Phase 3,05/14/2024,"Phase GLOW2 dosing initiated, noted May 14, 2024.",52.0
HCM,$21.40 ,HMPL-306 - (RAPHAEL),Relapsed / refractory acute myeloid leukemia (AML) ,Phase 3,05/14/2024,"Phase 3 initiated, noted May 14, 2024.",174.0
DVAX,$11.00 ,HEPLISAV-B,End Stage Renal Disease on Dialysis undergoing hemodialysis ,CRL,05/14/2024,"CRL announced May 14, 2024.",117.0
NNVC,$2.26 ,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infection ",Preclinical,05/14/2024,"Preclinical antiviral activity study resulted in full survival of lethally infected animals was achieved, noted May 14, 2024.",17.0
NMRA,$9.58 ,Navacaprant (NMRA-140),Bipolar Depression ,Phase 2,05/14/2024,"Phase 2 initiated, noted May 14, 2024.",161.0
EQ,$1.54 ,Itolizumab - (EQUATOR),1st line Acute graft-versus-host disease (aGVHD) ,Phase 3,05/14/2024,"Phase 3 enrollment target surpassed, noted May 14, 2024.",59.0
ATYR,$1.82 ,Efzofitimod - (EFZO-FIT),Pulmonary sarcoidosis ,Phase 3,05/14/2024,"Second DSMB recommended that the ongoing Phase 3 study could continue without any modifications after a second pre-planned, interim analysis, noted May 14, 2024.",97.0
GNPX,$2.57 ,REQORSA Immunogene Therapy (quratusugene ozeplasmid) - (Acclaim-3),Extensive-stage small cell lung cancer (ES-SCLC) ,Phase 1/2,05/14/2024,"Phase 1/2 trial dosing initiated, noted May 14, 2024.",
CRIS,$15.69 ,CA-4948 - (TakeAim Lymphoma),Relapsed or Refractory Non-Hodgkin Lymphoma ,Phase 2,05/14/2024,"Phase 2 data reported that 3 of 3 patients who were naïve to FLT3i treatment achieved objective response (2 CR, 1 MLFS), noted May 14, 2024.",12.0
KYMR,$35.09 ,KT-333,Cutaneous T-cell lymphoma (CTCL) ,Phase 1a,05/14/2024,"Phase 1a data reported two complete responses in two cHL patients at DL4, three partial responses in CTCL patients at DL2, 4 and 5, and stable disease in four solid tumor patients at DL3-4, noted May",71.0
TFFP,$2.01 ,TFF TAC (Tacrolimus Inhalation Powder),Lung transplant (post) ,Phase 2,05/15/2024,"Phase 2 additional data showed that patient enrollment has accelerated to now 10 patients, 6/6 who completed 12-week tratemetn chosen to remain on TFF TAC, 1 patient has been treated for over a year a",4.0
VNDA,$5.36 ,Tradipitant - (Motion Serifos),Motion sickness ,Phase 3,05/15/2024,"Phase 3 trial conducted in real-world conditions on boats in U.S. coastal waters, both the 170 mg and 85 mg doses of tradipitant demonstrated superiority over placebo in preventing vomiting, noted May",59.0
THRD,$12.92 ,THB335,Mast cell-mediated inflammatory diseases ,IND-Enabling,05/15/2024,IND was cleared by the FDA during 2Q 2024.,45.0
SGMT,$4.62 ,Denifanstat (PK Study),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 1,05/15/2024,"Phase 1 data reported that denifanstat was well-tolerated and no safety signals were reported, noted May 15, 2024.",32.0
IMMP,$2.82 ,Eftilagimod Alpha with weekly paclitaxel - (AIPAC-003),Metastatic breast cancer (MBC) ,Phase 2/3,05/15/2024,"Phase 2/3 data reported an 50% overall response rate, including one complete response and two partial responses, and a 100% disease control rate, with three patients having stable disease as best over",145.0
OLMA,$9.85 ,Palazestrant (OP-1250) and ribociclib - (OPERA-02),Breast Cancer ,Phase 1/2,05/15/2024,Phase 1b/2 data to be shared at ESMO Breast Cancer showed that treatment was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of eit,68.0
ACXP,$2.25 ,Ibezapolstat,C. difficile Infection ,Phase 2b,05/15/2024,"Phase 3 agreement with the FDA after EoP2 meeting, noted May 15, 2024.",1.0
BCAB,$3.00 ,Ozuriftamab Vedotin (BA3021),"Solid Tumors, Non-small cell lung cancer (NSCLC), recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) ",Phase 2,05/15/2024,"Phase 2 data reported 11 responses at the combined 2Q3W and Q2W dose regimens (5 confirmed, including 1 complete response), noted May 15, 2024.",58.0
BCDA,$6.00 ,BCDA-03,Ischemic heart failure ,Phase 1/2,05/15/2024,"Phase 1/2 data reported that treatment-emergent adverse events, arrhythmias, rejection, or allergic response have been observed, noted May 15, 2024.",5.0
PHIO,$7.20 ,PH-762 (direct drug therapy),Melanoma ,Phase 1b,05/15/2024,"Phase 1b dosing of the first cohort of patients was completed and screening for the next dose cohort is on-going, noted May 15, 2024",5.0
AXGN,$5.95 ,Avance Nerve Graf - (RECON),Severed peripheral nerves ,BLA Filing,05/15/2024,"BLA submitted on May 15, 2024.",46.0
LLY,$770.05 ,Insulin efsitora alfa (efsitora) - (QWINT-2 and QWINT-4),Type 2 diabetes ,Phase 3,05/16/2024,"Phase 3 data reported that trials met their primary endpoints, noted May 16, 2024.",946.0
PFE,$28.53 ,ARV-471 with IBRANCE (palbociclib) - (TACTIVE-N),ER+ positive / HER2- negative breast cancer ,Phase 1b,05/16/2024,"Phase 1b data reported a clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), noted May 16, 2024.",
ARVN,$32.11 ,ARV-471 with IBRANCE (palbociclib) - (TACTIVE-N),ER+ positive / HER2- negative breast cancer ,Phase 1b,05/16/2024,"Phase 1b data reported a clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), noted May 16, 2024.",73.0
AZN,$76.57 ,Sipavibart (AZD3152) - (SUPERNOVA),COVID‑19 ,Phase 3,05/16/2024,"Phase 3 data reported that the trial met both dual primary endpoints, noted May 16, 2024.",
RHHBY,$32.65 ,CT-388,Obesity and type 2 diabetes ,Phase 1b,05/16/2024,"Phase 1b data reported significant weight loss in healthy adults with obesity compared to placebo, noted May 16, 2024.",
BIIB,$230.04 ,ION582 (BIIB121) - (HALOS),Angelman Syndrome ,Phase 1/2,05/16/2024,"Phase 1b/2 enrollment completed, noted November 2, 2023. Phase 1b datademonstrated consistent improvements across multiple functional domains, noted May 16, 2024.",146.0
IONS,$37.62 ,ION582 (BIIB121) - (HALOS),Angelman Syndrome ,Phase 1/2,05/16/2024,"Phase 1b/2 enrollment completed, noted November 2, 2023. Phase 1b datademonstrated consistent improvements across multiple functional domains, noted May 16, 2024.",159.0
TRML,$15.00 ,TOUR006 - (TRANQUILITY),Atherosclerotic cardiovascular disease (ASCVD) ,Phase 2,05/16/2024,"Phase 2 dosing initiated, noted May 16, 2024.",25.0
BIIB,$230.04 ,BIIB105 (ATXN2 ASO) - (ALSpire),Amyotrophic Lateral Sclerosis (ALS) ,Phase 1/2,05/16/2024,"Phase 1/2 topline data reported that treatment did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage, noted May 16, 2024.",146.0
IONS,$37.62 ,BIIB105 (ATXN2 ASO) - (ALSpire),Amyotrophic Lateral Sclerosis (ALS) ,Phase 1/2,05/16/2024,"Phase 1/2 topline data reported that treatment did not result in a reduction in levels of plasma neurofilament light chain (NfL), a marker of neurodegeneration and neuronal damage, noted May 16, 2024.",159.0
ASND,$122.80 ,Breyanzi (lisocabtagene maraleucel) - (TRANSCEND FL),Follicular lymphoma ,Approved,05/16/2024,"Approved May 16, 2024.",60.0
BMY,$42.97 ,Breyanzi (lisocabtagene maraleucel) - (TRANSCEND FL),Follicular lymphoma ,Approved,05/16/2024,"Approved May 16, 2024.",
PHIO,$6.59 ,PH-762,Cutaneous Squamous Cell Carcinoma ,Phase 1b,05/16/2024,"Phase 1b data reported that treatment was well tolerated at the maximum administered dose and treatment with mPH-762 provided robust inhibition of tumor growth, noted May 16, 2024.",5.0
MLTX,$40.86 ,Nanobody (sonelokimab) - (VELA),Hidradenitis suppurativa ,Phase 3,05/16/2024,"Phase 3 trial VELA initiated, noted May 16, 2024.",64.0
ATXI,$3.63 ,AJ201,Spinal and bulbar muscular atrophy (SBMA) ,Phase 1/2,05/16/2024,"Phase 1b/2 last patient dosed completed, noted May 16, 2024.",3.0
IVA,$3.65 ,Lanifibranor - (NATiV3),Nonalcoholic steatohepatitis (NASH) ,Phase 3,05/16/2024,"Positive recommendation from DMC on May 16, 2024.",95.0
AMGN,$310.30 ,IMDELLTRA (tarlatamab-dlle),Extensive-stage small cell lung cancer (ES-SCLC) ,Approved,05/17/2024,"Approved May 17, 2024.",538.0
MRNS,$1.33 ,Ganaxolone - (TrustTSC),Tuberous Sclerosis Complex ,Phase 3,05/17/2024,"Phase 3 enrollment completed, noted May 17, 2024.",55.0
AZTR,$5.46 ,ATR04-484,EGFRi-associated rash ,Preclinical,05/17/2024,"Preclinical data reported that treatment reduced IL-36g, a pro-inflammatory cytokine that drives inflammation in EGFRi-induced toxicity, in human skin model by 75% compared to erlotinib-treated skin,",3.0
LEXX,$3.15 ,DehydraTECH-powered GLP-1 drugs (semaglutide) - (WEIGHT-A24-1),Diabetes ,Preclinical,05/17/2024,"Preclinical trial initiated, noted May 17, 2024.",19.0
ARWR,$24.77 ,Plozasiran (ARO-APOC3) - (CAPITAN),Mixed hyperlipidemia ,Phase 2b,05/18/2024,"Phase 2b data reported that treatment significantly reduced triglycerides and atherogenic triglyceride rich lipoproteins and increased HDL, across all dose levels at Week 24 in patients with mixed dys",138.0
NNVC,$2.12 ,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infection ",Preclinical,05/20/2024,"Preclinical data reported that NV-387 against RSV/A2 is clearly demonstrated by lungs remaining normal and showing no infection-related damage, when treated orally with NV-387, in a lethal lung RSV in",17.0
DYN,$35.38 ,DYNE-101 - (ACHIEVE),Myotonic Dystrophy Type 1 (DM1) ,Phase 1/2,05/20/2024,"Phase 1/2 data reported that patients in the 5.4 mg/kg Q8W cohort had a 27% mean splicing correction from baseline across a broad, 22-gene panel at 3 months, with all participants demonstrating splici",142.0
DYN,$35.38 ,DYNE-251 - (DELIVER),Duchenne muscular dystrophy (DMD) ,Phase 1/2,05/20/2024,"Phase 1/2 data reported that patients treated with 10 mg/kg of DYNE-251 Q4W had a mean absolute dystrophin level of 3.22% of normal and a 2.97% change, noted May 20, 2024.",142.0
BCLI,$8.51 ,NurOwn,Amytrophic lateral sclerosis (ALS) ,Phase 3,05/20/2024,"Phase 3 data reported a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively, noted May 20, 2024.",10.0
PLUR,$6.05 ,NurOwn,Amytrophic lateral sclerosis (ALS) ,Phase 3,05/20/2024,"Phase 3 data reported a 4% decrease from baseline in NfL in Phase 3 and a 27% and 36% decrease from baseline, at the ends of Period 1 and Period 2 of the EAP, respectively, noted May 20, 2024.",8.0
ESPR,$2.48 ,Bempedoic acid - (Japan trial),Hypercholesterolemia ,Phase 3,05/20/2024,"Phase 3 data reported that the percentage change from baseline in LDL-C at Week 12, the primary endpoint, was -25.25%% in the group receiving bempedoic acid placebo group and -3.46% in the placebo gro",201.0
ARWR,$24.82 ,ARO-RAGE-1001,Asthma ,Phase 1/2,05/20/2024,"Phase 1/2a trial data presented at ATS reported that after two doses of ARO-RAGE in patients with mild to moderate asthma, serum sRAGE was reduced up to 88% with a mean maximum reduction up to 77%, no",138.0
AMGN,$312.35 ,TEZSPIRE (tezepelumab-ekko) - (COURSE),Chronic obstructive pulmonary disease (COPD) ,Phase 2,05/20/2024,"Phase 2 data presented at ATS reported that a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placebo at week 52, which was not statistically significan",538.0
GILD,$66.49 ,Livdelzi (Seladelpar) - (ASSURE),Pruritus (itch) in people living with primary biliary cholangitis (PBC) ,Phase 3,05/20/2024,"Phase 3 data reported that 70% of patients achieved the composite response endpoint and 25% experienced ALP normalization, noted May 20, 2024.",
SONN,$13.92 ,SON-1010 with Trabectedin - (SB101),Solid tumors ,Phase 1,05/20/2024,"Additional safety data reported a 10-fold extended half-life for SON-1010 compared with rhIL-12 that induces prolonged and controlled IFNγ responses, with no evidence of cytokine release syndrome at a",6.0
RHHBY,$32.77 ,SON-1010 in combination with atezolizumab - (SB221),Platinum-resistant ovarian cancer ,Phase 1/2,05/20/2024,Phase 1b/2 data reported that one patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have,
SONN,$13.92 ,SON-1010 in combination with atezolizumab - (SB221),Platinum-resistant ovarian cancer ,Phase 1/2,05/20/2024,Phase 1b/2 data reported that one patient in Part 1 of SB221 with uterine sarcomas received 8 cycles of the SON-1010/atezolizumab combination therapy every 3 weeks before progressing; another two have,6.0
GRI,$5.59 ,GRI-0621,Idiopathic pulmonary fibrosis (IPF) ,Preclinical,05/20/2024,"Preclinical data reported that GRI-0621 was shown to reduce the fibrotic score, inhibit the production of TGFβ and VCAM-1 and reduce the immune cell, noted May 20, 2024.",2.0
KRRO,$54.60 ,KRRO-110 - (REWRITE),Alpha-1 Antitrypsin Deficiency (AATD) ,Preclinical,05/20/2024,Preclinical data presented at ATS showed sustained editing efficiency of approximately 60% and increased total alpha-1 antitrypsin (AAT) protein levels to greater than 60uM at week 13 in an in vivo ge,9.0
LRMR,$7.27 ,Nomlabofusp (CTI-1601),Friedreich’s ataxia (FA) ,Phase 2,05/20/2024,"Phase 2 clinical hold removed, noted May 20, 2024.",85.0
VTVT,$28.21 ,Azeliragon,Refractory to first-line treatment of metastatic pancreatic cancer ,Phase 1/2,05/20/2024,"Phase 1/2 Orphan Drug Designation granted by the FDA on May 20, 2024.",3.0
ARCT,$30.50 ,Kostaive (ARCT-154),COVID-19 variant vaccine ,Phase 1/2,05/20/2024,"Phase 1/2 additional results demonstrate that two 5 μg doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19, no",27.0
CSLLY,$92.08 ,Kostaive (ARCT-154),COVID-19 variant vaccine ,Phase 1/2,05/20/2024,"Phase 1/2 additional results demonstrate that two 5 μg doses of ARCT-154, sa-mRNA vaccine, were well-tolerated, immunogenic and provided significant protection against multiple strains of COVID-19, no",968.0
GLUE,$4.30 ,MRT-6160,Autoimmune conditions ,Preclinical,05/21/2024,"Preclinical data reported that MRT-6160-mediated murine (m)VAV1 degradation prevented disease progression by 85% compared to vehicle (P<0.0001), and also reduced the disease activity index (DAI) score",61.0
IRWD,$6.78 ,Apraglutide - (STARS),Short Bowel Syndrome with Intestinal Failure (SBS-IF) ,Phase 3,05/21/2024,"Additional Phase 3 data to be presented at the Digestive Disease Week reported that significantly more apraglutide-patients gained additional days off from PS per week at week 24 versus placebo, noted",162.0
GILD,$65.89 ,Depemokimab - (SWIFT-1 and SWIFT-2),Severe asthma with type 2 inflammation characterised by blood eosinophil count ,Phase 3,05/21/2024,"Phase 3 data reported that both trials met its primary endpoints, noted May 21, 2024.",
CTXR,$0.73 ,Mino-Lok,Catheter related blood stream infection (CRBSI) ,Phase 3,05/21/2024,"Phase 3 topline data study met its primary endpoint with a statistically significant improvement in the time to failure event, noted May 21, 2024.",17.0
PRTC,$29.50 ,VE303 - (RESTORATiVE303),Clostridioides difficile infection (CDI) ,Phase 3,05/21/2024,"Phase 3 dosing initiated, noted May 21, 2024.",24.0
ASLN,$3.84 ,eblasakimab versus dupilumab,human tissue model of chronic obstructive pulmonary disease (COPD) ,Preclinical,05/21/2024,"Preclinical data presented at American Thoracic Society results support further investigation of eblasakimab as a potential therapeutic option for COPD, noted May 20, 2024.",2.0
ONVO,$1.03 ,FXR314 with Tofacitinib,Inflammatory Bowel Disease ,Preclinical,05/21/2024,"Preclinical data reported that FXR314 alone improved measures of colon health and colon histopathology similarly to approved IBD therapies tofacitinib and IL-12/23 antagonist, noted May 21, 2024.",1.0
PALI,$5.41 ,PALI-2108,Moderate-to-severe ulcerative colitis (UC) ,Preclinical,05/21/2024,"Preclinical data presented at DDW exhibited a dose-dependent efficacy response in two DSS colitis mouse models, achieving efficacy comparable to doses of apremilast considered intolerable for human us",9.0
GRI,$5.39 ,GRI-0124,Systemic Lupus Erythematosus (SLE) ,Preclinical,05/21/2024,"Preclinical data reported that it inhibited pro-inflammatory cytokines and signaling pathways in NZBWF1 mice, noted May 21, 2024.",2.0
GRI,$5.39 ,GRI-0803,Systemic lupus erythematosus (SLE) ,Preclinical,05/21/2024,"Preclinical data reported favorable solubility profile, and an excellent bioavailability, noted May 21, 2024.",2.0
BDRX,$58.25 ,"eRapa (rapamycin, sirolimus) - (Serenta)",Familial Adenomatous Polyposis (FAP) ,Phase 2,05/21/2024,"Phase 2 results presented at DDW showed an 83% non-progression rate at 6 months and a statistically significant decrease in overall mean polyp burden at 6 months, noted May 21, 2024.",
BHC,—,larsucosterol (DUR-928) - (AHFIRM),Alcoholic hepatitis (AH) ,Phase 2b,05/21/2024,"Breakthrough Therapy designation (BTD) granted by the FDA, noted May 21, 2024.",369.0
LLY,$802.05 ,Mirikizumab - (VIVID-1),Crohn's disease ,Phase 3,05/21/2024,"Phase 3 data showed that nearly one-half of patients on mirikizumab achieved endoscopic response at 52 weeks; most of these patients were also in clinical remission, noted May 21, 2024.",946.0
XOMA,$25.90 ,RZ402,Diabetic macular edema (DME) ,Phase 2,05/21/2024,"Phase 2 study met its primary endpoint, noted May 21, 2024.",12.0
RZLT,$3.00 ,RZ402,Diabetic macular edema (DME) ,Phase 2,05/21/2024,"Phase 2 study met its primary endpoint, noted May 21, 2024.",90.0
LIPO,$0.73 ,LP-10 (liposomal tacrolimus),Hemorrhagic cystitis ,Phase 2b,05/21/2024,"Phase 2b type C meeting with the FDA resulted in a preliminary agreement to proceed to Phase 2b expected to initiated in 2H 2024, noted May 21, 2024.",4.0
ALGS,$15.96 ,ALG-055009 - (HERALD),Metabolic dysfunction-associated steatohepatitis (MASH) ,Phase 2a,05/21/2024,"Phase 2a enrollment completed, noted May 21, 2024",6.0
SANA,$8.30 ,SC379,Secondary progressive multiple sclerosis ,Preclinical,05/21/2024,"Preclinical data published in a paper showed that when healthy wild-type (WT), pluripotent stem cell-derived glial progenitor cells (hGPCs) – the cells that give rise to the glial support cells of the",237.0
IFRX,$1.52 ,Gohibic (vilobelimab) - (PANAMO),COVID-19 ,Phase 3,05/21/2024,"Phase 3 data shared at ATS 2024 showed that co-administration of vilobelimab with baricitinib or tocilizumab was not associated with safety concerns, noted May 21, 2024.",59.0
JBIO,—,AV-101 - (IMPAHCT),Pulmonary arterial hypertension (PAH) ,Phase 2b,05/21/2024,Phase 2b portion of study outcomes shared at the ATS conference showed that baseline characteristics reflect a patient population with significant disease despite treatment with two to three targeted,32.0
RVPH,$1.31 ,Brilaroxazine,Idiopathic pulmonary fibrosis (IPF) ,Preclinical,05/21/2024,"Preclinical data shared at ATS reported that interactions with multiple 5-HT targets, particularly 5-HT2B/7 receptors, within the pulmonary tissue, provide an underlying basis for this agent's effecti",68.0
LYRA,$0.36 ,LYR-220 - (BEACON),Chronic rhinosinusitis ,Phase 2,05/21/2024,"Development paused, noted May 21, 2024.",1.0
AMPH,$43.46 ,Albuterol Sulfate Inhalation Aerosol (AMP-008),Bronchospasm ,Approved,05/22/2024,"Approved May 22, 2024.",46.0
PLRX,$14.18 ,Bexotegrast (PLN-74809) - (INTEGRIS-IPF),Idiopathic pulmonary fibrosis (IFP) ,Phase 2a,05/22/2024,Phase 2a data reported that seven previously identified plasma biomarkers of interstitial lung disease (ILD) progression were significantly modulated in participants with IPF receiving bexotegrast ove,61.0
RNAC,$25.46 ,Descartes-08 - (AURORA),"Generalized myasthenia gravis (MG), Multiple Myeloma and Autoimmune Diseases ",Phase 2b,05/22/2024,"Regenerative Medicine Advanced Therapy (RMAT) granted by the FDA, noted May 22, 2024.",26.0
INKT,$1.00 ,AGENT-797,Acute respiratory distress (ARDS) secondary to COVID-19 ,Phase 1/2,05/22/2024,"Phase 1/2 data reported that allogeneic iNKT therapy was safely administered with rapid decrease in IL-18 and other inflammatory cytokines, noted May 22, 2024.",4.0
SRRK,$11.71 ,SRK-439 with apitegromab - (EMBRAZE),Obesity ,Phase 2,05/22/2024,"Phase 2 trial initiated, noted May 22, 2024.",96.0
ABUS,$3.41 ,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV) ,Phase 2a,05/22/2024,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",191.0
BRNS,$2.30 ,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV) ,Phase 2a,05/22/2024,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",40.0
CLYD,—,Imdusiran (AB-729 and VTP-300 with nivolumab) - (IM-PROVE I),Hepatitis B (HBV) ,Phase 2a,05/22/2024,"Phase 2a key findings noting that VTP-300 in combination with nivolumab has been generally well tolerated, with no observed treatment-related serious adverse events, and contributed to declines in hep",
INDP,$2.48 ,Decoy 20,Solid tumors ,Phase 1a,05/22/2024,"Phase 1a first-in-human trial confirms ""Pulse-Prime"" hypothesis targeting stimulation of innate and adaptive immune systems, this data to be presented at ASCO 24, noted May 22, 2024.",1.0
BIVI,$4.84 ,Bezisterim (NE3107) - (Biomarker Trial),Alzheimer's disease ,Phase 2a,05/22/2024,Phase 2a full dataset presented at IAPRD suggest patients treated with bezisterim experienced significant improvements in both non-motor symptoms and motor control while placebo-treated patients worse,7.0
ANL,$12.75 ,Palupiprant (AN0025) + Keytruda - (ARTEMIS),"TNBC, NSCLC, bladder cancer, microsatellite stable CRC and cervical cancer ",Phase 2,05/22/2024,"Phase 2 trial initiated, noted May 22, 2024.",36.0
PTIX,$1.80 ,PT00114,Major Depressive Disorder (MDD) / Generalized Anxiety Disorder (GAD) / Post-Traumatic Stress Disorder (PTSD) ,Phase 1/2,05/22/2024,"Phase 1/2a safety data demonstrated no clinically relevant Adverse Events Reported in the single-dose portion, with the multiple-dose portion to commence, noted May 22, 2024.",
KYMR,$35.70 ,KT-621 (STAT6),Type 2 inflammation in allergic diseases ,Preclinical,05/22/2024,"Preclinical data reported that KT-621 was comparable to a saturating dose of the IL-4Rα antibody, dupilumab, in an asthma efficacy model which demonstrated that KT-621 robustly inhibited all the teste",71.0
CNTB,$1.68 ,Rademikibart - (Seabreeze STAT Asthma),Asthma ,Phase 2b,05/22/2024,"Phase 2b data presented at ATS showed that treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24, noted May 22, 2024.",55.0
TNGX,$7.09 ,TNG348,"BRCA1/2-Mutant and Other HRD+ Cancers, Solid Tumors ",Phase 1/2,05/23/2024,"Phase 1/2 first patient dosed January 3, 2024. Phase 1/2 discontinued due to toxicity observed in the initial study cohorts. No patient had yet received a combination of TNG348 and olaparib., noted Ma",111.0
CYTO,$1.71 ,Bentrio (AM-301) - (NASAR),Seasonal allergic rhinitis (SAR) ,Phase 1,05/23/2024,"Phase 1 data published at in video format showed that the study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score",4.0
NNVC,$2.23 ,NV-CoV-2 (NV-387),"RSV (Respiratory Syncytial Virus), Coronavirus, Smallpox/Mpox related Ectromelia virus infection ",Phase 1b,05/23/2024,"Phase 1b trial completed, the company also engaged with Aagami, Inc for partnership developments and licensing opportunities, noted May 23, 2024.",17.0
EVGN,$7.20 ,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma ",Phase 1,05/23/2024,"Phase 1 data from ASCO abstract reported that one patient demonstrated partial response (PR) upon imaging and RECIST v1.1 assessment and remains actively responding to treatment. Additionally, 64% of",6.0
BMY,$40.47 ,BMC128 with Opdivo,"Non-small cell lung cancer (NSCLC), melanoma or renal cell carcinoma ",Phase 1,05/23/2024,"Phase 1 data from ASCO abstract reported that one patient demonstrated partial response (PR) upon imaging and RECIST v1.1 assessment and remains actively responding to treatment. Additionally, 64% of",
SUPN,$27.77 ,SPN-817,Treatment-resisted seizures ,Phase 2,05/23/2024,"Phase 2 interim data reported that 81% of subjects with focal seizures had 30% or more seizure reduction, noted May 23, 2024.",56.0
MRUS,$44.07 ,MCLA-145 with Keytruda (pembrolizumab),Solid tumors ,Phase 1,05/23/2024,"Phase 1 data from abstract reported that 5 partial responses (PRs) were observed with 1 complete response was observed in PD-L1+ NSCLC (treated 6+ mo) and 1 PR in Merkel cell carcinoma, noted May 23,",75.0
GMAB,—,MCLA-145 with Keytruda (pembrolizumab),Solid tumors ,Phase 1,05/23/2024,"Phase 1 data from abstract reported that 5 partial responses (PRs) were observed with 1 complete response was observed in PD-L1+ NSCLC (treated 6+ mo) and 1 PR in Merkel cell carcinoma, noted May 23,",661.0
BCYC,$23.48 ,BT5528 and OPDIVO (nivolumab),Solid tumors ,Phase 1/2,05/23/2024,"Phase 1/2 data from ASCO abstract reported that BT5528-related AEs occurred in 91% of patients, of which 22% were Grade ≥3, noted May 23, 2024.",69.0
BCAB,$2.10 ,Evalstotug (BA3071),Oncology (various) ,Phase 2,05/23/2024,"Phase 2 data from abstract reported two treatment related discontinuations with responses in three of eight patients who received evalstotug 350mg(1 CR, 1 PR, 1 unPR), noted May 23, 2024.",58.0
NKGN,$1.86 ,SNK02,Solid Tumors ,Phase 1,05/23/2024,"Phase 1 data from ASCO abstract reported that the best objective response of stable disease was demonstrated in 100% of patients that completed 8 treatment cycles of SNK02, noted May 23, 2024.",124.0
FGEN,$1.28 ,FG-3246 (FOR46) in combination with enzalutamide - (Investigator-sponsored trial),Metastatic castration-resistant prostate cancer (mCRPC) ,Phase 1/2,05/23/2024,"Phase 1b/2 data from abstract reported a preliminary estimate of median radiographic progression free survival (rPFS) of 10.2 months, noted May 23, 2024.",4.0
VSTM,$12.18 ,VS-6766 and defactinib - (RAMP 205),Metastatic pancreatic cancer ,Phase 1/2,05/23/2024,"Phase 1/2 study as of May 14, 2024, patients receiving the combination of avutometinib and defactinib with gemcitabine and Nab-paclitaxel in dose level 1 cohort achieved a confirmed overall response r",61.0
IMAB,$1.75 ,Ragistomig (ABL503),Solid tumors ,Phase 1,05/23/2024,"Phase 1 data from ASCO abstract reported an overall response rate of 25% at 5 mg/kg, based on 3 partial responses (PR) out of 12 patients with median progression free survival (PFS) of 15.6 weeks, not",81.0
CGEM,$22.65 ,CLN-619 - (MICA) monotherapy and in combination with pembrolizumab,Solid tumors ,Phase 1,05/23/2024,"Phase 1 data from ASCO abstract reported that confirmed partial responses (PR) were observed in 3 patients, noted May 23, 2024.",59.0
REGN,$980.57 ,REGN7075 in combination with cemiplimab,Solid Tumors ,Phase 1/2,05/23/2024,"Phase 1/2 updated data to be presented at ASCO on June 3, 2024. Phase 1/2 data from ASCO abstract reported a 6% (n=3) overall response rate (ORR) and 29% (n=15) disease control rate (DCR), noted May 2",105.0
MURA,$3.59 ,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid Tumors ,Phase 2,05/23/2024,"Phase 2 data from ASCO abstract reported that all dosing schedules tested in ARTISTRY-3 demonstrated the desired pharmacodynamic effects, including expansion of immune-stimulating NK and CD8+ cells, n",17.0
ALKS,$24.00 ,Nemvaleukin (ALKS 4230) - (ARTISTRY-3),Solid Tumors ,Phase 2,05/23/2024,"Phase 2 data from ASCO abstract reported that all dosing schedules tested in ARTISTRY-3 demonstrated the desired pharmacodynamic effects, including expansion of immune-stimulating NK and CD8+ cells, n",165.0
IOVA,$10.26 ,LN-145 - (IOV-COM-202),Non-small cell lung cancer (NSCLC) ,Phase 2,05/23/2024,"Phase 2 data from ASCO abstract reported a confirmed ORR was 65.2%, including 7 (30.4%) complete responses and 8 (34.8%) partial responses, noted May 23, 2024.",361.0
HOWL,$5.16 ,WTX-124,Solid Tumors ,Phase 1b,05/23/2024,"Phase 1/1b data from ASCO abstract reported that treatment was well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers, noted May 23, 2024.",45.0
CMPX,$1.50 ,CTX-471 (CD137 agonist),Solid tumors ,Phase 1,05/23/2024,"Phase 1 Dose Escalation and Dose Expansion, first-in-human monotherapy study in patients with metastatic or locally advanced malignancies who had progressed on approved PD-1 or PD-L1 inhibitors, noted",138.0
INAB,$1.04 ,INB-200,Glioblastoma ,Phase 1,05/23/2024,"Phase 1 data from ASCO reported no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity, noted May 23, 2024.",4.0
EVAX,$3.88 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2b,05/23/2024,"Phase 2 data from ASCO abstract reported that EVX-01 vaccine-induced specific and robust immune responses, mediated by both CD4+ and CD8+ T-cells, noted May 23, 2024.",6.0
MRK,$129.46 ,EVX-01 + KEYTRUDA (pembrolizumab) / OPDIVO (nivolumab),Metastatic Melanoma ,Phase 2b,05/23/2024,"Phase 2 data from ASCO abstract reported that EVX-01 vaccine-induced specific and robust immune responses, mediated by both CD4+ and CD8+ T-cells, noted May 23, 2024.",
AGEN,$12.35 ,Botensilimab plus balstilimab,Relapsed/refractory microsatellite stable colorectal cancer with no active liver metastases (r/r MSS CRC NLM) ,Phase 1b,05/23/2024,"Phase 1b data to be presented at ASCO 2024, ASCO abstract released across different NLM sites, overall response rates (ORR) ranged from 18-33%, and disease control rates (DCR) ranged from 67-82%. Over",31.0
MRUS,$44.07 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,05/23/2024,"Phase 2 data from abstract reported a 60% response rate observed among 10 evaluable patients, noted May 23, 2024.",75.0
GMAB,—,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 2,05/23/2024,"Phase 2 data from abstract reported a 60% response rate observed among 10 evaluable patients, noted May 23, 2024.",661.0
AFMD,$4.71 ,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancer ",Phase 2,05/23/2024,"Phase 2 data due to be presented at ASCO on June 1, 2024. Phase 2 ASCO abstract to be presented showed that of the March 18, 2024 data cut-off, the median progression free survival was 5.9 months and",15.0
ZNTL,$11.28 ,Azenosertib and gemcitabine,Relapsed or refractory (R/R) osteosarcoma ,Phase 1,05/23/2024,Phase 1 data from ASCO abstract support further investigation of azenosertib administered in combination with gemcitabine in patients with R/R osteosarcoma in an upcoming investigator-initiated Phase,72.0
BPMC,$102.39 ,BLU-222 - (VELA),(HR+/HER2-) breast cancer. ,Phase 1,05/23/2024,Phase 1 dose escalation data presented at ASCO abstract showed that BLU-222 in combination with ribociclib and fulvestrant was well-tolerated at clinically active dose levels with no dose-limiting tox,64.0
SNSE,$1.45 ,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancer ,Phase 1/2,05/23/2024,"Phase 1/2 data demonstrated initial signs of promising clinical activity, noted May 23, 2024.",1.0
REGN,$980.57 ,Solnerstotug (formerly SNS-101) with Libtayo - (VISTA),One microsatellite stable (MSS) endometrial cancer ,Phase 1/2,05/23/2024,"Phase 1/2 data demonstrated initial signs of promising clinical activity, noted May 23, 2024.",105.0
COGT,$7.49 ,Bezuclastinib and SUTENT (sunitinib) - (PEAK),Gastrointestinal Stromal Tumors (GIST) ,Phase 3,05/23/2024,Phase 3 updated data presented at an ASCO abstract showed d that study reached median progression free survival (mPFS) of 19.4-months and 33% ORR in subset of advanced GIST patients with one prior tre,139.0
HOOK,$10.40 ,Eseba-vec (formerly HB-200) in combination with KEYTRUDA (pembrolizumab),Head and neck squamous cell carcinoma (HNSCC) ,Phase 1/2,05/23/2024,"Phase 2 data due to be presented at ASCO 2024, abstract from updated data showed confirmed objective response rate (ORR) of 53%, complete response (CR) rate of 18%, and disease control rate (DCR) of 8",12.0
CADL,$10.69 ,CAN-2409 + valacyclovir,Non-small cell lung cancer (NSCLC) ,Phase 2,05/23/2024,"Phase 2 data from ASCO abstract showed that treatment resulted in activation of the systemic immune response after two administrations of CAN-2409, including increased numbers of circulating cytotoxic",54.0
ELTX,$8.85 ,ELI-002 - (AMPLIFY-7P),mKRAS-driven cancers ,Phase 2,05/23/2024,"Phase 2 ASCO abstract showed that treatment administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levels, noted May",16.0
PBYI,$3.99 ,Alisertib - (PUMA-ALI-4201) - (ALISCA-Lung1),Small Cell Lung Cancer (SCLC) ,Phase 1b,05/23/2024,Phase 1/1b data shared at ASCO abstract showed that intermittent dosing of alisertib 30 mg BID in combination with osimertinib 80 mg daily demonstrated no dose-limiting toxicities and was identified a,50.0
IPHA,$2.96 ,IPH6501,Relapsed and/or Refractory CD20-expressing B-cell Non-Hodgkin's Lymphoma (NHL) ,Preclinical,05/23/2024,"Preclinical data from ASCO abstract reported that IPH6501, at well-tolerated doses, significantly boosted peripheral NK cell proliferation, drove their accumulation at tumor locations, and effectively",92.0
ALXO,$14.69 ,Evorpacept w/ cetuximab and pembrolizumab,Colorectal cancer ,Phase 2,05/23/2024,"Phase 2 data from the abstract has ORR was 6.3% (1 ongoing partial response, 95% confidence interval [CI] 0.2-30.2%), disease control rate was 12.5% (95% CI 1.6-38.4%), median progression-free surviva",53.0
BNTX,$99.00 ,BNT327/PM8002,Non-small cell lung cancer (NSCLC) ,Phase 1/2,05/23/2024,"Phase 1b/2 data from ASCO abstract reported a 47% ORR in cohort 6, 19.4% ORR in cohort 7, noted May 23, 2024.",239.0
CUE,$1.74 ,CUE-102,Wilms' Tumor (WT1)-expressing cancers ,Phase 1,05/23/2024,"Phase 1 data from abstract reported that stable disease of ≥ 6 weeks (range 6-36 weeks), as determined by RECIST 1.1, has been observed in 10 of 23 patients (DCR 43.5%), noted May 23, 2024.",76.0
CUE,$1.74 ,CUE-101 and KEYTRUDA (pembrolizumab) - (KEYNOTE-A78),HPV16+ head and neck cancer ,Phase 1,05/23/2024,"Phase 1 data from ASCO abstract reported that of CUE-101 plus pembrolizumab, an ORR of 47% (1 CR, 8 PRs), a Disease Control Rate (ORR + durable SDs) of 74%, and mPFS of 5.8 months, noted May 23, 2024.",76.0
MRK,$129.46 ,Sacituzumab tirumotecan (SKB264/MK-2870) - (OptiTROP-Breast01),Locally recurrent or metastatic triple-negative breast cancer (TNBC) ,Phase 3,05/23/2024,"Phase 3 data from ASCO abstract reported an objective response rate assessed by BICR was 43.8% with SKB264 and 12.8% with chemotherapy, noted May 23, 2024.",
PFE,$28.30 ,PF-07248144,ER+ HER2− breast cancer ,Phase 1,05/23/2024,"Phase 1 data from ASCO abstract reported that for the fulvestrant combination (n=43), with median duration of follow-up of 9.2 mos, the ORR was 30.2% (17.2, 46.1), median DOR was 9.2 mos (7.2, NE), CB",
PFE,$28.30 ,Mevrometostat (PF-06821497),Castration-resistant prostate cancer (CRPC) ,Phase 1,05/23/2024,"Phase 1 data from ASCO abstract reported that the OR rate (95% CI) was 27.3% (10.7, 50.2), including 1 complete and 5 partial responses, noted May 23, 2024.",
PFE,$28.30 ,Elranatamab - (MagnetisMM-9),Multiple Myeloma ,Phase 1/2,05/23/2024,"Phase 1/2 data from ASCO abstract reported that after a median follow-up of 7.4 mo, the most common (>50%) AEs were CRS (63.5%; grade ≥2, 15.3%) and neutropenia (54.1%; all grade ≥2), noted May 23, 20",
PFE,$28.30 ,Sigvotatug vedotin (SGNB6A-001),Non-small cell lung cancer (NSCLC) ,Phase 1,05/23/2024,"Phase 1 data reported in ASCO abstract reported that the cORR was 19.5% (95% CI, 12.6-28.0) in all pts with NSCLC and 32.5% (95% CI, 18.6-49.1) in pts with non-squamous (non-Sq)/taxane-naive NSCLC. Ad",
MOLN,$3.81 ,MP0317,Solid Tumors ,Phase 1,05/23/2024,"Phase 1 data from ASCO abstract reported that one patient achieved unconfirmed partial response, and stable disease was observed in 11 patients (24%), noted May 23, 2024.",40.0
XLO,$1.07 ,XTX202,Solid Tumors ,Phase 1/2,05/23/2024,"Phase 1/2 data from ASCO abstract reported that the DCR was 62% at the 1.4 mg/kg dose-level and 80% at the 4 mg/kg dose-level, with 19 pts ongoing and awaiting first response assessment, noted May 23,",51.0
VSTM,$4.12 ,AVMAPKI FAKZYNJA CO-PACK,Recurrent low-grade serous ovarian cancer (LGSOC) ,NDA Filing,05/24/2024,"NDA and accelerated approval application submitted May 24, 2024.",61.0
IDYA,$37.71 ,Darovasertib - (neo-adjuvant and adjuvant settings) - (NADOM),Ocular Melanoma ,Phase 2,05/24/2024,Phase 2 clinical efficacy update presented at ASCO abstract showed that monotherapy neoadjuvant treatment was generally well tolerated. Drug-related adverse events (AEs) were predominantly Grade 1 or,87.0
BLRX,$0.69 ,"Motixafortide (BL-8040), gemcitabine, nab-paclitaxel and LIBTAYO (cemiplimab) - (Columbia University trial) - (CheMo4METPANC)",First-line pancreatic ductal adenocarcinoma (PDAC) ,Phase 2,05/24/2024,"Phase 2 data from ASCO reported that 7 of 11 patients in the pilot phase experienced a partial response, with 6 confirmed; 10 of 11 patients experienced disease control , noted May 24, 2024.",3.0
CHRS,$1.91 ,CHS-114 - (SRF114),Solid tumors ,Phase 1,05/24/2024,Phase 1 preliminary results from dose escalation in an ASCO abstract shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors,116.0
BCTX,$1.44 ,Bria-IMT - (BRIA-ABC),Advanced breast cancer ,Phase 2,05/24/2024,"Phase 2 data in an ASCO abstract resulted in an 83% intracranial objective response rate, median progression-free survival of 4.1 months in antibody-drug conjugate (ADC) resistant patients (double his",1.0
CGON,$32.71 ,Cretostimogene in combination with pembrolizumab - (CORE-001),Intermediate-risk NMIBC ,Phase 2,05/24/2024,"Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time. 95% of 12mo CRs maintained CR for 24mo. Median DoR >21mo. 24mo CR rate 69.6%.",76.0
MRK,$127.88 ,Cretostimogene in combination with pembrolizumab - (CORE-001),Intermediate-risk NMIBC ,Phase 2,05/24/2024,"Phase 2 final results to be presented at ASCO 2024, abstract released resulted in a ITT CR rate 57% at 12mo, 83% any time. 95% of 12mo CRs maintained CR for 24mo. Median DoR >21mo. 24mo CR rate 69.6%.",
IPHA,$2.90 ,Lacutamab (IPH4102) - (TELLOMAK),"Mycosis Fungoides, Sézary Syndrome ",Phase 2,05/24/2024,"Phase 2 topline results reported that the ORR was 16.8%, with the median time to response was 1.0 months and median PFS 10.2m, noted May 24, 2024.",92.0
AZN,$78.06 ,"Imfinzi (durvalumab), Monalizumab, and Oleclumab - (COAST)",Non-small cell lung cancer (NSCLC) ,Phase 2,05/24/2024,"Phase 2 data reported that D+O and D+M increased ORR and prolonged PFS and OS vs D alone, noted May 24, 2024.",
IPHA,$2.90 ,"Imfinzi (durvalumab), Monalizumab, and Oleclumab - (COAST)",Non-small cell lung cancer (NSCLC) ,Phase 2,05/24/2024,"Phase 2 data reported that D+O and D+M increased ORR and prolonged PFS and OS vs D alone, noted May 24, 2024.",92.0
ANL,$10.50 ,AN0025 + Keytruda,Solid tumors ,Phase 1b,05/24/2024,"Phase 1b data reported that the disease control rate (DCR) was 92% (11/12). The median progression-free survival (PFS) was not reached, with 6-month and 1-year PFS rates of 91% and 73%, respectively,",36.0
HCM,$18.73 ,Fruquintinib - (FRESCO),Metastatic colorectal cancer (CRC) ,Phase 3,05/24/2024,"Phase 3 data reported improvements in OS and PFS were seen with F vs P regardless of prior tx sequence (Table), with similar magnitudes of benefit for OS and PFS, noted May 24, 2024.",174.0
HCM,$18.73 ,Fruquintinib (HMPL-013) - (FRESCO-2),Metastatic Colorectal Cancer ,Phase 3,05/24/2024,"Phase 3 data reported at ASCO reported improvements in OS and PFS were seen with F vs P regardless of prior tx sequence, with similar magnitudes of benefit for OS (HRs 0.53–0.77) and PFS (HRs 0.25–0.3",174.0
HCM,$18.73 ,HMPL-295,Solid tumors ,Preclinical,05/24/2024,"Preclinical data from ASCO reported that stable disease with tumor shrinkage was also observed in 2 pts with NSCLC on 50 mg QD and 75 mg QD 2w on/1w off cohort respectively, and 1 pt with pancreatic d",174.0
HCM,$18.73 ,Stereotactic ablative radiotherapy (SABR) + fruquintinib and tislelizumab - (RIFLE),Metastatic colorectal cancer ,Phase 2,05/24/2024,"Phase 2 data from ASCO reported 1 CR, 8 PR, 14 SD and 8 PD, noted May 24, 2024.",174.0
INCY,$57.31 ,INCB099280,Solid Tumors ,Phase 1,05/24/2024,"Phase 1 data to be presented at ASCO on June 1, 2024, with abstract data reporting that 96.6% of pts had ≥1 tx-emergent adverse events, and decreased ctCNA was seen in all complete responders (n=2) an",195.0
INCY,$57.31 ,INCB057643,Myelofibrosis (MF) and Other Advanced Myeloid Neoplasms ,Phase 1,05/24/2024,"Phase 1 data from ASCO abstract reported that SVR35 was achieved by all 3 evaluable pts receiving ≥10 mg monotherapy, and 3/12 achieved a best response of SVR35, noted May 24, 2024.",195.0
ALXO,$13.17 ,Evorpacept with PADCEV (enfortumab vedotin-ejfv) - (ASPEN-07),Urothelial Carcinoma (UC) ,Phase 1a,05/24/2024,"Phase 1a data from abstract reported an overall response rate (ORR) was 63% (1CR, 9PR), noted May 24, 2024.",53.0
BNTX,$96.95 ,YL202/BNT326,Locally advanced or metastatic non-small cell lung cancer and breast cancer ,Phase 1,05/24/2024,"Phase 1 data from ASCO abstract reported an ORR of 42.2% (19/45) and disease control rate (DCR) of 93.3% (42/45), noted May 24, 2024.",239.0
GMAB,$28.00 ,Acasunlimab (GEN1046/BNT311),Non-small cell lung cancer (NSCLC) ,Phase 2,05/24/2024,"Phase 2 data from ASCO abstract reported confirmed ORRs (and mDoR) were 13% (2 mo), 21% (6 mo), and 22% (NR), with 6-mo PFS rates of 0%, 18%, and 33% for arms A, B, and C, respectively, noted May 24,",661.0
CGEN,$2.44 ,"COM701, COM902 and Pembrolizumab","Advanced malignancies, Ovarian cancer ",Phase 1,05/24/2024,"Data from abstract reported an ORR 2/17 (12%); disease control rate [DCR] 5/17 (29%) noted May 24, 2024,",93.0
NUVB,$3.08 ,Taletrectinib - (TRUST-I) (China),ROS1-positive non-small cell lung cancer (NSCLC) ,Phase 2,05/24/2024,"Phase 2 data from ASCO abstract reported that in TKI-pretreated patients, the ORR was 52% (95% CI: 40, 65) and IC-ORR was 75% , noted May 24, 2024.",342.0
APLS,$40.61 ,EMPAVELI (pegcetacoplan) - (VALIANT),C3G and IC-MPGN ,Phase 2,05/24/2024,"Phase 2 data from NOBLE study demonstrated a rreduction in disease activity seen at 12 weeks was sustained at one year, 55% of patients showed zero C3c staining intensity, indicating that C3c deposit",126.0
MRK,$124.52 ,KEYTRUDA (pembrolizumab) - (KEYNOTE-522),Triple negative breast cancer (TNBC) ,Phase 3,05/28/2024,"Phase 3 data reported that trial met its primary endpoint, noted May 28, 2024.",
INSM,$48.06 ,BRINSUPRI (Brensocatib) - (ASPEN),Non-Cystic Fibrosis Bronchiectasis (NCFBE) ,Phase 3,05/28/2024,"Phase 3 topline data reported that the trial met its primary endpoint, noted May 28, 2024.",211.0
ARCT,$38.41 ,ARCT-032 - (LUNAR-CF),Cystic Fibrosis ,Phase 1b,05/28/2024,"Phase 1b data reported that the first four patients had an average improvement of 4% FEV1 after two administrations, noted May 28, 2024.",27.0
UNCY,$0.84 ,UNI-494,Acute kidney injury (AKI) ,Preclinical,05/28/2024,"Preclinical model results of hyperphosphatemia demonstrated the relative potency of OLC Compared to tenapanor, noted May 28, 2024.",17.0
ALLK,$1.39 ,AK006 (IV),Chronic spontaneous urticaria (CSU) ,Phase 1,05/28/2024,"Phase 1 trial in CSU initiated, noted May 28, 2024.",90.0
MRUS,$54.87 ,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 1/2,05/28/2024,"Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression",75.0
GMAB,—,Petosemtamab (MCLA-158),"Recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC), Solid Tumors ",Phase 1/2,05/28/2024,"Phase 2 data to be presented at ASCO 2024, abstract released on May 23 showed that as of the March 6, 2024 data cutoff, the combination demonstrated a 67% overall response rate across PD-L1 expression",661.0
VERA,$37.13 ,Atacicept - (ORIGIN 3),IgA Nephropathy ,Phase 2b,05/28/2024,"Phase 2b 72-week data reported that participants who switched from placebo to atacicept also demonstrated stable eGFR, as well as similar reductions in Gd-IgA1, hematuria, and UPCR, noted May 28, 2024",63.0
CORT,$31.61 ,Relacorilant - (GRACE),Hypercortisolism (Cushing's Syndrome) ,Phase 3,05/28/2024,"Phase 3 trial met its primary endpoint, noted May 28, 2024.",105.0
ABBV,$152.69 ,ABBV-400,Colorectal cancer (CRC) ,Phase 1,05/28/2024,"Phase 1 preliminary data derived from ASCO abstract showed that among 122 heavily pre-treated advanced CRC patients, promising antitumor activity was observed at 2.4 and 3.0 mg/kg doses administered o",
ABBV,$152.69 ,ABBV-706,Solid Tumors ,Phase 1,05/28/2024,"Phase 1 data at ASCO abstract demonstrated that among a total of 48 efficacy-evaluable patients (23 SCLC and 25 NEN), the overall confirmed objective response rate was 43.8%. Within the SCLC group, th",
AZN,$76.15 ,DATROWAY (datopotamab deruxtecan-dlnk)- (TROPION-Lung01),Non-small cell lung cancer (NSCLC) ,Phase 3,05/28/2024,Phase 3 trial data reported numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small,
NVS,$99.68 ,Vanrafia (atrasentan),Proteinuria reduction in primary IgA nephropathy (IgAN) ,Phase 3,05/28/2024,"Phase 3 data reported a statistically significant 36.1% proteinuria (protein in urine) reduction vs. placebo + supportive care at 36 weeks, noted May 28, 2024.",
NVS,$99.68 ,Fabhalta (iptacopan),C3 glomerulopathy (C3G) ,Phase 3,05/28/2024,"Phase 3 data reported that patients treated with Fabhalta in addition to supportive care achieved a 35.1% reduction in proteinuria at 6 months when compared to placebo on top of supportive care, noted",
PROK,$3.71 ,RMCL-002 - (REACT),"Type 2 diabetes, prevent/delay CKD ",Phase 2,05/28/2024,"Phase 2 full results reported that patients s randomized to the deferred treatment arm experienced less decline in kidney function after rilparencel treatment versus standard of care , noted May 28, 2",294.0
VANI,$1.66 ,OKV-119,Obesity ,Preclinical,05/28/2024,"Preclinical data of proof-of-concept study in felines showed that a single OKV-119 implant effectively delivered therapeutic exenatide levels for the intended 3-month duration, achieving weight loss i",59.0
SRRK,$10.33 ,SRK-181 - (DRAGON),Solid Tumors ,Phase 1,05/28/2024,"Phase 1 data from abstract continued to showed that study continues to be well tolerated in the dose expansion portion of the DRAGON trial (Part B), noted May 28, 2024.",96.0
XENE,$38.61 ,azetukalner (XEN1101) - (X-NOVA),Major depressive disorder (MDD) ,Phase 2,05/28/2024,"Phase 2 data presented at American Epilepsy Society showed azetukalner 20mg achieved clinically meaningful reductions in depression scores on MADRS and HAM-D17 scales, with a 3.04 point difference vs",77.0
NRXP,$3.83 ,NRX-101,Bipolar Depression and Suicidal Ideation ,Phase 2/3,05/28/2024,Phase 2b/3 trial results evaluating NRX-101 versus lurasidone in bipolar depression with suicidal ideation/behavior at ASCP 2024. The data showed NRX-101 achieved similar efficacy to lurasidone on dep,19.0
JAGX,$4.03 ,Mytesi (crofelemer),Moderate-to-severe diarrhea including Vibrio cholerae ,Phase 1,05/28/2024,Phase 1 nnounced results from an investigator-initiated study showing that crofelemer led to statistically meaningful reductions in abdominal pain/discomfort and improved stool consistency compared to,2.0
APRE,$5.19 ,ATRN-119 - (ABOYA-119),Solid tumors ,Phase 1/2,05/28/2024,Phase 1/2a Safety Review Committee has approved opening enrollment for the 800mg once daily dosing cohort after reviewing favorable safety and pharmacokinetic data from the 550mg cohort. Initial signs,5.0
NLSP,$6.98 ,KO-874,Sleep and wakefulness disorders ,Preclinical,05/28/2024,"Preclinical results results suggested that mazindol may modulate the orexin system through direct or indirect mechanisms. While lower 1 mg/kg doses were not effective, the dose-dependent response and",3.0
AZN,$76.15 ,IK-930,"Solid tumors, non-small cell lung cancer ",Phase 1,05/28/2024,"Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024",
IMA,—,IK-930,"Solid tumors, non-small cell lung cancer ",Phase 1,05/28/2024,"Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024",4.0
IKNA,$1.33 ,IK-930,"Solid tumors, non-small cell lung cancer ",Phase 1,05/28/2024,"Phase 1 trial discontinued based on a clinical data review, noted May 28, 2024",48.0
TELO,$6.23 ,Telomir-1,Age-related conditions ,Preclinical,05/28/2024,"Preclinical canine study dosing initiated, noted May 28, 2024.",32.0
VTGN,$3.96 ,Fasedienol (PH94B) - (PALISADE-2),Social Anxiety Disorder (SAD) ,Phase 3,05/29/2024,Phase 3 results presented at the American Society of Clinical Psychopharmacology Conference reported that a single dose of fasedienol prior to a stressful PSC reduced anxiety levels as measured by SUD,30.0
AFMD,$4.02 ,AFM24-102 and TECENTRIQ (atezolizumab),"EGFR Expressing Solid Tumors, Non-small cell lung cancer, and Gastric/gastroesophageal junction (GEJ) cancer ",Phase 2,05/29/2024,"Fast Track Designation granted May 29, 2024.",15.0
